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Abstract
Abnormal scarring is a type of benign fibrosis of the skin that can restrict mobility, dexterity
and quality of life. There are few, if any, truly effective treatment options for these
conditions. Hypertrophic scarring is a common form of abnormal scarring characterized by
increased fibroblast proliferation and differentiation of apoptosis-resistant and hypercontractile myofibroblasts that promote excessive deposition and contracture of the
extracellular matrix (ECM). Periostin, a secreted ECM protein, is transiently expressed
during normal cutaneous wound repair, but is abnormally abundant and persistent in
abnormal scars and other benign fibroses that display enhanced fibroblast proliferation and
myofibroblast differentiation. The objectives of this study were to elucidate the effects of
periostin on fibroblast proliferation, myofibroblast differentiation and myofibroblast
persistence in an in vitro human fibroblast model of hypertrophic scarring. Primary
fibroblasts derived from patients with hypertrophic scars (HTS) or normal skin (NS) were
cultured in two- and three-dimensional collagen cultures to more closely mimic their in vivo
microenvironment. A series of in vitro techniques, including adenoviral transduction, WST-1
assays, stressed fibroblast populated collagen lattices (sFPCLs), western immunoblotting and
immunofluorescence confocal microscopy were employed to assess periostin effects on
fibroblast proliferation and myofibroblast differentiation under these culture conditions.
Periostin treatment was shown to enhance HTS fibroblast proliferation in compliant 2D
collagen cultures through Akt and Rho kinase dependent pathways. When subjected to
isometric tension in sFPCLs, periostin enhanced myofibroblast differentiation, as evidenced
by increases in collagen contraction, alpha smooth muscle actin (αSMA) and the formation
of supermature focal adhesions. In contrast, no discernible effects of periostin treatment were
evident in NS fibroblasts. Periostin signalling maintained αSMA levels in HTS fibroblasts in
an environment of decreasing ECM tension, and this was correlated with changes in focal
adhesion kinase, cofilin and myosin light chain activities. These studies are the first to
identify periostin as a mediator of excessive proliferation, myofibroblast differentiation and
persistence in human fibroblasts derived from hypertrophic scars. The findings reported here
suggest that novel therapeutic interventions designed to deplete periostin levels in the dermis
of hypertrophic scars may have utility for attenuating fibroblast proliferation and depleting
myofibroblast populations, and thereby enhance scar resolution.
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Chapter 1

1

Introduction

1.1 The integumentary system
The integumentary system, which is comprised of the skin and its appendages, is the
largest organ in the body and accounts for up to 15% of the total adult body weight (1, 2).
The main function of the skin is to provide a physical, chemical, and adaptive barrier to
protect the body from external damage (1, 3, 4). The skin also plays important roles in
hydration, sensation, thermoregulation, vitamin D synthesis, immune function and
ultraviolet radiation protection (2, 5). This unique tissue is composed of two
morphologically and functionally distinct layers: the epidermis and the dermis (1, 6).

1.1.1

The epidermis

The superficial protective layer known as the epidermis is largely composed of stratified
epithelium that continuously renews itself (1). The epidermis is mostly comprised of
keratinocytes (90-95%) that originate from progenitor cells adjacent to the dermis. These
cells undergo progressive differentiation resulting in flattened, anucleated, keratin-rich
cells that form the physical barrier of the skin (1, 5). The epidermis also contains
Langerhan’s cells, melanocytes, Merkel cells, and lymphocytes (1, 2). Immune function
in the epidermis is maintained by lymphocytes and Langerhan’s cells, which are dendritic
cells that process and present antigens to T-cells (1, 2). Melanocytes produce the protein
melanin, which is responsible for skin colour and protection from ultraviolet radiation (1,
2). Lastly, Merkel cells are mechanoreceptors that make contact with sensory neurons
and are involved with the sensation of touch (1, 2).
The epidermis is typically composed of four, and in some cases five, continuous layers
known as stratum. From lower to upper epidermis, they are the stratum basale (the only
layer capable of cell division), stratum spinosum, stratum granulosum, stratum luciderm
(a layer only found in the palms and soles) and the stratum corneum (1, 2, 6). Since the
epidermis is avascular, it relies on the vasculature in the adjacent dermis to provide
nutrients. Therefore, as keratinocytes divide and move up through the epidermal layers
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and away from the dermis, they receive fewer nutrients, undergo terminal differentiation
and are ultimately shed by abrasion (1, 2). The epidermis is connected to the underlying
dermis by the dermal-epidermal junction that facilitates the exchange of metabolic
products between the stratum basale and the dermis (1, 2).

1.1.2

The dermis

The primary role of the dermis is to provide structure and tensile strength to the skin (1,
2, 6). The dermis is divided into 2 layers, the papillary and reticular dermis (1, 2, 6). The
papillary region is adjacent to the epidermis and contains the vasculature that allows for
the exchange of metabolic products between the epidermis and dermis (1, 2, 6). The
papillary dermis is also rich in nerves and nerve endings, both of which are responsible
for transmitting the sensation of heat and touch (1, 6). The deeper reticular dermis is
composed of fibroblasts, blood vessels, lympathic vessels and extracellular matrix (ECM)
proteins including collagens and elastins (1, 6). Fibroblasts are the heterogeneous
population of cells of mesenchymal origin that synthesize and secrete collagens,
proteoglycans, fibronectin, matrix metalloproteinases (MMPs) and other ECM proteins
that make up the papillary and reticular dermal layers (7). The organization of these ECM
proteins provides tensile strength and structure to the skin (2). The reticular dermis also
supports the skin’s appendages including hair follicles and various glands, including
sweat glands (1, 2, 6).
Below the dermis is a layer known as the hypodermis that primarily consists of
subcutaneous fat. Although not technically part of the skin, the hypodermis functions to
anchor the skin to the underlying muscle and bone, and supplies the dermis with blood
vessels and nerves (1, 6). Other than adipocytes, the hypodermis is also home to mast
cells, lymphocytes, and fibroblasts, and contributes to thermoregulation, energy storage,
immune response, and protection from mechanical injuries (1, 6).
Since the skin acts as a physical, chemical, and adaptive barrier to external insults,
damage to the skin can leave an individual susceptible to a number of pathological
conditions (8). Upon injury, the body needs to rapidly and effectively repair the wound to
prevent infection and restore integrity to the skin (8).
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1.2 Normal cutaneous wound repair
Integumental injuries are defined as any insult or disruption to the normal structure and
function of the skin (9, 10). These injuries can range from a small break that disrupts
epithelial integrity to injuries extending deep into the dermis and subcutaneous tissue (11,
12). The complex process required to repair injury, wound repair, is divided into 3
overlapping phases: the inflammatory, proliferation and remodelling phases (Figure 1.1,
(10)). In each phase, several important molecular, humoral and cellular events occur in
order to regenerate the protective barrier of the skin (10). The important features of each
phase of normal cutaneous wound repair are described in the following sections.

1.2.1

Hemostasis and the inflammatory phase

Immediately after insult to the dermis, the inflammatory phase begins with a process
known as hemostasis, characterized by the formation of a blood clot and cessation of
bleeding (8). Fibrin, platelets and disrupted blood vessels play an important role in
mediating this process. Minutes after injury, a clot is formed comprised mainly of fibrin
and platelets (8). The formation of the clot not only prevents blood flow, it also acts as a
provisional matrix for inflammatory cells and fibroblasts to infiltrate the wound (12).
This provisional matrix is also a repository for growth factors and cytokines (12). During
hemostasis, activated platelets in the provisional matrix excrete the growth factors and
cytokines in their granules. One of these cytokines is transforming growth factor (TGF)β,
a molecule that is utilized by numerous cell types in all phases of wound healing (8, 13,
14). In addition to the formation of a fibrin clot, vasoconstriction occurs at the site of
injury, thereby preventing blood flow and contributing to hemostasis (8).
Vasoconstriction lasts upwards of 15 minutes and is mediated by the release of
vasoactive amines from injured cells (15, 16). Local vasoconstriction, in concert with
activated platelets, allows for the accumulation of growth factors and cytokines in the
provisional matrix and promotes the recruitment of inflammatory cells and fibroblasts to
the wound (10).
Once hemostasis is achieved, vascular changes occur that result in vasodilation and
increased capillary permeability (8). The increased blood flow into the wound facilitates
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Figure 1.1 Schematic representation of the phases of cutaneous wound repair.
Normal cutaneous wound repair progresses through three overlapping phases following
insult to the dermis. (a) The inflammatory phase is characterized by clot formation,
vascular changes and recruitment of inflammatory cells, including macrophages, to the
wound. Inflammatory cells are a major source of growth factors and cytokines that
promote the proliferation phase. (b) The proliferation phase is marked by
reepithelialization, angiogenesis, fibroblast migration and proliferation, collagen
deposition and myofibroblast-mediated wound closure. (c) During the remodelling phase,
collagen synthesis, degradation and ECM remodelling occur in order to restore strength
to the wound. As the wound heals and the mechanical tension in the ECM is reduced,
myofibroblasts and inflammatory cells undergo apoptosis. (d) The net result is a mature
scar with high tensile strength. (e) When wound healing signals persist, excessive
fibroblast proliferation and myofibroblast differentiation promote “overhealing”
characterized by excessive ECM deposition and remodelling leading to the formation of
abnormal scars.
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the migration of inflammatory cells (8), such as polymorphonuclear cells (PMNs) and
macrophages, that are attracted to the wound by growth factors and cytokines such as
TGFβ-1 (10, 12, 16, 17). PMNs and activated macrophages remove cellular debris,
foreign particles and bacteria, and are a major source of the proinflammatory cytokines
(13, 16, 18, 19) that regulate the inflammatory phase and initiate the proliferation phase
(8, 13, 20, 21).

1.2.2

The proliferation phase

The proliferation phase is characterized by the formation of granulation tissue, dermal revascularization and the re-establishment of the protective barrier of the skin. Fibroblasts
play a vital role in the proliferation phase as they produce the ECM proteins, including
collagens, that make up the granulation tissue (8). The provisional matrix is initially
devoid of fibroblasts, therefore fibroblast migration, proliferation, and ECM deposition
are vital for the regeneration of a functional dermis (8). Plasma-derived fibronectin (22)
and TGFβ-1 are components of the provisional matrix that stimulate fibroblast migration
to the wound (13, 23). Once within the wound, fibroblasts secrete components of the
ECM, including collagens and fibronectin, and growth factors that regulate the function
of other cells in the matrix (8). The ECM provides a scaffold for cell adhesion and
regulates the growth, migration, and differentiation of the cells within it (24, 25).
Collagen production begins approximately 3-5 days after injury and is stimulated by a
number of cytokines including TGFβ-1 (13, 16). In normal skin and mature scars, dermal
collagen is composed of 80-90% type I collagen and 10-20% type III collagen. In the
early stages of wound healing, the proportion of type III collagen increases to
approximately 30% (8). Collagen deposition not only provides strength to the wound but
also provides structural support for capillary formation and re-epithelialization (8) .
The revascularization of the wound is a complex, but important, component of the
proliferation phase. Cytokines, including TGFβ-1 (26), activate endothelial cells at the
wound site, resulting in the release of proteolytic enzymes, such as MMPs, that dissolve
the basal lamina (10). This allows the activated endothelial cells to proliferate and
migrate within the wound. These newly built vessels interconnect with each other
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forming a vessel loop (10). These new vessels differentiate into arteries and venules and
restore blood flow to the newly formed granulation tissue (10).
Re-epithelialization is another important process in the proliferation phase and is required
to restore the protective barrier of the skin. Keratinocyte migration across the provisional
matrix and newly formed granulation tissue is stimulated by a lack of contact inhibition
and growth factor stimulation (8, 10). As migration proceeds, keratinocyte proliferation
occurs at the wound edge to replace the cells and provide more cells for the migrating
sheet (8, 10). Migration ceases when cells from opposing sides of the wound come in
contact (8, 10). Once contact inhibition is established, the keratinocytes proliferate and
differentiate to re-establish the stratified epithelium, thus restoring the skin’s protective
barrier (8, 10).

1.2.3

Myofibroblast differentiation

A major event in the proliferation phase is the differentiation of fibroblasts into
contractile myofibroblasts. Myofibroblasts are the primary ECM producing cells in
normal cutaneous wound healing and are responsible for the contracture of the
granulation tissue during repair (27, 28). The myofibroblast was first identified in
granulation tissue over forty years ago as a fibroblastic cell with a prominent
endoplasmic reticulum and contractile microfilament bundles (29). The primary
distinguishing feature of myofibroblasts is the neo-expression of alpha smooth muscle
actin (αSMA) in stress fibres, allowing these cells to exhibit a hyper-contractile
phenotype (30). Myofibroblasts are generally negative for smooth muscle myosin heavy
chain, desmin, h-caldesom, and smoothelin, thereby distinguishing myofibroblasts from
smooth muscle cells (31). In addition to fibroblasts, pericytes, vascular smooth muscle
cells, cells undergoing epithelial-mesenchymal transition (EMT) and fibrocytes have all
been implicated as precursors for myofibroblasts (32-37). Myofibroblasts combine the
contractile features of smooth muscle cells with the extensive ECM production of
fibroblasts (29, 31) thus allowing for deposition, contraction, and remodelling of the
granulation tissue.
Fibroblasts in unwounded skin are stress shielded by the highly organized and crosslinked ECM that surrounds them. Following insult to the dermis, the initial contraction of
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the wound by the tractional forces imposed by migrating fibroblasts, increases the
mechanical tension in the granulation tissue (29, 38). This increase in ECM tension
promotes the differentiation of fibroblasts into “proto”-myofibroblasts, characterized by
the formation of stress fibres containing β and γ actin, mature focal adhesion formation,
and de novo expression of the fibronectin splice variant, ED-A fibronectin (38, 39). Stress
fibres connect to the ECM through integrin-associated focal adhesion complexes, while
cell-cell interactions occur through de novo N-cadherin expression. The net result is an
environment under high mechanical tension that allows the fibroblasts to stabilize their
proto-myofibroblast phenotype (37).
Three events are required for the differentiation of proto-myofibroblasts into
differentiated myofibroblasts characterized by the de novo expression of αSMA in their
stress fibres (Figure 1.2, (30)). The first is the accumulation of cytokines such as active
TGFβ-1, which induces αSMA expression (40, 41). Platelet granules, immune cells, and
fibroblasts secrete TGFβ-1 in a latent form that is activated by increased mechanical
tension within the ECM and by ECM-associated proteases (13, 42). Second, an
accumulation of ED-A fibronectin in the ECM is required for myofibroblast
differentiation (39). Lastly, the cells need to be stimulated by the increase in ECM
tension generated by ECM remodelling (30). Specialized cell-ECM junctions termed
fibronexus (in vivo) or “supermature” focal adhesions (in vitro) mediate this
mechanoperception (43). The rigidity of the ECM determines the size of these cellular
attachments to the ECM (43). αSMA can only become incorporated into pre-existing
actin stress fibres once the ECM is stiff enough to allow the formation of supermature
focal adhesions (suFAs, (43)). The formation of suFAs in combination with αSMA
induction allows myofibroblasts to exert a 2-4 fold higher contractile stress on the ECM
(43). A feedback loop between enhanced suFA formation and an ECM tension that is
above threshold levels can maintain myofibroblasts in a differentiated state (43, 44).
In addition to secreting ECM proteins into the granulation tissue, myofibroblasts utilize
their contractile machinery to achieve wound closure. This contractile force is generated
by contractile stress fibres composed of actin bundles, non-muscle myosin, and actinbinding proteins, and is regulated by myosin light chain (MLC) phosphorylation
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Figure 1.2 Schematic representation of the events required for myofibroblast
differentiation. Fibroblasts in unwounded tissue are void of stress fibers and focal
adhesions. Upon wounding, initial closure of the wound by migratory fibroblasts
increases ECM tension leading to the formation of proto-myofibroblasts. Protomyofibroblasts are characterized by the formation of stress fibers, mature focal adhesions
and de novo expression of the fibronectin splice variant, ED-A fibronectin. Contractile
forces generated by proto-myofibroblasts increase the mechanical tension in the ECM
resulting in the formation of supermature focal adhesions and increased levels of active
TGFβ-1 and ED-A fibronectin. The presence of mechanical tension, TGFβ-1 and ED-A
fibronectin leads to myofibroblast differentiation characterized by de novo expression and
incorporation of alpha smooth muscle actin into their stress fibers, giving these cells a
hypercontractile phenotype. Figure adapted with permission from the authors from
Tomasek et al (30).
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(30, 45-47). Myofibroblasts utilize two signalling pathways to regulate MLC
phosphorylation, the calcium dependent MLC kinase pathway and the Rho kinase
(ROCK) pathway. An increase in intracellular concentrations of calcium activates MLC
kinase, which promotes myofibroblast contraction through direct phosphorylation of
MLC (46, 48). Since increased calcium levels are often transient, this contraction is rapid
and short-lived and is actively inhibited by the effects of MLC phosphatase on MLC
(30). In the ROCK pathway, guanosine-5’-triphosphate (GTP) bound RhoA activates
ROCK (49, 50), which leads to increased MLC phosphorylation by two mechanisms. The
first mechanism is by direct phosphorylation of MLC (51). The second mechanism is
through MLC phosphatase inhibition (52, 53). Since MLC phosphatase activity is
required for terminating myofibroblast contraction, its inhibition results in sustained
contraction (30). Myofibroblast contractility in combination with ECM synthesis and
degradation leads to connective tissue remodelling that includes the irreversible and longterm contracture events that result in wound closure and increased wound strength.

1.2.4

Remodelling phase

The remodelling phase represents a balance between collagen synthesis, collagen
degradation, and collagen remodelling (8, 12) with the net result of increasing the
strength of the wound. Net collagen production by fibroblasts peaks around three weeks
after wounding, after which collagen production decreases (8, 16). As collagen
production decreases, collagen degradation increases and several remodelling processes
are initiated to enhance the strength of the wounded skin. Type III collagen and
proteoglycan levels decrease while fibroblasts secrete increasing amounts of type I
collagen, which imposes greater mechanical strength (8, 10). In the early stages of wound
repair, the collagen is arranged haphazardly, resulting in the visual appearance of a “scar”
(8). As the scar matures, wound strength increases as the collagen fibers become shorter,
thicker, more organized and cross-linked due to contraction by myofibroblasts (8, 12). A
mature scar has approximately 80% of the strength of unwounded skin (8, 12), indicating
that wound repair falls short of true skin “regeneration”. As the wound heals and
mechanical stress of the ECM is relieved, the number of myofibroblasts and macrophages
is reduced via apoptosis (8, 12). Over time, capillary growth ceases and blood flow to the
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wound site decreases, resulting in reduced metabolic activity within the wound site (12).
The net result is a relatively acellular and avascular mature scar with high tensile strength
that approaches, but does not achieve, that of unwounded skin.

1.3 Abnormal cutaneous wound healing
Potentially, non-healing chronic wounds or excessive cutaneous scarring can arise from
any aberration of processes that contribute to normal cutaneous wound healing.
Abnormalities in cell migration, proliferation, inflammation, ECM secretion, cytokine
synthesis, and apoptosis can prevent normal wound repair (54) or conversely, contribute
to excessive scar formation (55). Factors that promote excessive fibroblast proliferation
and myofibroblast persistence leads to an “overhealing” phenomenon characterized by
excessive collagen deposition at the site of injury, termed fibrosis (10), and contracture of
the ECM (56, 57) that result in raised, collagenous scars. The associated pathological
contracture of the skin can cause major clinical problems, and there are few treatment
options. Abnormal cutaneous scarring can be divided into two broad categories,
hypertrophic scarring and keloid scarring. The following sections will discuss the
clinical, histological, and epidemiological characteristics of both hypertrophic and keloid
scars and their treatment options.

1.3.1

Clinical features of abnormal cutaneous wound healing

Hypertrophic scars are clinically defined as raised collagenous scars that are confined to
the borders of the initial wound (58). These scars occur 4-8 weeks following insult to the
dermis, have a rapid growth phase of up to six months, then gradually regress over a
period of years, eventually leading to a flat scar (59). In contrast, keloid scars extend
beyond the borders of the initial wound, may develop several years after injury, or
spontaneously, and do not regress over time (Figure 1.3, (58, 59)). Hypertrophic scars
tend to occur at areas of high tension such as the shoulders, neck, pre-sternum, knees and
ankles (59). In comparison, keloid scars tend to form on the shoulders, anterior chest, ear
lobes, upper arms and the cheeks (59). Recurrence of hypertrophic scars following
surgical incision is rare, however recurrence rates are high with keloid scars (59). Other
than imposing a financial burden, these conditions impose morbidity that is difficult to
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Figure 1.3 Clinical presentation of hypertrophic and keloid scars. (a) Clinical
presentation of hypertrophic scarring following lymph node resection in the inguinal
region. Hypertrophic scars present as raised collagenous scars that are confined to the
borders of the initial wound. (b) Clinical presentation of keloid scarring on the anterior
chest and the neck. In contrast to hypertrophic scars, keloid scars are able to extend
beyond the borders of the initial wound. Photographs c/o Roth|McFarlane Hand and
Upper Limb Centre.
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quantify, including pain and loss of mobility, especially if the scar is associated with a
joint (60). Furthermore, these scars are disfiguring and can adversely affect a patient’s
quality of life both physically and psychologically (60, 61).

1.3.2

Histological features of abnormal cutaneous wound healing

Histologically, both hypertrophic and keloid scars contain excessive amounts of collagen
(59). Hypertrophic scars contain primarily type III collagen fibres arranged in a wavy
pattern parallel to the epidermal surface (58). These scars also contain abundant nodules
of myofibroblasts, small blood vessels, and large extracellular collagen filaments (58,
59). In contrast, keloid scars are composed of disorganized type I and III collagen fibres
randomly oriented to the epidermal surface (59). These scars have poor vasculature,
contain hypocellular collagen bundles and lack the excessive numbers of myofibroblasts
evident in hypertrophic scars (59). Proliferating cell nuclear antigen, p53 and adenosine5’-triphosphate (ATP) levels are elevated in keloid scars, suggesting that they are
primarily the result of excessive fibro-proliferation and potentially explaining why they
grow beyond the site of the original injury (62, 63). Both hypertrophic and keloid scars
display increased immune cell infiltration, increased levels of TGFβ-1 and myofibroblast
persistence, however these features decline over time in hypertrophic scars and may
explain why hypertrophic scars regress (58, 59, 62).

1.3.3

Epidemiological features of abnormal cutaneous wound
healing

Hypertrophic and keloid scars have equal sex distribution and have the highest incidence
rates in the second and third decade of life (59). Hormones may affect hypertrophic and
keloid scar formation, as these scars tend to occur during puberty and pregnancy and the
scars can decrease in size following menopause (59, 64, 65). The incidence of
hypertrophic scars is probably higher than keloid scars, however there is currently
insufficient data available to make robust comparisons (62). Incidence rates for
hypertrophic scars vary from 40-70% following surgical incision and up to 91%
following burns (66, 67). With the exception of albino individuals, keloid scars can
develop in people of any skin color, however, dark skinned individuals are more
susceptible with incidence rates as high as 16% in African populations (59). The
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formation of hypertrophic scars does not appear to have any association with skin
pigmentation (68). The notion of genetic predisposition has been suggested, as patients
with keloid scars report a positive family history that is strongly associated with keloid
formation at multiple anatomical sites (59, 69). In contrast, patients with hypertrophic
scars typically report no family history of scar development (59).

1.3.4

Treatments

Increased tension at wound margins has been implicated in the development of
hypertrophic scars, and several prophylactic approaches have been implemented on this
basis to reduce hypertrophic scar development (59). Pressure therapy and silicone gel
sheeting have been used to apply continuous pressure to the scar during wound repair.
These approaches have shown little success and cause discomfort leading to reduced
patient compliance (70). TGFβ-3, which has been shown to reduce connective tissue
deposition and is induced during the late stages of wound healing (71-73), has been used
as a prophylactic approach to prevent scar formation. While initial studies showed
evidence for the benefits of recombinant TGFβ-3, further independent studies revealed
that this treatment was unsuccessful in improving scar resolution (74). Current treatment
strategies include corticosteroid injections, cryotherapy, surgical resection, radiotherapy,
and laser therapy. These treatment strategies have varied success rates in the resolution of
hypertrophic and keloid scars and can be associated with painful and disfiguring side
effects, risk of malignancy (in the case of radiotherapy), and high recurrence rates
(surgical and laser therapy) (59, 70) . Emerging treatment strategies include interferon
injections, which reduces collagen synthesis, and 5’-fluorouracil treatment to increase
fibroblast apoptosis. These treatments have also demonstrated varied success rates and
can present painful and harmful side effects (59, 70).
Although some treatments have been shown to be effective in reducing hypertrophic and
keloid scar formation in individuals, few of these studies have been supported by welldesigned studies with adequate control groups (59). Despite numerous studies, both in
vitro and in vivo, there is limited information available regarding the cellular mechanisms
that induce hypertrophic and keloid scar formation (59). One reason for our lack of
knowledge of the cellular and molecular mechanisms involved in the development of

14
abnormal scars is a lack of representative and physiologically relevant animal models of
hypertrophic scar formation (59). Therefore, gaining a better understanding of the
biochemical processes involved in abnormal wound healing is crucial if we hope to
achieve normal skin repair or, optimally, true skin regeneration in patients prone to
abnormal scarring.

1.4 TGFβ-1 is a difficult therapeutic target
As highlighted in the previous sections, TGFβ-1 plays essential roles in normal cutaneous
wound healing. In addition to these roles, excessive signalling by this cytokine has been
implicated in hypertrophic and keloid scar formation (58, 59, 62). TGFβ-1 has proven to
be a difficult therapeutic target in many disease processes including abnormal scar
formation, as it can exert pleiotropic effects on different cell types that can be diverse
and, in some cases, seemingly paradoxical (75, 76). While TGFβ-1 is one of several
cytokines that attract PMNs and macrophages to the wound (10, 12, 16, 17), depletion of
TGFβ-1 in Tgfb null mouse models results in a lethal and widespread inflammatory
response, revealing an essential anti-inflammatory role for this cytokine (77, 78).
Knockdown of TGFβ-1, its receptor, or signalling components in mouse models inhibits
normal repair in the dermis (79-82), whereas TGFβ-1 promotes matrix formation for
keratinocyte migration while inhibiting keratinocyte proliferation (83, 84). In vitro
studies demonstrate that TGFβ-1 can promote fibroblast proliferation without affecting
myofibroblast differentiation or myofibroblast differentiation without affecting
proliferation, in the same cell line (75). These apparently paradoxical outcomes are likely
to be the result of concurrent activation of other signalling pathways that modify and
supplement the downstream effects of TGFβ-1 signalling intermediates. For this reason,
the identification of TGFβ-1-inducible proteins that supplement, enhance or modify
TGFβ-1 signalling to promote pathological, rather than normal, fibroblast proliferation
and/or myofibroblast differentiation may have greater utility as therapeutic targets than
TGFβ-1 itself.
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1.5 Identification of TGFβ-1-inducible proteins in abnormal
wound healing
During cutaneous wound healing, TGFβ-1 is released into the ECM by platelet granules,
inflammatory cells and fibroblasts (13, 83) in an inactive form in association with
latency-associated peptide (LAP) and latent TGFβ-1 binding protein-1 (LTBP-1) (31).
Extracellular matrix proteins associate with LTBP-1 creating a reservoir of latent TGFβ-1
(85-87). Latent TGFβ-1 bound in the ECM can interact with cells through integrin
binding sites located in the LAP (85, 88). Stress applied to these integrins, either by
stretching the ECM or by inducing cellular contraction, results in a conformational
change in the large latent complex allowing the release of TGFβ-1 in an active form (42).
Mechanical activation of TGFβ-1 enhances tissue remodelling by translating the level of
ECM stiffness into pro-fibrotic signals (31). Therefore, the ECM is an important
regulator of TGFβ-1 activation in both normal and abnormal wound healing.

The ECM is comprised of both structural and non-structural proteins (89, 90). Structural
proteins, such as collagens and fibronectin, provide strength to the dermis and act as
scaffolds for migrating cells and as reservoirs for growth factors (8). Non-structural
proteins within the ECM include cytokines like TGFβ-1 and the family of “matricellular”
proteins that modify cell signalling in response to extracellular stimuli, such as changes in
mechanical tension of the ECM (40, 42, 90). Given the well-established roles of the
ECM in scar formation, studies were focused on the roles of non-structural proteins in the
ECM that might be activated by and/or act in combination with TGFβ-1 to promote
excessive scarring.

Initial studies in our laboratory showed increased expression of genes encoding ECM
proteins in Dupuytren’s Disease, a fibro-contractile disease of the palmar fascia that has
many similarities to abnormal scarring. Microarray analyses of tissues derived from
patients with or without Dupuytren’s disease identified POSTN, encoding the
matricellular protein periostin, as a very highly upregulated transcript (91). Subsequent in
vitro experiments demonstrated that periostin induced fibroblast survival and
myofibroblast differentiation in primary fibroblasts derived from Dupuytren’s disease
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tissue and induced proliferation of fibroblasts derived from “pre-diseased” palmar fascia
(91). As excessive fibroblast proliferation and increased myofibroblast differentiation
and persistence are also characteristics of hypertrophic scarring (56, 57, 92-94), further
studies were performed to investigate whether periostin expression was abundant in
hypertrophic scar tissue. Western immunoblotting, immunohistochemistry and in-situ
hybridization data performed by our laboratory (95, 96) and reports by other groups (9799) demonstrated that POSTN expression was upregulated in the basal stratum of
hypertrophic and keloid scar tissue relative to mature normal scar tissue. Levels of the
translated product of POSTN mRNA, periostin, were also upregulated in the dermis (but
not the basal stratum) of hypertrophic and keloid scar tissue relative to normal mature
scars. Based on these studies, it was proposed that periostin might contribute to
excessive fibroblast proliferation and myofibroblast differentiation in hypertrophic
scarring.

1.6 Periostin
1.6.1

Gene and protein structure

Periostin was originally identified as osteoblast-specific factor 2, a novel cell-adhesion
molecule, in a mouse osteoblastic cell line (100, 101). Using murine cDNAs as probes,
human homologs encoding a protein with a molecular weight of up to 93 kDa were
subsequently identified in placental and osteosarcoma cDNA libraries (100, 102).
Osteoblast-specific factor 2 was later renamed periostin due to its preferential expression
in cells of mesenchymal origin located in the collagen rich ECM surrounding the
periosteum and periodontal ligament (101). The murine periostin gene, Postn, located on
chromosome three and the human gene, POSTN, located on chromosome 13, are highly
homologous. Amino acid identity between the two species is 89.2% for the entire protein
and 90.1% for the mature processed forms (100). POSTN encodes 23 protein-coding
exons over a genetic footprint of 36 kilobases (102). POSTN expression is upregulated by
a number of factors involved in wound healing including TGFβ-1, interleukins, plateletderived growth factor and fibroblast growth factor (101, 103, 104).
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The N-terminal signal sequence of periostin consists of 23 amino acids and lacks a
transmembrane domain, suggesting that periostin is a secreted protein (100). This is
consistent with pronounced immunoreactivity to periostin in the ECM surrounding the
periosteum and periodontal ligaments (101). Following the signal sequence is a cysteinerich Emilin-like (EMI) domain encoded by exons two and three (100, 102). EMI domains
are typically involved in protein-protein interactions (105) and protein multimerization,
and periostin dimers have been reported in some studies (106). Adjacent to the EMI
domain are four repeated regions of 150 amino acids encoded by exons 3-14 (100, 102).
These repeats share homology with the insect axon guidance protein fasciclin 1 (FAS1),
an adhesion module (100, 107). Since periostin contains FAS1 domains, it has been
assigned to the fasciclin family of proteins that includes stabilin 1 and 2, and TGFβinduced gene clone 3 (βig-h3) (108). Each FAS1 domain contains two conserved regions
of 13-14 amino acids that have high sequence similarity. However, the conserved repeats
between the FAS1 domains have relatively low sequence homology (100). Each FAS1
domain contains glutamate residues and contains N-terminal recognition sites for γglutamylcarboxylase, an enzyme responsible for posttranslational modification of
glutamate residues (109). The FAS1 domains are believed to be involved in cell adhesion
and protein-protein interactions, as bone morphogenic protein-1, tenascin C, and integrins
have been suggested to bind this region of periostin (110-112). Interestingly, periostin
does not contain any canonical Arg-Gly-Asp (RGD) integrin binding motifs, suggesting
that integrin binding by periostin is independent of these motifs (102). βig-h3, which has
a domain structure similar to periostin (102), has been demonstrated to bind α3β1
integrins at sites that are independent of the RGD motif (112). This interaction occurs by
two pentapeptides containing a central Asp-Ile (DI) dimer located in the second and
fourth FAS1 domain (112). The DI dimer has a similar conformation to the RGD binding
motif (113) and suggests a mechanism for periostin-integrin interactions (102).

Lastly, exons 16-23, accounting for 182 amino acids, make up the hydrophilic or Cterminal domain (102). This region is devoid of known domains, contains few known
sequence motifs and contains a C-terminal nuclear localization signal at exon 22-23
(102), suggesting that periostin may also have intracellular functions (114). Exons 17-21
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Figure 1.4 Schematic representation of the human POSTN gene and domain
structures. The human POSTN gene contains 23 protein-coding exons. Exon 1 encodes a
signal sequence (SS), characteristic of secreted proteins. Exons 2-3 encode for the
Emilin-like (EMI) domain involved in protein-protein interactions and protein
multimerization. Exons 3-14 encode four repeated fasciclin 1 (FAS1) domains involved
in cellular adhesion and protein-protein interactions. Purple arrows represent recognition
sites for γ-glutamylcarboxylase and vertical black bars represent proposed integrin
binding sites in FAS1 repeats 2 and 4. Exons 17-21 present themselves as exon cassettes
that can be present or deleted in mature mRNA through alternative splicing events. Exons
22-23 encode a C-terminal nuclear localization signal (NLS). Red oval represents heparin
binding site in exon 23.
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can be considered as “exon cassettes” that can be included or deleted in mature mRNA in
various combinations through alternative splicing events (100-102). This results in
several periostin isoforms ranging in size from 83-93 kDa (115) . The number of
nucleotide residues in each exon cassette is a multiple of three, and therefore deletion or
inclusion of any of these cassettes in the mature mRNA does not result in frameshift
mutations (100). Initial studies identified four periostin isoforms in mouse and five
isoforms in human tissues (100, 101), with additional studies expanding the latter to eight
isoforms (116, 117). These isoforms appear to be differentially expressed during
development and injury and appear to be tissue, developmental stage or disease specific
(114, 118-121). However, the function(s) of each individual isoform remain unclear.
Secondary structure predictions demonstrate consecutive beta strands as the predominant
structure in the C-terminal domain (102). βig-h3, which lacks this domain, has not been
reported to interact with collagen or fibronectin. Therefore it has been proposed that the
C-terminal domain’s beta strand structure may facilitate periostin binding to collagen and
fibronectin (102). Periostin contains similar repeats to those found in various bacteria that
are able to bind fibronectin through an extended beta zipper (102, 122). Therefore, the
strength of periostin’s interaction with the ECM would be influenced by the number of
beta strands present in the mature protein determined by alternative splicing (102).
Lastly, the C-terminal domain contains a heparin binding site in exon 23, creating a
potential binding site for glycoproteins and proteoglycans (Figure 1.4, (101)).

1.6.2

Classification as a matricellular protein

Periostin has been classified as a matricellular protein (123), i.e. one of a family of
structurally unrelated ECM proteins that do not serve a structural role in the ECM but
instead serve as a link between the ECM and cells and modify cell behavior in response
to external stimuli (90, 124). Originally, this family of proteins consisted of
thrombospondin, tenascin-C and SPARC but recent studies have classified osteopontin,
periostin and members of the CCN family, including CCN2, as matricellular proteins
(125). Several characteristics have been identified for the classification of matricellular
proteins. 1) Matricellular proteins interact with structural components of the ECM,

20
receptors, growth factors and proteases thereby allowing these proteins to regulate
cellular signalling cascades (125). 2) Matricellular proteins promote an intermediate
cellular adhesive state (126) that activates survival signals and increases expression of
genes associated with adaptation and repair (125). 3) In normal adult tissue, expression of
matricellular proteins is low, but is upregulated in response to injury or during
development (125). 4) Mice with targeted disruption in matricellular genes have subtle
abnormalities in the absence of injury. However, loss of these proteins results in a wide
range of alterations in injured and remodelled tissue (125).

The first characteristic of matricellular proteins is their ability to bind ECM proteins,
proteases and growth factors and to transmit external signals to the cell to modulate
cellular phenotypes through receptor-mediated activation. Periostin has been
demonstrated to bind several structural ECM proteins including type I and V collagen
and fibronectin as well as other matricellular proteins including tenascin-C (104, 106).
Bone morphogenic protein-1, a metalloproteinase, interacts with periostin inducing the
cleavage and activation of lysyl oxidase required for collagen cross linking (127).
Periostin has been shown to bind integrins αvβ3, αvβ5, α5β1, β1 and α6β4 in various systems
(127-135), presumably through its FAS1 domains. Integrins mediate cell-ECM
interactions and transmit signals from the ECM to modulate cell behavior (136, 137).
Periostin signalling through αvβ3 and α6β4 has been shown to promote tumour cell
survival through PI3K/Akt in human colon cancer cells and pancreatic ductal
adenocarcinoma cells cultured on tissue culture plastic (129, 130). Periostin signalling
through αvβ3 and αvβ5 can promote the migration of human ovarian epithelial cells,
pancreatic ductal adenocarcinoma cells and mouse smooth muscle cells through Akt and
FAK dependent pathways (128, 130, 134). Additionally, periostin has been shown to
signal through αvβ3, αvβ5 and β1 integrins to induce the proliferation of rat
cardiomyocytes (132). It should be noted, however, that very few of these signalling
intermediates and pathways were assessed on physiologically relevant culture substrates
or within an ECM, where periostin could act as a matricellular molecule.
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The second characteristic of matricellular proteins is their ability to promote cellular deadhesion that activates survival signals and induces expression of genes associated with
repair. Periostin has been implicated in promoting a “de-adhesive” state in the stroma of
cancers and its presence is correlated with malignant tumor invasion and metastasis (128,
129, 138-141). In the presence of periostin, tumour cells enhance their invasive activity
by forming fewer stress fibres and increasing motility (128). Periostin transfected cancer
cells demonstrate morphological changes and increased mesenchymal cell markers
suggesting that periostin may induce cancer cell invasion through EMT (142). Periostin
has also been shown to promote survival through ECM-receptor activation in cancers,
bone and periodontal ligaments. Enhanced survival induced by periostin in cancers is
mediated through PI3K and Akt activation (129, 130). In the periosteum and periodontal
ligament, periostin-null mice have reduced expression of Notch 1 and its downstream
effector Bcl-xL (143, 144). Notch proteins are transmembrane receptors that play an
important role in cell survival under mechanical stress (145). Periostin binding to notch
under stressed conditions increases expression of Bcl-xL leading to inhibition of
apoptosis (121). Periostin expression has also been correlated with proteins associated
with repair. Studies utilizing periostin-null mice have demonstrated reduced collagen
fibrillogenesis and aSMA levels in cardiac repair and normal cutaneous wound healing
(106, 120, 133). Collagen remodelling and myofibroblast differentiation are important
processes in normal wound repair.

The expression of matricellular proteins is usually low in most normal adult tissues but is
upregulated during embryonic development and in response to injury. Periostin is highly
expressed by fibroblasts in the embryonic myocardium and developing neonatal heart. In
adult hearts, periostin expression is decreased and is primarily localized to the supporting
structures of the heart valves that are subjected to mechanical tension. (123, 146, 147). In
mouse skin, periostin is highly expressed during embryonic development in
keratinocytes, at the basement membrane and in the dermis, however expression
significantly decreases in adult mice (97). Unlike most matricellular proteins that are
expressed at low levels in adult tissue, periostin expression in adult tissue is high in
collagen-rich tissues under mechanical stress such as the periosteum, periodontal
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ligaments, tendons, cardiac valves, and the skin (98, 101, 106, 123). A marked increase in
periostin is seen in patients with myocardium infarction, advanced heart failure, and
atherosclerotic and rheumatic value disease (120, 148, 149). Up-regulation of periostin in
myocardium infarction plays an important role in early scar formation by promoting
migration, myofibroblast differentiation and collagen deposition thereby preventing
cardiac rupture (120, 150). Periostin expression is also upregulated during cutaneous
wound healing (98, 151, 152) and its roles in this process will be discussed in more detail
in the following section.

The final unifying characteristic of matricellular proteins is that their deletion in mouse
models generally results in subtle abnormalities in the absence of injury, but much more
obvious abnormalities following injury. Despite high levels of periostin during
embryonic development in the periosteum, periodontal ligament and heart valves,
periostin-null mice are not embryonic-lethal and appear grossly normal at birth (150,
153). Three to four weeks after birth, periostin-null mice display growth retardation and
dental defects (153). Approximately 15% of periostin-null mice die in the first three
weeks due to cardiac defects (153, 154). Alterations in repair are evident following injury
in periostin-null mice. Following myocardium infarction, periostin-null mice have
increased rates of cardiac rupture resulting from impaired collagen fibrillogenesis and
myofibroblast differentiation (120, 150). Defects in collagen fibrillogenesis and
osteoclast inactivation are evident in the periosteum resulting in decreased bone
formation and mass (121, 155). In normal cutaneous wound healing, periostin-null mice
displayed delayed wound healing caused by defective re-epithelialization and decreased
myofibroblast populations (133, 151, 152). These studies suggest that periostin fulfills the
requirements of a matricellular protein and has roles in tissue repair.

1.7 Periostin in normal cutaneous wound healing
Several groups have assessed the expression of POSTN and periostin during normal
cutaneous wound repair using murine excisional wound healing models. POSTN
expression is detectible in the wound at Day 1 after injury, with peak expression at Day 7
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with an ongoing decrease thereafter approaching baseline levels by Day 18 (152).
Periostin expression is evident in the granulation tissue and in migrating keratinocytes as
early as three days post wounding (98, 151). As increased periostin expression correlates
with increased αSMA levels in the granulation tissue at Day 7 post wounding, some
authors have suggested that periostin may contribute to normal myofibroblast
differentiation (98). By Day 21, periostin expression is absent in keratinocytes and is only
evident in the remodeled ECM (98, 152) and levels return to baseline by Day 28 (98).
The expression pattern of POSTN and periostin over time are currently unclear in human
cutaneous wound healing, due to obvious ethical restrictions in using humans as in vivo
wound healing models.

Only three groups have utilized periostin-null mice in excisional wounding studies to
investigate the roles of periostin during cutaneous wound repair. Periostin-null mice
display delayed wound closure (133, 151, 152) suggesting that periostin may have a role
in re-epithelialization or granulation tissue formation. As periostin-null mice displayed
decreased re-epithelialization despite evidence that periostin does not affect keratinocyte
proliferation or migration (151), it is likely that loss of periostin impairs reepithelialization through an indirect mechanism.

Of the three groups to report excisional wound healing studies in periostin-null mice,
only one has investigated the effects of periostin in the dermis (133). This group
demonstrated that the granulation tissue in periostin-null mice displayed decreased
expression of αSMA and its gene, Acta2, at Day 7 post wounding relative to wild type
controls (133). Similar results were identified in vitro, with decreased αSMA levels
observed in periostin-null fibroblasts cultured in anchored collagen lattices, which
resembles the matrix stiffness of granulation tissue (133, 156). The decrease in
myofibroblast populations in the granulation tissue in these in vivo studies was not due to
impaired fibroblast migration or proliferation (133). However, in vitro studies using
embryonic mouse fibroblasts provided conflicting data, as periostin-null fibroblast
exhibited decreased proliferation, while over expression of periostin induced their
proliferation (152). It is difficult to draw conclusions from these studies as they lacked
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parallel in vivo experiments and utilized embryonic fibroblasts that may have
characteristics that are distinct from adult murine fibroblasts (157). In vitro and in vivo
experiments demonstrated that periostin-null dermal fibroblasts were significantly less
contractile than wild type fibroblasts and that the addition of recombinant periostin was
able to rescue this effect (133). This effect was blocked in the presence of inhibitors
against integrin β1 and FAK and addition of periostin induced FAK phosphorylation
(133, 152). These studies suggest that periostin contributes to normal murine cutaneous
wound healing by facilitating myofibroblast differentiation and contraction through an
integrin-focal adhesion dependent pathway (133).

While these studies suggest that periostin can facilitate myofibroblast differentiation in
murine wound healing models, the substantial differences between mouse and human
skin make it unclear if these findings can be translated to normal human cutaneous
wound healing. Mouse skin is covered in dense hair, lacks rete ridges and adipose sweat
glands, has a thinner epidermis and dermis, has a faster keratinocyte turnover rate and is
significantly more compliant than human skin (158, 159). In contrast, human skin has a
thicker epidermis and dermis, less hair follicles, is relatively stiffer and is adherent to the
underlying subcutaneous tissue (158-161). Mice and humans also heal cutaneous wounds
by different mechanisms. Mice have a muscle layer below the hypodermis in the flanks,
known as the panniculus carnosus, that is absent in most areas of human skin (158). This
muscle layer allows mice to rapidly contract wounds following injury and enhances skin
regeneration with minimal scarring. In contrast, human cutaneous wounds lacking a
similar muscle layer heal through the formation of granulation tissue and reepithelialization, typically leading to the formation of a scar (158, 160, 162). These
profound differences in wound healing mechanisms between mice and humans make it
unclear if the roles of periostin in murine excisional wound healing can be translated to
normal, or particularly abnormal, cutaneous repair in humans.
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1.8 Periostin in abnormal wound healing
Currently, there are no studies in the literature investigating the roles of periostin in the
development of hypertrophic scars in humans. The molecular mechanisms implicated in
the development of excessive scarring remain poorly understood. One reason for this is a
lack of truly representative and physiological relevant animal models of human
hypertrophic scar formation (59). Hypertrophic scarring does not normally occur in
animals (163), and our current understanding of the mechanisms that promote excessive
scarring are largely based on studies of chemically and/or genetically manipulated mice
(164-166). These models can be very useful for investigating the cell types and molecules
involved in scar formation at specific time points. More recently, animals with skin that
more closely resembles human skin, such as the red Duroc pig (167), have been used as
models with and without chemical or other treatments to induce scarring. While more
physiologically relevant than mice, they cannot capture the multifactorial influences, such
as age, sex, wound site and genetic predisposition that promote abnormal scarring in
human patients. Since using humans as wound healing models is not ethically feasible,
the next best option is analyze human scar tissue from patients undergoing surgical
resections. By utilizing primary samples derived from human normal and abnormal scar
tissue, we are able to perform a “top down” approach to identify factors that are elevated
during abnormal scar formation relative to normal skin. Upon identification of such
factors, in vitro studies can be performed on primary human fibroblasts that exhibit many
clinically relevant features of both normal and abnormal scarring. As an in vitro model,
these cells have the disadvantage of being obtained after scar formation has occurred, and
are therefore unlikely to be informative of the initial stages of scar development, such as
those induced by inflammation (59). However, primary fibroblasts derived from
surgically resected hypertrophic tissue can provide clinically relevant models of the
cellular processes that cause the abnormal persistence of scars for months or years,
compared to normal skin wounds that typically heal in weeks.

In situ hybridization studies performed by our lab demonstrated that POSTN expression
was upregulated and persistent in the basal epithelium of human hypertrophic scar
(Figure 1.5a) and keloid scar tissue relative to normal mature scars (96), consistent with
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previous reports (99). Immunohistochemistry studies performed by our laboratory (95,
96) and other groups (97, 98) have shown that periostin levels are abnormally abundant
and localized to dermis in hypertrophic scars (Figure 1.5b and c) and keloid scars.
Periostin is absent in the epidermis, despite clear evidence of POSTN expression,
suggesting that the epidermis may be an additional source of dermal periostin in
abnormal scarring conditions. Based on these findings, we hypothesize that the increased
and persistent levels of periostin in the dermis of hypertrophic and keloid scars may
contribute to excessive fibroblast proliferation and myofibroblast differentiation and
persistence in these fibrotic conditions.

1.9 Assessing the function of periostin in hypertrophic scar
formation in an in vitro model system
In order to assess the role(s) of a matricellular molecule like periostin in abnormal scar
formation in vitro, studies must be performed in a model system that closely resembles
the granulation tissue during wound healing in vivo. Excisional wound healing models
and in vitro studies have been utilized to measure the stiffness of the ECM during wound
healing. Matrix stiffness can be represented by Young’s modulus, which is the ratio of
stress to strain of an elastic substrate. The Young’s modulus of the provisional matrix is
10-1000 Pascals (Pa), indicating that it is very compliant (31). The proto-myofibroblast
phenotype is only evident when matrix stiffness reaches 3000 Pa (168). The stiffness of
granulation tissue in seven day old rat granulation tissue is approximately 18 000 Pa,
consistent with αSMA being incorporated into stress fibers at a Young’s modulus of 16
000 - 20 000 Pa (31). Fibrotic tissue and contracting granulation tissues can exhibit a
matrix stiffness of 25 000 – 50 000 Pa (169). Tissue-culture plates provide an extremely
stiff substrate (~3 gPa, or 3 000 000 000 Pa (170)). A culture substrate of this stiffness
inevitably induces robust and non-physiological influences on myofibroblast
differentiation (31) that has the potential to overshadow any other effects of potential
inducers of myofibroblast formation (133). Despite its routine use for culturing
fibroblasts, tissue culture plastic is a very non-physiological model system in which to
assess cellular processes that are sensitive to matrix tension. To address this issue, our
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Figure 1.5 POSTN expression and periostin levels are increased in hypertrophic
scars. (a) In situ hybridization studies were performed using S35 labeled sense and
antisense transcripts derived from a 391-bp fragment from the 5’ end of a POSTN cDNA.
Paraffin-embedded mixed scar derived from a patient with a phenotypically normal scar
at one edge transitioning to a hypertrophic scar at the opposite edge was exposed to
antisense POSTN mRNA probe to compare POSTN expression across the normalabnormal scarring transition zone (indicated with an arrow). Silver grains deposited due
to exposure to S35 labeled transcripts are evident as white specks under dark field
microscopy. As shown, POSTN expression is much more abundant in the basal
epithelium along the hypertrophic scar section of the mixed scar relative to the normal
scar area. Immunohistochemistry of paraffin-embedded (b) hypertrophic scar and (c)
normal scar tissue with a periostin polyclonal antibody. Periostin immunoreactivity is
evident as brown staining from di-amino precipitation. Periostin is more abundant in
hypertrophic scars relative to normal scars and expression extends deep into the dermis.
Images c/o Cell and Molecular Biology Laboratory, Roth|McFarlane Hand and Upper
Limb Centre.
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laboratory takes the approach of routinely culturing primary fibroblasts on type I collagen
substrates. Type I collagen is the most abundant collagen in the skin and mature scars (8)
and our laboratory has demonstrated that the change in substrate stiffness induced by
culture on collagen substrates can modify gene expression and protein levels in primary
fibroblasts relative to the same cells cultured on stiff tissue culture plastic (91, 171).
Based on these observations, the effects of periostin on fibroblast proliferation and
myofibroblast differentiation were assessed in two- (2D) and three-dimensional (3D)
collagen-based cultures in this thesis to more closely mimic the ECM and substrate
stiffness experienced by these fibroblasts in vivo.

Currently, three dimensional collagen lattices are utilized for examining in vitro the
mechanical interactions that occur between cells and the ECM and how these interactions
induce myofibroblast differentiation (47, 156). When cultured within a collagen lattice,
fibroblasts experience a more complex environment and geometry compared to cells
cultured on plastic (172). Fibroblast attachment, spreading, and migration through the
collagen lattice generate mechanical signals that can modulate cellular phenotype. If the
collagen lattice is mechanically restrained, such as in stressed Fibroblast Populated
Collagen Lattices (sFPCLs) (47), tension develops as tractional forces compact the
collagen fibers (30, 172). As the mechanical tension progressively increases in the
collagen lattice, the fibroblasts will form stress fibers and focal adhesions associated with
proto-myofibroblast and myofibroblast differentiation (156) similar to ECM remodelling
in vivo (30). This tension is sustained in the lattice until it is released from its points of
attachment (30). Newly polymerized 2D and 3D collagen gels have a matrix stiffness of
300-400 Pa (173), which is similar to that seen in the provisional fibrin matrix (31). The
Young’s modulus has not been reported for sFPCLs; however, it is believed to closely
mimic the mechanical environment of the granulation tissue in Day 7 rat wounds, i.e.
approximately 18 000 Pa (31, 44, 156). Using collagen substrates, periostin can be
incorporated into collagenous ECM matrices to mimic its localization in vivo and provide
a reproducible culture system to investigate periostin effect(s) on fibroblast proliferation
and myofibroblast differentiation and persistence under physiological relevant conditions.
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1.10 Hypothesis and objectives
When wound healing signals become abnormal, excessive fibroblast proliferation and
myofibroblast persistence can be induced, resulting in excessive ECM deposition and
remodelling and hypertrophic scarring (56, 57, 92-94). TGFβ-1 is a potent inducer of
myofibroblast differentiation in this context, however it is also implicated in regulating
many of the processes that are essential for normal wound healing (13, 41, 174-177),
making this cytokine a difficult therapeutic target. Therefore, TGFβ-1-inducible proteins
that act in combination with and/or sequentially to TGFβ-1 signalling to promote
pathological, rather than normal, fibroblast proliferation and/or myofibroblast
differentiation may have greater utility as therapeutic targets. Periostin is a novel
matricellular protein that is upregulated in the ECM of hypertrophic scars and may have
potential as such a target. Although several studies have demonstrated that periostin
regulates fibroblast proliferation and myofibroblast differentiation in other systems (91,
132, 133, 152, 178-180), the roles of periostin in hypertrophic scar formation in human
fibroblasts has not been assessed. Therefore, this thesis focuses on identifying the role(s)
of periostin on hypertrophic scar fibroblast proliferation and myofibroblast differentiation
and persistence in 2D and 3D collagen cultures.
The central hypothesis of this thesis is that ECM-associated periostin contributes to
hypertrophic scar formation by promoting excessive fibroblast proliferation and
myofibroblast differentiation and by maintaining myofibroblasts in a differentiated
state.
The following objectives were designed to test this hypothesis:
Objective 1: To assess the effects of periostin on the proliferation of normal skin and
hypertrophic scar derived fibroblasts
Objective 2: To assess the effects of periostin on the differentiation of fibroblasts
derived from normal skin and hypertrophic scar tissues
Objective 3: To identify the mechanism(s) utilized by periostin to induce and maintain
hypertrophic scar myofibroblasts in a differentiated state
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Chapter 2

2

Materials and Methods

2.1 Materials
2.1.1

Biochemicals

Bovine serum albumin (BSA)

Sigma-Aldrich, St. Louis, MO

Glycine

Fisher Scientific, Hampton, NH

Sodium hydroxide

Sigma-Aldrich, St. Louis, MO

Hydrochloric acid

Merck KGaA, Darmstadt, GER

Sodium dodecyl sulfate (SDS)

Sigma-Aldrich, St. Louis, MO

Tris Base

Fisher Scientific, Hampton, NH

Sodium chloride (NaCl)

Fisher Scientific, Hampton, NH

Glacial acetic Acid

Fisher Scientific, Hampton, NH

Potassium chloride (KCl)

Fisher Scientific, Hampton, NH

Potassium phosphate (KH2PO4)

Fisher Scientific, Hampton, NH

Sodium phosphate, monobasic (NaH2PO4) Fisher Scientific, Hampton, NH
Sodium phosphate, dibasic (Na2HPO4)

Fisher Scientific, Hampton, NH

Imidazole

Sigma-Aldrich, St. Louis, MO

Glycerol

Fisher Scientific, Hampton, NH

Bromophenol blue

Fisher Scientific, Hampton, NH

2.1.2

Cell culture

100 mm and 24-well tissue culture plates

Becton Dickinson, Franklin Lakes, NJ

Alpha Modified Eagle’s medium (αMEM) Life Technologies, Carlsbad, CA

31
Dulbecco’s modified Eagle’s medium
(DMEM)

Life Technologies, Carlsbad, CA

100x L-glutamine

Life Technologies, Carlsbad, CA

100x antibiotic-antimycotic

Life Technologies, Carlsbad, CA

Fetal bovine serum (FBS)

Life Technologies, Carlsbad, CA

Tryspin-EDTA

Life Technologies, Carlsbad, CA

Type I rat tail collagen

Made in our laboratory

Waymouth medium

Sigma-Aldrich, St. Louis, MO

Dimethyl sulfoxide (DMSO)

Sigma-Aldrich, St. Louis, MO

Recombinant human periostin

R&D systems, Minneapolis, MN

Recombinant human TGFβ-1

R&D systems, Minneapolis, MN

Hank’s balanced salt solution

Sigma-Aldrich, St. Louis, MO

Collagenase

Sigma-Aldrich, St. Louis, MO

Nalgene® cryogenic vials

Thermo Scientific, Waltham, MA

Sircol collagen quantification assay

Biocolor Ltd., Carrickfergus, UK

Table 2.1 Buffers and medium for cell culture
Buffer/medium

Application

Composition

Phosphate buffered saline Wash buffer
(PBS)

8 g NaCl, 0.2 g KCl, 1.44 g
Na2HPO4, 0.24 g KH2PO4, reverse
osmosis (R.O) H2O up to 1 L, pH 7.4

Freezing Medium

50% FBS, 35% αMEM, 15% DMSO

Primary cell storage
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2.1.3

Cell proliferation assay

Cell Proliferation Reagent WST-1

Roche Diagnostics, Mannheim, GER

96-well tissue culture plates

Becton Dickinson, Franklin Lakes, NJ

Table 2.2 Inhibitors for cell proliferation assays
Inhibitor

Mode of Action

Concentration

PI3K inhibitor,
LY294002

Inhibition is
competitive with
respect to ATP
binding site
Binds pleckstrin
homology
domain and
prevents
activation by
PI3K
Inhibition is
competitive with
respect to ATP
binding site

10 μM

DMSO

Cell Signaling
Technologies,
Danvers, MA

0.5 μM

DMSO

Merck KGaA,
Darmstadt,
GER

1 μM

DMSO

Merck KGaA,
Darmstadt,
GER

Inhibition is
competitive with
respect to ATP
binding site
Binds to ERK
specific MAP
kinase, MEK,
preventing
activation of
ERK 1/2 by
MEK

10 μM

H2O

Sigma Aldrich,
St. Louis, MO

20 μM

DMSO

Sigma Aldrich,
St. Louis, MO

AKT inhibitor
VIII

GSK3β
inhibitor VIII

Rho Kinase
inhibitor,
Y27632
ERK 1/2
inhibitor,
PD98059

Vehicle

Supplier
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2.1.4

Protein chemistry

RIPA lysis buffer

Teknova Inc., Hollister, CA

Proteinase inhibitor cocktail

Sigma-Aldrich, St. Louis, MO

Phenylmethanesulfonyfluoride (PMSF)

Sigma-Aldrich, St. Louis, MO

Sodium fluoride (NaF)

Sigma-Aldrich, St. Louis, MO

Sodium orthovanadate (Na3VO4)

Sigma-Aldrich, St. Louis, MO

Pierce® BCA protein assay kit

Thermo Scientific, Waltham, MA

30% Acrylamide/Bis solution (29:1)

BioRad, Hercules, CA

Ammonium persulphate

BioRad, Hercules, CA

N,N,N’,N’-tetramethylethylenediamine
(TEMED)

BioRad, Hercules, CA

Dithiotreitol (DTT)

Sigma-Aldrich, St. Louis, MO

polyvinylidene difuoride (PVDF) – plus,
0.45 micron transfer membranes

Santa Cruz Biotechnology, Santa Cruz, CA

Tween®20

Merck KGaA, Darmstadt, GER

Novex sharp molecular weight markers

Life Technologies, Carlsbad, CA

Immobilon™ western chemiluminescent
HRP substrate

Millipore Corporation, Billerica, MA
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Table 2.3 Buffers for protein analysis
Buffer

Application

Composition

RIPA lysis buffer

Cell lysis

150 mM NaCl, 1% Triton X100, 1% sodium deoxycholate,
0.1% SDS, 50 mM Tris-HCl
(pH 7.5), 2 mM EDTA (pH 8.0)

SDS gel-loading buffer

SDS-PAGE

R.O. H2O with 50 mM Tris-HCl
(pH 6.8), 100 mM DTT, 2%
SDS, 0.1% bromophenol blue,
10% glycerol

1.0 M Tris

SDS-PAGE stacking gel

121.0 g Tris base dissolved in
R.O. H2O to 1 L, pH 6.8

1.5 M Tris

SDS-PAGE resolving gel

181.65 g Tris base dissolved in
R.O. H2O to 1 L, pH 8.8

5x electrophoresis
running buffer

SDS-PAGE

15.1 g Tris Base, 94.0 g glycine,
25 ml 20% (w/v) SDS, R.O.
H2O up to 1 L

10x electrophoresis
transfer buffer

SDS-PAGE

30.3 g Tris base, 144.4 g
glycine, R.O. H2O up to 1 L

1x electrophoresis
transfer buffer

SDS-PAGE

1 part 10x electrophoresis
transfer buffer, 2 parts methanol,
7 parts R.O. H2O

10x Tris buffered saline
(TBS)

Western immunoblotting

80.8g NaCl, 60.6 g Tris Base,
R.O. H2O up to 1 L, pH 7.4

TBS/tween20

Western immunoblotting

1x TBS with 0.1% Tween®20
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Table 2.4 Primary antisera for western immunoblotting
Antibody

Description

Antibody dilution
(western blotting)
1:1000 in 5% BSA,
TBS/tween20

Supplier

Phospho-Akt

Rabbit antiphospho-Akt (ser
473), polyclonal

Cell Signaling
Technology,
Danvers, MA

Total Akt

Rabbit anti-Akt,
polyclonal

1:1000 in 5% BSA,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Phospho-GSK-3β

Rabbit antiphospho-GSK-3β
(ser 9), polyclonal

1:1000 in 5% BSA,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Total GSK-3β

Mouse anti-GSK3β, clone 7/GSK3b, monoclonal

1:1000 in 5% nonfat milk,
TBS/tween20

BD Biosciences
Canada,
Mississauga, ON

β-catenin

Rabbit anti-βcatenin, polyclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Millipore
Corporation,
Billerica, MA

Phospho-ERK 1/2

Rabbit antiphospho-p44/42
MAPK (Thr 202,
Tyr 204)

1:1000 in 5% BSA,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Total ERK 1/2

mouse anti-p44/42
MAPK (ERK1/2),
clone L34F12,
monoclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Alpha smooth
muscle actin
(αSMA)

Mouse anti-αSMA,
monoclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Sigma-Aldrich, St.
Louis, MO

OB cadherin

Mouse antiCadherin 11, clone
5B2H5, monoclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Life Technologies,
Carlsbad, CA

Periostin

Rabbit antiperiostin, clone H300, polyclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Santa Cruz
Biotechnology,
Santa Cruz, CA
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Phospho-Focal
adhesion Kinase
(FAK)

Rabbit antiphospho-FAK (Tyr
397), polyclonal

1:500 in 5% BSA,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Total FAK

Rabbit anti-FAK,
polyclonal

1:500 in 5% BSA,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Phospho-myosin
light chain (MLC)

Rabbit antiphospho-MLC 2
(ser 19), polyclonal

1:500 in 5% BSA,
TBS/tween20

Thermo Scientific,
Rockford, IL

Total MLC

Rabbit anti-MLC 2,
polyclonal

1:500 in 5% BSA,
TBS/tween20

Thermo Scientific,
Rockford, IL

Phospho-cofilin

Rabbit anti1:500 in 5% BSA,
phospho-cofilin (Ser TBS/tween20
3), clone 77G2,
monoclonal

Cell Signaling
Technology,
Danvers, MA

Total cofilin

Rabbit anti-cofilin,
clone D3F9,
monoclonal

1:500 in 5% non-fat
milk, TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Alpha V integrin
(αV)

Rabbit anti-αV,
clone Q-20,
polyclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Santa Cruz
Biotechnology,
Santa Cruz, CA

Alpha 5 integrin
(α5)

Rabbit anti-α5,
polyclonal

1:1000 in 5% nonfat milk,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

β-actin

Mouse anti-β-actin,
HRP-linked, clone
C4, monoclonal

1:2500 in 5% nonfat milk,
TBS/tween20

Santa Cruz
Biotechnology,
Santa Cruz, CA
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Table 2.5 Secondary antisera for western immunoblotting
Antibody

Description

Mouse secondary

Horse anti-mouse
IgG, HRP-linked

Rabbit Secondary

Goat anti-rabbit
IgG, HRP-linked

2.1.5

Antibody dilution
(western blotting)
1:1000 in 5% nonfat milk,
TBS/tween20

Supplier
Cell Signaling
Technology,
Danvers, MA

1:1000 in 5% nonfat milk,
TBS/tween20

Cell Signaling
Technology,
Danvers, MA

Polymerase Chain Reaction (PCR)

RNeasy mini kit

Qiagen, Venlo, Netherlands

High-capacity cDNA archive kit

Life Technologies, Carlsbad, CA

10X PCR buffer, minus Mg

Life Technologies, Carlsbad, CA

50 mM Magnesium chloride

Life Technologies, Carlsbad, CA

Custom primers

Sigma Aldrich, St. Louis, MO

Platinum® Taq DNA polymerase

Life Technologies, Carlsbad, CA

100 mM dNTP set, PCR grade

Life Technologies, Carlsbad, CA

UltraPure™ Agarose

Life Technologies, Carlsbad, CA

QIAEX® II Gel extraction kit

Qiagen, Venlo, Netherlands

MicroAmp Optical 384-well reaction plate Life Technologies, Carlsbad, CA
TaqMan universal PCR master mix

Life Technologies, Carlsbad, CA

TaqMan gene expression assay primers

Life Technologies, Carlsbad, CA
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Table 2.6 TaqMan gene expression assay primers
Primer

Protein Encoded

Assay ID

POSTN

Periostin

Hs00170815_m1

CCND1

Cyclin D1

Hs00765553_m1

BCL2

Bcl2

Hs00608023_m1

BAX

Bax

Hs00180269_m1

GAPDH

GAPDH

Hs99999905_m1

ACTB

β-actin

Hs99999903_m1

2.1.6

Flow cytometry

Guava ViaCount® reagent

Millipore, Billerica, MA

MCDB 105 medium

Sigma-Aldrich, St. Louis, MO

2.1.7

Immunoprecipitation

Protein A/G magnetic beads

Thermo Scientific, Waltham, MA

Coomassie brilliant blue R-250

Fisher Scientific, Hampton, NH

Amicon® Ultra centrifugal 10 kDa filters

Millipore Corporation, Billerica, MA

Table 2.7 Antisera for immunoprecipitation
Antibody

Description

Antibody
Concentration

Suppliers

Periostin

Rabbit antiperiostin, clone H300, polyclonal

2 μg / 500 μg total
cell lysate

Santa Cruz
Biotechnology,
Santa Cruz, CA

IgG

Rabbit anti-human
IgG3, clone H-270,
polyclonal

2 μg / 500 μg total
cell lysate

Santa Cruz
Biotechnology,
Santa Cruz, CA

IgG

Anti-human IgG
from rabbit serum

2 μg / 500 μg total
cell lysate

Sigma-Aldrich, St.
Louis, MO
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Table 2.8 Buffers and solutions for immunoprecipitation
Buffer

Application

Composition

Lysis buffer

Cell lysis

R.O. H2O with 20 mM
Tris-HCl (pH 8.0), 137 mM
NaCl, 1% Triton® X-100, 2
mM EDTA

Wash buffer

Wash buffer

TBS with 0.05%
Tween®20 and 0.5 M NaCl

Elution buffer

Protein elution

4 parts lysis buffer, 1 part
SDS gel-loading buffer

Gel fixation solution

Fixing polyacrylamide gels

50% methanol, 10% acetic
acid, 40% R.O. H2O

Coomassie brilliant blue
concentrated stain solution

Protein staining

12.0 g coomassie brilliant
blue, 300 ml methanol, 60
ml acetic acid

Coomasie brilliant blue
staining solution

Protein staining

500 ml methanol, 30 ml
coomassie brilliant blue
concentrated stain solution,
400 ml R.O H2O, 100 ml
acetic acid, filtered using
0.22 μm filter

Destaining solution

Wash solution

45% methanol, 10% acetic
acid, 45% R.O. H2O

Gel storage solution

Polyacrylamide gel storage

R.O. H2O with 5% acetic
acid

2.1.8

Nickel magnetic bead precipitation

37% formaldehyde

Merck KGaA, Darmstadt, GER

10x glycine solution

Cell Signaling Technology, Danvers, MA

Nonidet P40 (NP-40)

Merck KGaA, Darmstadt, GER

PureProteome™ nickel magnetic beads

Millipore, Billerica, MA
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Table 2.9 Buffers for Nickel Magnetic Bead precipitation
Buffer

Application

Composition

Lysis buffer

Cell lysis

R.O. H2O with 50 mM
NaH2PO4, 300 mM NaCl, 10
mM imidazole (pH 8), 0.1%
NP-40

Wash buffer

Wash buffer

R.O. H2O with 50 mM
NaH2PO4, 300 mM NaCl, 20
mM imidazole (pH 8), 0.1%
NP-40

Elution Buffer

Protein elution

R.O. H2O with 50 mM
NaH2PO4, 300 mM NaCl, 300
mM imidazole (pH 8)

2.1.9

Loss-of-function studies

Table 2.10 Adenoviral shRNA constructs
Construct

Promoter

Targeting sequence

Multiplictiy of
infection (MOI)

Supplier

Ad-GFPU6-hPOSTNshRNA

U6

CGGTGACAGTATA
ACAGTAA

25

Vector Biolabs,
Philadelphia,
PA

Ad-U6RNAi-GFP

U6

GACACGCGACTTG
TACCACT

25

Vector Biolabs,
Philadelphia,
PA

2.1.10

Immunofluorescence confocal microscopy

35 mm, poly-D-lysine coated glass bottom MatTek Corporation, Ashland, MA
tissue culture plates (No. 1.5 coverslip,
10 mm glass diameter)
Paraformaldehyde 16% solution

Electron Microscopy Sciences, Hatfield, PA
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Background Sniper

Biocare Medical, Concord, Ca

Dako antibody diluent

Dako Canada Inc., Burlington, ON

Negative control mouse IgG1

Dako Canada Inc., Burlington, ON

Hoeschst 33342

Life Technologies, Carlsbad, CA

ProLong® Gold antifade reagent

Life Technologies, Carlsbad, CA

18 x 18 mm, No.1 coverslips

Fisher Scientific, Hampton, NH

Table 2.11 Buffers for immunofluorescence confocal microscopy
Buffer

Application

Composition

Immunofluorescence
phosphate buffered solution
(IF-PBS)

Wash buffer

0.2 g NaH2PO4, 1.375 g
Na2HPO4, 8.8 g NaCl,
R.O. H2O up to 1 L

Cell permeabilization
solution

Cell permeabilization

PBS with 0.1% Triton® X100

Table 2.12 Antisera for immunofluorescence confocal microscopy
Antibody

Description

Dilution

Supplier

Vinculin

Mouse antivinculin, clone
VIN-11-5,
monoclonal

1:200 in Dako
antibody diluent

Sigma-Aldrich, St.
Louis, MO

Negative control
mouse IgG1

Mouse antiAspergillus niger
glucose oxidase,
clone DAK-GO1,
monoclonal

4 μg/ml in Dako
antibody diluent

Dako Canada Inc.,
Burlington, ON
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Table 2.13 Spectral properties of molecular probes and LSM 510 Duo Vario
confocal microscope
Molecular
Probe

LSM Laser
Lines for
Excitation

Dilution

LSM Emission
Filters

Supplier

αSMA-cy3

1:100 in
Dako
antibody
diluent

30 mW 514 nm
Argon/2 Ion
laser

BP 560-615 IR

Sigma-Aldrich,
St. Louis, MO

Alexa Fluor 647

1:100 in
Dako
antibody
diluent

5 mW 633 nm
HeNe

LP 650

Life
Technologies,
Carlsbad, CA

Alexa Fluor 594

1:100 in
Dako
antibody
diluent

30 mW 514 nm
Argon/2 Ion
laser

BP 560-615 IR

Life
Technologies,
Carlsbad, CA

Hoechst

1:10 000 in
PBS

50 mW 405-50
nm Diode

BP 420-480

Life
Technologies,
Carlsbad, CA

2.2 Methods
2.2.1

Clinical specimen collection

Surgically resected normal skin, hypertrophic scar and keloid scar tissue samples were
collected from patients in the clinics of the Roth|McFarlane Hand and Upper Limb Centre
or in the operating rooms of St. Joseph’s Hospital, London, Ontario. All subjects
provided written informed consent and specimens were collected with the approval of
Western University Research Ethics Board for Health Sciences Research involving
Human Subjects (HSREB protocol # 08222E).

2.2.2

Primary cell culture

Primary cells were harvested from surgically resected hypertrophic scar, keloid scar and
normal skin tissue as previously described (181). A total of eight patient-derived
hypertrophic scar samples, three keloid scar samples and six normal skin samples were
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used to derive primary fibroblasts for analyses in this thesis. In brief, tissue samples were
finely minced, adhered to the bottom of 100 mm dishes and cultured in αMEM
supplemented with 10% fetal bovine serum (FBS), 1x L-glutamine and 1x antibioticantimycotic solution at 37˚C in 5% CO2. Explant cultures (passage 0) were incubated for
2-4 weeks allowing for the migration, and subsequent proliferation, of fibroblasts from
the tissue to the 100 mm dish. Upon reaching 50% confluency, primary cultures were
sub-cultured using 0.05% Trypsin-EDTA. Primary fibroblast cultures at passage 1 were
frozen down in freezing medium (Table 2.1) in Nalgene® cryogenic vials at -80°C
overnight then stored in liquid nitrogen. All primary cell lines were used up and until a
maximum of four passages, during which no changes in cell behavior or morphology
attributable to serial passage were evident.

2.2.3

Preparation of rat tail type I collagen

Frozen rat tails were obtained from the laboratories of Drs. Ruud Veldhuizen and TingYim Lee (Western University, London, ON). Frozen rat tails were thawed in 70% ethanol
for one hour. Rat tails were skinned and collagen fibers were mechanical extracted from
rat tail tendons. Collagen fibers were soaked in 70% ethanol for 30 minutes then placed
under ultraviolet light overnight in a tissue culture cabinet. Under sterile conditions,
collagen fibers were incubated in sterile 0.017M acetic acid with mechanical stirring for
seven days at 4°C. Undissolved collagen fibers were removed from the solution by
centrifugation at 18 000 x g at 4°C overnight. The supernatant was collected into sterile
bottles and stored at 4°C. Collagen concentration was determined using the Sircol
collagen quantification assay (Biocolor Ltd., Carrickfergus, UK) in accordance with the
manufacturer’s instructions.

2.2.4

WST-1 cell proliferation assay

The WST-1 proliferation assay was utilized to measure the proliferation of hypertrophic
scar and normal skin fibroblasts grown in collagen cultures. Collagen lattices were cast in
96-well tissue culture trays. For each well, 48 μl of type I rat tail collagen (final
concentration of 1.8 mg/ml) was quickly mixed with 12 μl of neutralization solution (3
parts Waymouth media: 2 parts 0.34 M NaOH), and 2 μg/ml human recombinant
periostin or vehicle (0.1% BSA-PBS). Collagen lattices were incubated at 37°C in 5%
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CO2 for 20 minutes to allow for collagen polymerization. 1x103 cells in 100 μl of 2%
FBS-αMEM ± inhibitors (Table 2.2) were seeded onto the collagen lattices and incubated
at 37°C in 5% CO2. 10 μl of WST-1 reagent was added at days 1, 3, 5 and 7 post seeding
and incubated for 2 hours at 37˚C to allow for the cleavage of tetrazolium salt to
formazan by the succinate-tetrazolium reductase system. Equal volumes of media (90 µl)
were transferred to an additional 96-well tissue culture tray and absorbencies were
measured at 450 and 650 nm (reference wavelength) using an iMARK Microplate Reader
(Bio-Rad, Hercules, CA). Difference scores were calculated relative to day 1 absorbance
readings.

2.2.5

Fibroblast Populated Collagen Lattices (FPCLs)

Collagen contraction assays were carried out using primary normal skin, hypertrophic
scar and keloid scar fibroblasts based on Tomasek and Rayan (182). Collagen lattices
were cast in 24-well tissue culture trays. For each well, 1x105 cells were quickly mixed
with 400 μl of type I rat tail collagen (final concentration of 1.8 mg/ml), 100 μl of
neutralization solution and 2 μg/ml human recombinant periostin or vehicle. In a subset
of experiments, normal skin fibroblasts were primed with 5 ng/ml recombinant TGFβ-1
or vehicle (PBS with 1% BSA and 4 mM HCl) in 2% FBS-αMEM for 72 hours prior to
sFPCL setup. Collagen lattices were incubated at 37°C in 5% CO2 for 45 minutes to
allow for collagen polymerization. Wells were then flooded with 1 ml of 2% FBSαMEM. In a subset of experiments, wells were flooded with fibroblast-conditioned media
(section 2.2.9.2). For stressed FPCLs (sFPCLs), collagen cultures were maintained for 72
hours. During this time, the primary fibroblasts in three-dimensional cultures respond to
stress within the tethered, polymerized collagen lattice and differentiate into contractile
myofibroblasts (183). After three days in culture, collagen lattices were simultaneously
released from the wells using a metal spatula, thereby allowing the differentiated
myofibroblasts to contract the untethered lattice. Floating lattices were digitally scanned
within two minutes (designated time 0), 0.5, 2, 6, and 24 hours after release and the area
of each lattice was determined using the freehand tool in ImageJ software (National
Institutes of Health, Bethesda, MD). Sequential area calculations were normalized to the
area of the well prior to release.
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For relaxed FPCLs (rFPCLs), lattices were cultured for one hour prior to being
mechanical released from the wells. Fibroblasts cultured in rFPCLs are not subjected to
mechanical tension and do not differentiate into myofibroblasts. Therefore, rFPCLs
undergo gradual lattice contraction over a 24 hour period due to fibroblast attachment,
spreading and migration (183). Floating lattices for rFPCLs were digitally scanned at 24
hours after release.

2.2.6
2.2.6.1

Western immunoblotting
Protein extraction

For total protein extraction from fibroblasts cultured on collagen substrates, cultures were
washed in PBS and incubated with 1 ml collagenase solution (final concentration of 0.25
mg/ml) for 30 minutes with gentle rocking at 37˚C using a thermal rocker, in order to
detach the fibroblasts from the collagen substrates. The collagenase solution was
collected from each well and centrifuged at 600 x g for 4 minutes to pellet the cells. Cell
pellets were washed with PBS and centrifuged at 16 000 x g for 1 minute. Cell pellets
were resuspended in 100 μl of ice cold RIPA lysis buffer supplemented with proteinase
inhibitor cocktail, 0.1M sodium fluoride (NaF), 10 mM phenylmethanesulfonyfluoride
(PMSF) and 10 mM sodium orthovanadate (Na3VO4). Cell pellets were incubated on ice
for 30 minutes then subjected to needle aspiration. Cell lysates were centrifuged at 16
000 x g for 10 minutes and the supernatant was stored at -80°C.
For total protein extraction from sFPCLs, lattices were collected immediately prior to
collagen lattice release (after 72 hours in culture), 24 and 48 hours after collagen lattice
release and transferred to a 2 ml microcentrifuge tube containing 100 – 400 μl of ice cold
RIPA lysis buffer supplemented with proteinase inhibitor, NaF, PMSF and NA3VO4.
Collagen lattices were homogenized using an Ultra-Turrax T25 tissue homogenizer
(IKA® Works Inc., Wilmington, NC) at 16 000 x g for 30 seconds. Cell extracts were
incubated on ice for 30 minutes then subjected to needle aspiration. Cell extracts were
centrifuged at 16 000 x g for 10 minutes to remove insoluble material and the supernatant
was stored at -80°C.
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2.2.6.2

Bicinchoninic acid (BCA) total protein assay

Bovine serum albumin (BSA) standards were prepared by serial dilution with RIPA lysis
buffer to concentrations of 2000, 1000, 500, 250, 125, 62.5, 31.25 and 0 μg/ml. Total cell
lysates were prepared in a 1/5 and 1/10 dilution in RIPA lysis buffer and 10 μl of each
dilution and standard was added in triplicate to 96-well tissue culture trays. 200 μl of
Pierce® BCA protein assay reagent A:B (49:1) was added to each well and samples were
incubated for 30 minutes at 37°C in 5% CO2. The colourimetric reaction was analyzed at
595 nm using an iMARK Microplate Reader. The data was used to construct a standard
curve and protein concentrations were calculated from the obtained absorbance values to
ensure equal loading into polyacrylamide gels. We were unable to perform BCA analyses
on sFPCL lysates due to the high collagen concentration in the lysates and phenol red in
the media. Therefore, 40 μl of total cell lysate was used for western immunoblotting and
densitometry was performed to correct for unequal loading.

2.2.6.3

SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)

8-10% polyacrylamide resolving gels were made with a 5% stacking gel and set up in the
Bio-Rad Mini Protean III apparatus (Biorad, Hercules, CA). 8% polyacrylamide
resolving gels were used for the analysis of αSMA, OB cadherin, periostin, integrins, βcatenin, FAK, Akt, ERK1/2 and GSK-3β. 10% polyacrylamide resolving gels were used
for the analysis of myosin light chain and cofilin levels. Samples were diluted to load
either 25 µg of total protein or 40 μl of sFPCL lysate per well and SDS gel-loading buffer
(Table 2.3) was added to each sample at a 1:4 (v/v) ratio. Samples were boiled at 95oC
for 5-10 minutes, placed on ice for 2 minutes and centrifuged at 16 000 x g for 1 minute.
Samples were loaded into 1.5 mm wells and subjected to SDS-PAGE in 1x
electrophoresis running buffer (Table 2.3) using a PowerPac 3000 (Bio-Rad, Hercules,
CA) set to 80 V though the stacking gel and 120 V through the resolving gel.

2.2.6.4

Transfer, blocking, incubation, detection and densitometry

Proteins were transferred to polyvinylidene difluoride (PVDF) – plus, 0.45 micron
transfer membranes in ice cold 1x electrophoresis transfer buffer (Table 2.3) on ice at 225
mA for two hours. The PVDF membranes were blocked for one hour in 5% non-fat milk
(w/v) or 5% BSA (w/v) in TBS-0.1% Tween®20 (TBS/tween, Table 2.3) depending on
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the primary antibody (Table 2.4). Membranes were washed with TBS/tween (3 x 5
minutes) and incubated with primary antibody overnight at 4°C with gentle rotation.
Membranes were washed with TBS/tween (3 x 5 minutes) and probed with the
corresponding horseradish peroxidase (HRP)–conjugated secondary antibody (Table 2.5)
for 90 minutes at room temperature with gentle rotation. Membranes were washed with
TBS/tween (3 x 5 minutes) and incubated with 1 ml Immobilon™ western
chemiluminescent HRP substrate (1:1 ratio of luminal to HRP solution) and imaged using
the ChemiGenius2 Bio Imaging System (Syngene, Frederick, MD). Images were captured
using Gene Snap (Syngene, Frederick, MD) and densitometry analysis was performed
using the manual band quantification analysis function in Gene Tools (Syngene,
Frederick, MD).

2.2.7

PCR

2.2.7.1

RNA extraction and cDNA synthesis

Cell pellets were collected from sFPCLs or two-dimensional collagen substrates using
collagenase treatment (2.2.6.1). Cell pellets were lysed and total RNA was extracted
using the RNeasy mini kit in accordance with the manufacturer’s instructions. Total RNA
was eluted in 50 μl of RNase-free water. Total RNA concentration and quality was
assessed using the NanoDrop-1000 spectrophotometer (Thermo Scientific, Waltham,
MA). 2 μg of high quality total RNA was reversed transcribed into cDNA first strand
using the High-Capacity cDNA archive kit in accordance with the manufacturer’s
instructions.

2.2.7.2

Real time PCR

cDNA samples were diluted to a final concentration of 10 ng/μl in RNase/DNase free
water and 20 ng of cDNA was loaded in triplicate into MicroAmp Optical 384-well
reaction plates. TaqMan gene expression assays were used to measure POSTN, CCND1,
BAX and BCL2 expression in accordance with the manufacturer’s instructions (Table 2.6
for primers). POSTN and BAX expression was measured relative to GAPDH endogenous
control and CCND1 and BCL2 expression was measured relative to ACTB using the
ΔΔCt method (relative quantification, RQ) after confirmation of parallel PCR
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amplification efficiencies using the 7900HT Sequence Detection System (Life
Technologies, Carlsbad, CA). PCR reactions were carried out under the following
conditions: Initial denaturation at 95°C for 5 minutes followed by cycles of denaturation
(95°C for 15 seconds), primer annealing (60°C for 1 minute) and transcript extension
(50°C for 2 minutes) for 40 cycles. The relative quantification for each gene normalized
to vehicle controls was analyzed using RQ Manager 1.2.1 software (Life Technologies,
Carlsbad, CA).

2.2.7.3

Reverse-transcription PCR

20 ng of cDNA was subjected to PCR analysis with Platinum®Taq DNA polymerase in
accordance with the manufacturer’s instructions. PCR reactions were carried out under
the following conditions: initial denaturation at 95°C for 3 minutes, followed by cycles of
denaturation (95°C for 30 seconds), primer annealing (58°C for 30 seconds) and
transcript extension (72°C for 2 minutes) for 40 cycles, with a final extension at 72C for
7 minutes. The primers (Forward 5’- ACAACGGGCAAATACTGGAA-3’, Reverse 5’AACTTCCTCACGGGTGTGTCA-3’) were designed to have 100% sequence identity
with four POSTN mRNA isoforms originally reported ((101), NCBI Reference
Sequences: NM_006475.2, NM_001135934.1, NM_001135935.1 and
NM_001135936.1). PCR products were visualized by agarose gel electrophoresis,
amplicons were isolated using the QIAEX® II Gel extraction kit and sequenced at the
Robarts Research Institute DNA sequencing facility (Western University, London, ON).

2.2.8

Flow Cytometry

Cell viability was assessed using the Guava ViaCount® assay that distinguishes between
viable and non-viable cells based on the differential permeability of DNA-binding dyes in
the ViaCount® reagent. Primary fibroblasts were cultured in sFPCLs treated with 2
μg/ml human recombinant periostin or vehicle for 72 hours. Cells were extracted from
sFPCLs using collagenase (2.2.6.1). Cell pellets were resuspended in 1 ml of MCDB
medium and cell number was assessed using a hemocytometer. Accurate cell counting on
the Guava system occurs at a cell concentration of 1x104 - 5x105 cells/ml. Cell
suspensions of appropriate concentrations were diluted to 300 μl in MCDB media and
incubated with 100 μl of Guava ViaCount reagent for 5 minutes. Flow cytometry analysis
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was performed using the Guava EasyCyte Mini (Millipore, Billerica, MA). Using a
stained cell sample, threshold levels were set to separate nucleated cells from debris and
viable cells from non-viable cells using CytoSoft 4.2.1 software (Millipore, Billerica,
MA). Once threshold levels were set, samples were analyzed in triplicate for 1000
cellular events. Viability data was exported to FlowJo 7.6.5 (Tree Star Inc, Ashland, OR)
and plotted with cell viability on the y-axis and forward scatter on the x-axis to separate
collagen debris from the viable and non-viable cell populations. Manual gates were set
and applied to all the samples within the experiment. Viability was assessed by
calculating the percentage of viable versus non-viable cells from the total cell population.

2.2.9
2.2.9.1

Immunoprecipitation (IP)
Fixation

Primary hypertrophic scar fibroblasts were cultured on 100 mm tissue culture plates in
10% FBS-αMEM. When 85% confluency was achieved, fibroblasts were fixed with
formaldehyde (final concentration of 1%) for 10 minutes at room temperature. 25 mM
glycine solution (final concentration of 2.5 mM) was added to each plate and incubated
for an additional five minutes at room temperature to quench the formaldehyde. Plates
were washed with ice-cold PBS (5 x 1 minute), incubated with 100 µl non-denaturing
lysis buffer (Table 2.8) and cells were lysed using a cell scraper. Total protein extracts
were collected in a 1.5 ml microcentrifuge tube, incubated on ice for 30 minutes and
subjected to needle aspiration. Cell extracts were centrifuged at 16 000 x g for 10 minutes
and the supernatant was stored at -80˚C.

2.2.9.2

Generation of conditioned media

Primary hypertrophic scar or normal skin fibroblasts were cultured on 100 mm tissue
culture plates in 10% FBS-αMEM until the cells achieved 80% confluency. Cells were
washed overnight in serum free αMEM then cultured in 5 ml fresh serum-free αMEM for
96 hours. Conditioned media was collected, supplemented with proteinase inhibitor
cocktail and stored at -80°C. For immunoprecipitation studies, fresh conditioned media
was concentrated 50x using 10 kDa Amicon® Ultra centrifugal filters and the
concentration was assessed by BCA assay (2.2.6.2).
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2.2.9.3

Immunoprecipitation

1 mg of hypertrophic scar-conditioned media or total cell lysate (2.2.9.1), in a final
volume of 1 ml, was incubated with 4 μg of periostin-specific antibody or IgG control
(Table 2.7) overnight at 4˚C with gentle rotation. Protein A/G magnetic beads were
washed twice with wash buffer (175 µl and 1 ml for 1 minute each, Table 2.8), and
incubated with the antigen/antibody mixture for 1 hour at room temperature with gentle
rotation. Magnetic beads were washed with 500 μl wash buffer (3 x 5 minutes) and 500
μl purified water (1 x 2 minutes). Magnetic beads were resuspended in 80 μl lysis buffer
(Table 2.8) and 20 μl SDS gel-loading buffer (Table 2.3) and boiled at 95°C for 5
minutes (conditioned media samples) or 70°C for 45 minutes to reverse formaldehyde
crosslinks (total cell lysate samples). The supernatant was collected and 50 µl was loaded
into 1.5 mm wells and subjected to SDS-PAGE. PVDF membranes were probed with
antibodies against periostin and integrins αV and α5 (Table 2.4). 50 μg of total cell lysate
or conditioned media (input samples) was analyzed to confirm the presence of periostin
and integrins αV and α5 in the pre-immunoprecipitated sample.

2.2.9.4

Gel fixation and coomassie brilliant blue staining

Immunoprecipitated samples were subjected to SDS-PAGE and stained with coomassie
brilliant blue for liquid chromatography tandem mass spectrometry analysis.
Polyacrylamide gels were fixed for 30 minutes at room temperature with gentle rocking
in gel fixation solution (Table 2.8). Gels were stained with coomassie brilliant blue
staining solution (Table 2.8) for 30 minutes at room temperature with gentle rocking.
Gels were then destained in destaining solution (Table 2.8) for 2-3 hours at room
temperature with gentle rocking. Destaining solution was replaced every 45 minutes.
Gels were imaged using the ChemiGenius2 Bio Imaging System and images were
captured using Gene Snap. Gels were stored at 4°C in 5% acetic acid.

2.2.9.5

Spot picking, in-gel digestion and mass spectrometry

Differential protein bands in periostin immunoprecipitated samples relative to IgG
controls were isolated using the Ettan spot picker (GE Healthcare, Little Chalfont, UK) at
the Functional Proteonomic Facility (FPF) at Western University (London, ON). Isolated
samples were stored in R.O H2O with 45% methanol and 5% acetic acid and submitted to

51
the FPF for in-gel digestion. In-gel digestion was performed using a MassPREP
automated digester station (PerkinElmer, Waltham, MA). In brief, gel pieces were
coomassie brilliant blue destained using 50 mM ammonium bicarbonate and 50%
acetonitrile. Proteins were reduced using 10 mM DTT, followed by alkylation using 55
mM iodoacetamide and tryptic digestion. Peptides were extracted using a solution of 1%
formic acid and 2% acetonitrile and lyophilized.
Lyophilized samples were submitted to the Biological Mass Spectrometry Laboratory
(Western University, London, ON) for quadrupole time-of-flight (Q-TOF) liquid
chromatography tandem mass spectrometry (LC-MS/MS) analysis. In brief, lyophilized
fractions were reconstituted in 0.1% formic acid prior to injection. For gel-enhanced
analysis, excised band samples were identified as having low, medium, or high
complexity based on clear, light, or dark coomasie staining, respectively. Depending
upon the anticipated complexity of the sample, ∼1/2, 1/5, or 1/8 of each fraction was
analyzed using a 60-, 90-, or 150-min LC method, respectively. Separation using LC (5–
40% acetonitrile, 0.1% formic acid gradient) was performed on a NanoAcquity Ultra
Performance Liquid Chromatography (UPLC, Waters Corporation, Milford, MA) with a
25 cm x 75 μm C18 reverse phase column. Peptide ions were detected in data-dependent
acquisition mode by tandem MS using a Q-ToF Ultima-Global mass spectrometer
(Waters Corporation, Milford, MA). Raw data was refined, deNovo sequenced and
searched using Peaks 6.0 (Bioinformatics Solutions Inc., Waterloo, ON) against NCBInr
– human database. Results were filtered using a false discovery rate of 1% and a
minimum of two unique peptides were required for positive protein identification.

2.2.10

Nickel magnetic bead precipitation

Primary hypertrophic scar fibroblasts were cultured on 100 mm tissue culture plates in
10% FBS-αMEM until 80% confluency was achieved. Cultures were then treated with 2
µg/ml human recombinant periostin or vehicle in 2%FBS-αMEM overnight. Samples
were fixed and lysed as described 2.2.9.1. PureProteome™ Nickel Magnetic Beads
(Millipore, Billerica, MA) were used to precipitate the histidine-tagged human
recombinant periostin from total cell lysates. Nickel magnetic beads were placed in a
magnetic stand to remove the storage buffer and washed for 1 minute with gentle rotation
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with 500 µl lysis buffer (Table 2.9). 1 mg of total cell lysate, in a final volume of 1 ml,
was added to the magnetic beads and incubated at room temperature with gentle rotation
for 2 hours. Magnetic beads were washed for 10 minutes with sterile water, 2.5 hours
with wash buffer (Table 2.9), twice for 10 minutes with wash buffer then quickly in
sterile water. Magnetic beads were incubated with 100 µl elution buffer (Table 2.9) for 5
minutes at room temperature with gentle rotation. 25 μl of SDS gel-loading buffer (Table
2.3) and 1 μl proteinase inhibitor cocktail was added to the supernatant and samples were
incubated at 70°C for 45 minutes to reverse the formaldehyde crosslinks. 50 µl of the
supernatant was loaded into 1.5 mm wells and subjected to SDS-PAGE. PVDF
membranes were probed with antibodies against periostin and integrins αV and α5 (Table
2.4). 50 μg of total cell lysate (input sample) was analyzed to confirm the presence of
periostin and integrins αV and α5 in the pre-precipitated samples.

2.2.11

Loss-of-function studies

Adenoviral shRNA constructs were purchased from Vector Biolabs (Philadephia, PA).
Both POSTN shRNA and scrambled control vectors have an adenoviral-type 5 (dE1/E3)
backbone, are regulated by the U6 promoter and co-express green fluorescent protein
(GFP), allowing for visualization of transduction efficiency by epifluorescent
microscopy. POSTN and scrambled shRNA sequences (Table 2.10) were analyzed by
BLAST to confirm that the POSTN shRNA sequence was present in all POSTN variants
and that the scrambled shRNA sequence was not directed against any known human
target.

2.2.11.1 Amplification of adenoviral shRNA constructs
Adenoviral POSTN and scrambled shRNA vectors were amplified using HEK 293 cells
(Gift from Dr. Lina Dagnino, Western University, London, ON). HEK 293 cells were
cultured in 100 mm tissue culture plates to confluency in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 4% FBS. Adenovirus, at a multiplicity of infection
(MOI) of 2, was added to fresh 4% FBS-DMEM and HEK 293 cells were incubated in
this inoculum for 4-5 days. When 70% of the cells floated off the plate, cells were
harvested by rinsing the plate with media. Cells were pelleted by centrifugation at 1300 x
g for 5 minutes. The media was aspirated and cell pellets were resuspended in 1 ml sterile
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10% glycerol-PBS. Cell pellets were subjected to four rounds of freeze/thaw cycles using
liquid nitrogen and a warm water bath. Cell pellets were vortexed gently after each thaw.
Cellular debris was removed from the samples by centrifugation at 16 000 x g for 10
minutes and the supernatant containing the virus was stored at -80°C.

2.2.11.2 GFP adenovirus titering
Primary hypertrophic scar fibroblasts were seeded in 10% FBS-αMEM in 24-well trays at
a cell concentration of 100 000 cells/well and cultured overnight at 37°C in 5% CO2.
Viral dilutions of the amplified stocks were prepared by serially diluting virus in αMEM
supplemented with 2% FBS. Viral dilutions were added to each well at 300 μl/well in
triplicate and incubated for 48 hours. After 48 hours, non-transduced cells were collected
following trypsin digestion and counted using a hemocytometer to obtain a total cell
count per well. The cells transduced with virus were fixed in 4% paraformaldehyde for
10 minutes at room temperature. Wells were washed with PBS (3 x 5 minutes) and
stained with Hoescht for 5 minutes. Wells were then washed in PBS (2 x 5 minutes) and
imaged using the Olympus IX81 deconvolution microscope (Olympus Corporation,
Tokyo, Japan). Cell numbers per field were assessed by counting the number of Hoescht
positive cells. The number of GFP positive-viral transduced cells were counted in the
same field. The percentage of virus transduced cells was calculated in the lowest viral
dilution where at least 70% of the cells were transduced. The percentage of viral
transduced cells per field was multiplied by the total number of cells present in the well
to determine the total number of cells transduced per well. Using the dilution factor and
the number of transduced cells, the concentration of the virus was determined.

2.2.11.3 Multiplicity of infection (MOI) optimization studies
Primary hypertrophic scar fibroblasts were cultured on 100 mm tissue culture plates in
10% FBS-αMEM until the cells reached 60% confluence. The media was replaced with
2% FBS –αMEM containing adenoviral POSTN or scrambled shRNA constructs at an
MOI of 0, 10, 25, 50 and 100. Cells were cultured for 72 hours at 37°C in 5% CO2. After
72 hours, cell pellets were collected following digestion with trypsin (5 minutes at 37˚C).
Total protein and RNA was extracted from cells using methods described in 2.2.6 and
2.2.7. POSTN expression and periostin levels were assessed in POSTN shRNA treated
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fibroblasts relative to scrambled shRNA controls using real time PCR and western
immunoblotting, respectively.

2.2.11.4 Viral transduction
Primary fibroblasts were cultured in 10% FBS-αMEM on 100 mm tissue culture plates.
When 60% confluency was achieved, fibroblasts were transduced with adenovirus
constructs expressing shRNAs against POSTN or scrambled shRNA controls at an MOI
of 25 in 2% FBS-αMEM. After 72 hours in culture, fibroblasts were assessed for GFP
expression using an Olympus IX81 deconvolution microscope to determine transduction
efficiency. If transduction efficiency was greater than 90%, the cells were collected by
trypsin digestion and seeded into sFPCLs.

2.2.12

Immunofluorescence (IF) confocal microscopy

2.2.12.1 sFPCL setup for immunofluorescence confocal microscopy
Miniature collagen lattices were cast in 35 mm, poly-D-lysine coated glass bottom tissue
culture plates with a No.1.5 cover slip with a glass diameter of 10 mm. For each glass
bottom plate, 1 x104 cells were quickly mixed with 40 μl of type I rat tail collagen (final
collagen concentration of 1.8 mg/ml), 10 μl of neutralization solution and 2 μg/ml human
recombinant periostin or vehicle. Collagen lattices were incubated at 37°C in 5% CO2 for
45 minutes to allow for collagen polymerization. Wells were then flooded with 1 ml 2%
FBS-αMEM and incubated for 72 hours to achieve a stressed collagen matrix. After 72
hours, the media was aspirated and lattices were fixed with 4% paraformaldehyde for 10
minutes at room temperature. Plates were washed with PBS (3 x 5 minutes) and stored in
70% ethanol at 4°C.

2.2.12.2 Immunofluorescence staining with two primary antibodies
from the same host species
Glass bottom plates were washed with IF-PBS (Table 2.11, 5 x 5 minutes) to remove the
ethanol. Cell membranes were permeabilized (5 minutes, Table 2.11), washed with IFPBS (3 x 5 minutes) and blocked with Background Sniper for 5-10 minutes. Incubation
with Background Sniper for longer than 10 minutes resulted in loss of signal. Samples
were washed briefly with IF-PBS and incubated with a primary vinculin antibody (Table
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2.12) for 1 hour at room temperature in a covered humidity chamber. Samples were
washed with IF-PBS (3 x 5 minutes) then incubated with an Alexa Fluor 647 conjugated
secondary antibody (Table 2.13) for 1 hour at room temperature in a covered humidity
chamber in the dark. Samples were washed with IF-PBS (3 x 5 minutes) then blocked
with negative control mouse IgG1 (Table 2.12) for 45 minutes at room temperature in a
covered humidity chamber in the dark. Samples were washed with IF-PBS (3 x 5
minutes) and incubated with a primary αSMA antibody conjugated to cy3 (Table 2.13)
for 1 hour at room temperature in a covered humidity chamber in the dark. Samples were
washed with IF-PBS (3 x 5 minutes), incubated with Hoechst (Table 2.13) for 5 minutes
in the dark then washed with IF-PBS(2 x 5 minutes). Prolong Gold anti-fade reagent was
added to the samples and a cover slip was applied over top. Samples were incubated
overnight at 4° C then coverslips were sealed with nail polish. Samples were stored at
4°C in the dark.

2.2.12.3 Imaging and data analysis
Triple immunofluorescence-labelled cells were observed with a Zeiss LSM 510 Duo
Vario confocal microscope (Zeiss Canada Inc., Toronto, ON) equipped with three lasers
used simultaneously; an Argon/2 ion laser, a HeNe laser and a Diode laser (Table 2.13
for LSM laser lines for excitation and emission filters). All images were captured using a
40x/1.3 Oil Plan Apochromat objective lens. The pinhole was set to match 1 AU (airy
unit) to ensure the best signal to noise ratio. Each channel was adjusted for gain and
digital offset to achieve optimal fluorescent signal using Zen 2009 Software (Zeiss
Canada Inc., Toronto, ON). Serial optical sections of individual cells were taken in a total
depth of 3-6 μm with an optimal z-step of 0.38 μm determined by Zen 2009 Software. A
minimum of 30 images from three different experiments (10 images per experiment)
were captured per treatment. Images were exported as TIFFs using Zen Software and
extended depth of field composite images of maximum intensity were generated for
vinculin stained images using Image-Pro Plus 7.0 (Media Cybernetics, Inc., Rockville,
MD). Length of focal adhesions (FA), determined by vinculin staining, was manually
measured using the straight line tool in Image J. The length of vinculin-stained FAs were
defined by their longest axis regardless of orientation. Total FA numbers, average FA
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length and the classification of FAs were calculated using Excel. Focal adhesions were
arbitrarily classified into three categories: immature FAs (≤ 2 μm), mature FAs (2-6 μm)
and supermature FAs (> 6 μm, (184)).

2.2.13

Statistical analyses

Statistics were calculated using SPSS Statistics 17.0 software (IBM Corporation,
Armonk, NY) and Microsoft Excel 2007 (Microsoft, Redmond, WA). All data sets
consist of data obtained from a minimum of three patients from three independent
experiments assessed in triplicate unless otherwise stated. ANOVA of repeated measures
were used to assess significant treatment effects and significant treatment/time
interactions to distinguish between overall treatment-induced effects from treatmentinduced effects that become significant over time. When a significant treatment/time
interaction was observed, simple main effects analyses were further performed to
determine at which time point treatment had a significant effect. Significant treatment
effects at individual time points were assessed by paired t-tests. Results were deemed
significant when p<0.05.
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Chapter 3

3

In vitro analysis of the effects of periostin on fibroblast
proliferation in hypertrophic scarring

3.1 Rationale
Excessive fibroblast proliferation is one of the hallmarks of “overhealing” conditions like
hypertrophic scarring (55, 185, 186). Periostin has been demonstrated to induce
proliferation in several cell types including human dermal fibroblasts (152), mouse
embryonic fibroblasts (152), phenotypically normal palmar fascia fibroblasts from
patients with Dupuytren’s disease (91), human periodontal ligament fibroblasts (178),
mouse mesenchymal cells (179), colorectal cancer cells (180), human retinal pigment
epithelial cells (187) and rat cardiomyocytes (132). Of these previous in vitro studies,
only two groups (132, 187) have investigated the signalling pathways utilized by
periostin to induce cellular proliferation. These studies have demonstrated that periostininduced human retinal pigment epithelial cell and rat cardiomyocyte proliferation was
dependent on phosphatidylinositide 3-kinases (PI3K)/Akt activation. However, there
have been no studies in the literature investigating the effects of periostin on hypertrophic
scar-derived fibroblast proliferation or the signalling intermediates activated by it, nor
have these pathways been assessed in fibroblasts grown on physiologically relevant
culture substrates. Since periostin has been demonstrated to induce proliferation in other
cell types, it was hypothesized that periostin contributes to the excessive fibroblast
proliferation characteristically observed in hypertrophic scarring.
The aim of this chapter is to describe the effects of periostin on hypertrophic scar (HTS)and normal skin (NS)-derived fibroblast proliferation and to identify potential signalling
pathways utilized by periostin to elicit these effects.

3.2 Assessment of POSTN expression and periostin levels
in fibroblasts derived from hypertrophic scar tissue
Previous in situ hybridization studies performed in our laboratory demonstrated that
POSTN expression was upregulated and persistent in keratinocytes in the basal stratum
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and in dermal fibroblasts in hypertrophic scar tissue relative to normal scar tissue (96),
consistent with a previous report (99). To confirm the increased expression of POSTN in
primary HTS-derived fibroblasts relative to fibroblasts derived from NS, real time PCR
for POSTN expression was performed as described in 2.2.7.2. POSTN expression was
increased approximately six fold in primary fibroblasts derived from HTS tissue relative
to NS tissue (Figure 3.1a, N=1 patient, n=1). These findings were consistent with our
previous in vivo studies (96) and previously published data (99).
In parallel, western immunoblotting studies were performed to assess the levels of
periostin in primary fibroblasts derived from HTS and NS tissue. Alternative splicing in
the C-terminal region of POSTN results in periostin isoforms that range in size from 8393 kDa (115). Western immunoblotting of total cell lysates with a periostin-specific
antibody revealed two bands approximately 85 and 90 kDa in size. Densitometry analysis
of both bands revealed that periostin levels were increased approximately five fold in
primary fibroblasts derived from HTS tissue relative to NS tissue (Figure 3.1b, N=2
patient, n=1). These findings are consistent with previous immunohistochemistry studies
performed by our group (95, 96) and others (97) that demonstrated that periostin was
abnormally abundant in the dermis of hypertrophic and keloid scar tissue.

3.3 Identification of POSTN variants in fibroblasts derived
from hypertrophic scar tissue
Up to eight human POSTN variants have been reported in various systems to date (101,
102, 116, 117, 188-190). To determine which POSTN variants were present in abnormal
scar tissue, total RNA was extracted from HTS fibroblasts and amplified by reversetranscription PCR. Forward and reverse primers designed to anneal to regions outside of
the variable region in the C-terminal domain, as described in 2.2.7.3 (Figure 3.2a),
revealed four amplicons (variants 1-4) representing four human POSTN variants
originally reported by Horiuchi et al., (101) in human placental and osteosarcoma cDNA
libraries (Figure 3.2b, N=2 patients, n=1). The predicted amplicon sizes were 1120 base
pairs (bp) for variant 1, 946 bp for variant 2, 955 bp for variant 3 and 865 bp for variant
4. The identity of each POSTN variant was confirmed by DNA sequencing. Although not
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Figure 3.1 POSTN expression and periostin levels are abundant in primary
fibroblasts derived from hypertrophic scar tissue. Primary hypertrophic scar (HTS)and normal skin (NS)-derived fibroblasts were cultured on two-dimensional collagen
substrates for 72 hours in 10% FBS-αMEM. (a) POSTN expression was assessed in total
RNA by real time PCR as described in 2.2.7.2. As shown, POSTN expression was
increased approximately five to six fold in HTS fibroblasts relative to NS fibroblasts.
Expression data are normalized to NS (N=1 patient, n=1). (b) Periostin levels were
assessed in total cell lysates by western immunoblotting and densitometry as described in
2.2.6. Periostin levels were increased five to six fold in HTS fibroblasts relative to NS
fibroblasts. Values were normalized to NS patient 11 (N=2 patients, n=1). β-actin
immunoreactivity was assessed to ensure equal protein loading. Human recombinant
periostin (1 µg/ml, hrPN) was used as a positive control. Data are represented by mean
values and SEM. RQ= relative quantification, AU= arbitrary units.
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Figure 3.2 POSTN variant 1 is the most abundant transcript in hypertrophic scar
fibroblasts. (a) Schematic representation of POSTN variants 1-4 and location of PCR
primers within the cDNA (red arrows). Breaks in black bars represent deleted exon
cassettes through alternative splicing. (b) Primary hypertrophic scar (HTS)-derived
fibroblasts were cultured on two-dimensional collagen substrates for 72 hours in 10%
FBS-αMEM. POSTN variants were assessed by reverse-transcription PCR of total RNA
using primers designed to amplify the alternatively spliced C-terminal region. The
identity of the largest MW amplicon was confirmed as isoform 1 by DNA sequencing
(N=2 patients, n=1). MW= molecular weight ladder, bp= base pairs.
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quantitative, these PCR analyses were performed using a single primer set and the
relative intensity of each amplicon was predicted to approximate the amount of each
variant in the sample. Based on this assumption, POSTN variant 1 was identified as the
most abundant POSTN variant in hypertrophic scars. Western immunoblotting studies
confirmed the most abundant periostin isoform in HTS cells was the same molecular
weight as human recombinant periostin variant 1 (Figure 3.1b, N=2 patients, n=1).

3.4 Assessment of the basal proliferation rates of
hypertrophic scar- and normal skin-derived fibroblasts
in 2D collagen cultures
The “basal” (unstimulated) proliferation rates of primary fibroblasts derived from HTS
and NS tissue were assessed on type I collagen substrates using the water soluble
tetrazolium-1 (WST-1) proliferation assay as described in 2.2.4. Primary fibroblasts were
seeded onto a thin two-dimensional (2D) type I collagen substrate in 2% FBS-αMEM and
proliferation was assessed over a seven day period. As shown in Figure 3.3a, no
significant differences between the basal proliferation rates of HTS and NS fibroblasts
were observed over the course of the assay (N=3 patients, n=3).

3.5 Assessment of the effects of periostin on hypertrophic
scar and normal skin fibroblast proliferation in 2D
collagen cultures
To determine the effects of periostin on fibroblast proliferation, primary HTS and NS
fibroblasts were seeded onto a type I collagen substrate containing 2 μg/ml human
recombinant periostin or vehicle (PBS with 0.1% BSA) and proliferation was assessed
over a seven day period using the WST-1 proliferation assay (2.2.4). A significant
interaction between periostin treatment and time was observed (p<0.05) and the presence
of periostin in the culture substrate enhanced HTS fibroblast proliferation over a seven
day period relative to vehicle controls with significant differences evident at day five and
seven (Figure 3.3b, p<0.05, N=3 patients, n=3). In contrast, exogenous periostin
treatment had no discernible effect on the proliferation of normal skin fibroblasts under
identical culture conditions (Figure 3.3c, N=3 patients, n=3).
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Figure 3.3 Periostin enhances the proliferation of hypertrophic scar-derived
fibroblasts. Primary hypertrophic scar (HTS)- and normal skin (NS)-derived fibroblast
proliferation was assessed using the WST-1 proliferation assay described in 2.2.4.
Primary fibroblasts were seeded onto a two-dimensional type 1 collagen substrate
containing periostin (PN, 2µg/ml) or vehicle (veh, 0.1% BSA in PBS) and proliferation
was assessed over seven days. (a) No significant differences between the basal
proliferation rates of HTS and NS fibroblasts were observed (N=3 patients each, n=3). (b)
Incorporation of exogenous periostin into two-dimensional collagen lattices significantly
enhanced HTS fibroblast proliferation relative to vehicle controls over a seven day period
(N=3 patients, n=3). (c) Exogenous periostin treatment had no discernible effect on NS
fibroblast proliferation under identical culture conditions (N=3 patients, n=3). Significant
treatment/time interactions are denoted by #p<0.05 (ANOVA of repeated measures).
Significant treatment effects at individual time points are denoted as *p<0.05 (simple
main effects analyses). Data are presented by mean difference scores relative to day one
absorbance readings and SEM.
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3.6 Identification of the signalling pathway(s) utilized by
periostin to induce hypertrophic scar fibroblast
proliferation in 2D collagen cultures
A central aim of this chapter was to identify the signalling intermediates utilized by
periostin to induce the proliferation of HTS fibroblasts. To achieve this, a series of
pharmacological inhibitors were assessed. These inhibitors were targeted against
signalling intermediates previously shown to be activated by periostin or other mitogens.

3.6.1

Assessment of PI3K inhibition effects on periostin-induced
HTS fibroblast proliferation.

LY294002 is a small molecule inhibitor that competes with the ATP binding site in the
catalytic domain of PI3K. To determine if periostin signalling required PI3K activity to
enhance proliferation, LY294002 and periostin (2 µg/ml) were included in a subset of
cultures of HTS fibroblasts and proliferation was assessed using WST-1 assays. 10 µM
LY294002 was used in these experiments as this concentration has been demonstrated to
inhibit human fibroblast proliferation in other systems (191-193). LY294002 has modest
off-target effects at this concentration (194). As shown in Figure 3.4a, a significant
interaction between LY294002 treatment and time was observed (p<0.05) and PI3K
inhibition attenuated periostin-induced HTS fibroblast proliferation over seven days
relative to vehicle controls with significant differences evident at day three and seven
(p<0.01, N=3 patients, n=3). Similarly, a significant LY294002 treatment and time
interaction was observed (p<0.05) and LY294002 treatment was found to attenuate basal
HTS fibroblast proliferation over the course of the assay relative to vehicle controls with
significant effects observed at day five and seven (Figure 3.4b, p<0.05, N=3 patients,
n=3).

3.6.2

Assessment of Akt inhibition effects on periostin-induced
HTS fibroblast proliferation

Akt inhibitor VIII is a small molecule inhibitor that binds to the pleckstrin homology
domain of Akt and prevents activation by PI3K. To determine if periostin signalling
required Akt activity to enhance HTS fibroblast proliferation, Akt inhibitor VIII and
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Figure 3.4 Inhibition of phosphatidylinositide 3-kinases attenuates periostin-induced
and basal hypertrophic scar fibroblast proliferation. Primary hypertrophic scar
(HTS)-derived fibroblasts were cultured onto two-dimensional collagen substrates
containing periostin (PN, 2 µg/ml) or vehicle (veh). Culture medium was supplemented
with 10 µM LY294002 (PI3Ki) or DMSO control and proliferation was assessed in
WST-1 assays. As shown in (a), PI3K inhibition significantly attenuated PN-induced
HTS fibroblast proliferation relative to vehicle controls (N=3 patients, n=3). (b) PI3K
inhibition significantly attenuated basal proliferation over a seven day period relative to
vehicle controls (N=3 patients, n=3). Significant treatment/time interactions are denoted
by #p<0.05 (ANOVA of repeated measures). Significant treatment effects at individual
time points are denoted by *p<0.05, **p<0.01 and ***p<0.001 (simple main effects
analyses). Data are presented by mean difference scores relative to day one absorbance
readings and SEM.
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Figure 3.5 Inhibition of Akt attenuates periostin-induced hypertrophic scar
fibroblast proliferation. Primary hypertrophic scar (HTS)-derived fibroblasts were
cultured on two-dimensional collagen substrates containing periostin (PN, 2 µg/ml) or
vehicle (veh). Culture medium was supplemented with 0.5 µM Akt inhibitor VIII (Akti)
or DMSO and proliferation was assessed in WST-1 assays. (a) Akt inhibition
significantly attenuated PN-induced HTS fibroblast proliferation over seven days relative
to vehicle controls (N=3 patients, n=3). (b) Akt inhibition had no discernible effects on
basal HTS fibroblast proliferation over seven days relative to vehicle controls (N=3
patients, n=3). Significant treatment/time interactions are denoted by #p<0.05 (ANOVA
of repeated measures). Significant treatment effects at individual time points are denoted
by *p<0.05 (simple main effects analyses). Data are presented by mean difference scores
relative to day one absorbance readings and SEM. (c) Primary HTS fibroblasts were
cultured on two-dimensional collagen cultures for 72 hours, washed overnight in serumfree medium and treated with 2 µg/ml PN or vehicle for 60 minutes in serum-free
medium. Total cell lysates were assessed for phosphorylated (ser 473) and total Akt
immunoreactivity by western immunoblotting as described in 2.2.6. Exogenous PN
treatment had no effect on Akt activation (N=1 patient, n=3). β-actin immunoreactivity
was assessed to ensure equal protein loading. Representative immunoblots are shown.
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periostin (2 µg/ml) were included in a subset of cultures of HTS fibroblasts and
proliferation was assessed using WST-1 assays. 0.5 µM Akt inhibitor VIII was used in
these experiments based on previous studies investigating the effect of Akt inhibition on
B-cell proliferation (195). At 1 µM, Akt inhibitor VIII does not significantly inhibit other
kinases (194). A significant interaction between Akt inhibitor VIII treatment and time
was observed (p<0.05) and Akt inhibition attenuated periostin-induced HTS fibroblast
proliferation over the course of the assay relative to vehicle controls with significant
differences evident at day seven (Figure 3.5a, p<0.05, N=3 patients, n=3). In contrast,
Akt inhibition had no discernible effects on the proliferation of untreated HTS fibroblasts
(Figure 3.5b, N=3 patients, n=3). In addition to WST-1 proliferation assays, western
immunoblotting was performed to determine if exogenous periostin treatment induced the
phosphorylation of Akt at serine 473. As shown in Figure 3.5c, addition of periostin had
no discernible effects on the phosphorylation of serine 473 in HTS fibroblasts after
treatment with periostin in media for 60 minutes relative to vehicle controls (N=1 patient,
n=3).

3.6.3

Assessment of Glycogen synthase kinase - 3 beta (GSK-3β)
inhibition effects on periostin-induced HTS fibroblast
proliferation

GSK-3β inhibitor VIII is a small molecule inhibitor that competes with the ATP binding
site in the catalytic domain of GSK-3β. To determine if periostin signalling required
GSK-3β activity to promote HTS fibroblast proliferation, GSK-3β inhibitor VIII and
periostin (2 µg/ml) were included in a subset of cultures of HTS fibroblasts and
proliferation was assessed using WST-1 assays. 1 µM GSK-3β inhibitor VIII was used in
these experiments as this concentration has been demonstrated to enhance prostate cancer
cell proliferation (196). GSK-3β inhibitor VIII has no discernible off-target effects at
concentrations up to 10 µM (194). GSK-3β inhibition had no discernible effects on
periostin-induced or basal HTS fibroblasts proliferation relative to vehicle controls
(Figure 3.6a and b, N=3 patients, n=3). In addition to WST-1 proliferation assays,
western immunoblotting studies were performed to determine if exogenous periostin
treatment increased β-catenin levels or the phosphorylation of GSK-3β at serine 9. As
shown in Figure 3.6c, addition of periostin did not enhance β-catenin levels or induce
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Figure 3.6 Glycogen synthase kinase–3 beta inhibition had no effect on hypertrophic
scar fibroblast proliferation. Primary hypertrophic scar (HTS)-derived fibroblasts were
cultured onto two-dimensional collagen substrates containing periostin (PN, 2 µg/ml) or
vehicle (veh). Culture medium was supplemented with 1 µM GSK-3β inhibitor VIII
(GSK-3βi) or DMSO and proliferation was assessed in WST-1 assays. GSK-3β inhibition
had no discernible effect on (a) PN-induced or (b) basal HTS fibroblast proliferation
relative to vehicle controls (N=3 patients, n=3). Data are presented by mean difference
scores relative to day one absorbance readings and SEM. (c) Primary HTS fibroblasts
were cultured on two- dimensional collagen cultures for 72 hours, washed overnight in
serum-free medium and treated with 2 µg/ml PN or vehicle for 60 minutes in serum-free
medium. Total cell lysates were extracted and assessed for β-catenin and total and
phosphorylated (ser 9) GSK-3β immunoreactivity by western immunoblotting as
described in 2.2.6. Exogenous PN treatment did not affect β-catenin levels or induce
GSK-3β phosphorylation relative to vehicle controls (N=1 patient, n=3). (d) Positive
control demonstrating that 1 µM GSK-3β inhibitor VIII was effective in inhibiting GSK3β activity by increasing β-catenin levels. β-actin immunoreactivity was assessed to
ensure equal protein loading. Representation immunoblots are shown.
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GSK-3β phosphorylation at serine 9 in HTS fibroblasts after exposure to periostin in
media for 60 minutes relative to vehicle controls (N=1 patient, n=3).

3.6.4

Assessment of Rho kinase (ROCK) inhibition effects on
periostin-induced HTS fibroblast proliferation.

Y27632 is a small molecule inhibitor that competes with the ATP binding site in the
catalytic domain of ROCK. To determine if periostin signalling required ROCK activity
to enhance HTS fibroblast proliferation, Y27632 and periostin (2 µg/ml) were included in
a subset of cultures of HTS fibroblasts and proliferation was assessed using WST-1
assays. 10 µM Y27632 was used in these experiments which has been demonstrated to
inhibit NIH 3T3 and human gingival fibroblast proliferation (197, 198). Y27632 has
modest off-target effects at this concentration (194). A significant interaction between
Y27632 treatment and time was observed (p<0.05) and ROCK inhibition significantly
attenuated periostin-induced HTS fibroblast proliferation over seven days relative to
vehicle controls with a strong trend (p=0.051) towards decreased proliferation evident at
day seven (Figure 3.7a, N=3 patients, n=3). In contrast, ROCK inhibition had no
discernible effects on the basal proliferation of HTS fibroblasts cultured under identical
conditions (Figure 3.7b, N=3 patients, n=3). In parallel, western immunoblotting was
performed to determine if exogenous periostin treatment induced the phosphorylation of
myosin light chain (MLC), an established downstream target of ROCK. MLC
phosphorylation at serine 19 was not detected under these culture conditions (data not
shown).

3.6.5

Extracellular signal-regulated kinase (ERK) inhibition effects
on periostin-induced HTS fibroblast proliferation

ROCK has previously been shown to enhance proliferation through ERK (197-201).
Therefore, the effects of ERK inhibition were assessed on periostin-induced HTS
fibroblast proliferation. PD98059 is a small molecule inhibitor that prevents binding and
activation of ERK1/2 by the ERK specific mitogen-activated protein kinase, MEK. To
determine if periostin signalling required ERK1/2 activity to promote HTS fibroblast
proliferation, PD98059 and periostin (2 µg/ml) were included in a subset of cultures of
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Figure 3.7 Rho kinase inhibition attenuates periostin-induced hypertrophic scar
fibroblast proliferation. Primary hypertrophic scar (HTS)-derived fibroblasts were
cultured onto two-dimensional collagen substrates containing periostin (PN, 2 µg/ml) or
vehicle (veh). Culture medium was supplemented with 10 µM Y27632 (ROCKi) or
vehicle and proliferation was assessed in WST-1 assays. (a) ROCK inhibition
significantly attenuated PN-induced HTS fibroblast proliferation relative to vehicle
controls over the course of the assay (N=3 patients, n=3). (b) In contrast, ROCK
inhibition had no discernible effect on basal HTS fibroblast proliferation (N=3 patients,
n=3). Significant treatment/time interactions are denoted by #p<0.05 (ANOVA of
repeated measures). Data are presented by mean difference scores relative to day one
absorbance readings and SEM.
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Figure 3.8 Extracellular signal-regulated kinase inhibition had no effect on basal or
periostin-induced hypertrophic scar fibroblast proliferation. Primary hypertrophic
scar (HTS)-derived fibroblasts were cultured on two-dimensional collagen substrates
containing periostin (PN, 2 µg/ml) or vehicle (veh). Culture medium was supplemented
with 20 µM PD98059 (ERKi) or DMSO and proliferation was assessed in WST-1 assays.
ERK inhibition had no discernible effect on (a) PN-induced or (b) basal HTS fibroblast
proliferation over the course of the assay relative to vehicle controls (N=3 patients, n=3).
Data are presented by mean difference scores relative to day one absorbance readings and
SEM. (c) Primary HTS fibroblasts were cultured on two-dimensional collagen cultures
for 72 hours, washed overnight in serum-free medium and treated with 2 µg/ml PN or
vehicle for 60 minutes in serum-free medium. Total cell lysates were assessed for total
and phosphorylated (thr 202/tyr 204, thr185/tyr187) ERK immunoreactivity by western
immunoblotting as described in 2.2.6. Exogenous PN treatment did not enhance ERK
phosphorylation relative to vehicle controls (N=1 patient, n=3). (d) Positive control
demonstrating that 20 µM ERK inhibitor, PD98059, was effective at inhibiting TGFβ-1induced ERK1/2 phosphorylation. β-actin immunoreactivity was assessed to ensure equal
protein loading. Representative immunoblots are shown.
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HTS fibroblasts and proliferation was assessed using WST-1 assays. 20 µM PD98059
was used in these experiments based on previous studies investigating the effects of ERK
inhibition on human cardiac and dermal fibroblast proliferation (195). At 50 µM,
PD98059 has no discernible off-target effects (202). Inhibition of ERK activity had no
discernible effects on periostin-induced or basal HTS fibroblast proliferation relative to
vehicle controls (Figure 3.8a and b, N=3 patients, n=3). In parallel, western
immunoblotting studies were performed to determine if exogenous periostin treatment
induced the phosphorylation of ERK1/2. As shown in Figure 3.8c, periostin treatment did
not increase ERK1/2 phosphorylation relative to vehicle controls after exposure to
periostin in media for 60 minutes (N=1 patient, n=3).

3.7 Discussion
A central hypothesis of this thesis was that periostin contributes to excessive fibroblast
proliferation in hypertrophic scarring. The in vitro studies presented in this chapter
demonstrate that exogenous periostin treatment was able to enhance the proliferation of
fibroblasts derived from abnormal scar tissue, supporting the central hypothesis. Periostin
appears to elicit this effect in HTS fibroblasts through Akt and ROCK dependent
pathways. In contrast, exogenous periostin had no discernible effects on the proliferation
of NS fibroblasts cultured under identical conditions on type I collagen substrates.
One of the molecular features of hypertrophic scarring is the increased expression of
POSTN and the abnormal abundance and persistence of its protein product, periostin.
Real time PCR and western immunoblotting studies indicated that POSTN expression and
periostin levels were increased in primary fibroblasts derived from HTS tissue relative to
NS tissue in in vitro cultures. These data are consistent with previous in vivo studies
performed by our laboratory (95, 96) and by other groups (97, 99) which demonstrated
that POSTN expression is markedly increased in the basal epithelium and in dermal
fibroblasts, and that periostin is abnormally abundant in the dermis of hypertrophic scar
tissue relative to normal scar tissue. These findings indicate that POSTN expression and
periostin levels in primary fibroblasts derived from NS and HTS tissues reflect the tissues
from whence they were derived and these cells are therefore likely to be representative in
vitro models of scarring.
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As discussed in section 1.6.1, POSTN is alternatively spliced and up to eight human
POSTN variants have been reported (101, 102, 116, 117, 188-190). The expression and
function of these variants is currently unclear and the identity of specific POSTN variants
expressed in hypertrophic scarring has not been previously reported. With reversetranscription PCR, four amplicons were identified in total RNA extracted from HTS
fibroblasts, and these amplicons corresponded to four of the POSTN variants previously
identified (101). The largest and most abundant of these amplicons was identified as
POSTN variant 1 by DNA sequencing. In addition, three additional splice variants (2, 3
and 4) were detected in HTS fibroblasts and sequenced. To our knowledge, this is the
first study to identify different POSTN variants in hypertrophic scarring. Comparisons
between the immunoreactivity of recombinant periostin and the endogenously produced
periostin in human hypertrophic scar tissue lysates revealed that 2 µg/ml of recombinant
periostin approximated the levels of periostin in hypertrophic scars in vivo (91, 96).
Based on these findings, the effects of treating HTS and NS fibroblasts with recombinant
periostin isoform 1 at 2 µg/ml were investigated in the remainder of the thesis.
A small number of in vitro studies have assessed the effects of periostin on proliferation
in cells cultured on substrates that mimic the microenvironment (91, 203). However, the
majority of in vitro studies (132, 152, 178-180, 187) have assessed periostin effects on
proliferation in cells cultured on rigid tissue culture plastic. Tissue culture plastic
provides an extremely stiff substrate that greatly exceeds the stiffness of the ECM of
contracting or fibrotic tissues in vivo (169, 170) and invariably leads to robust
myofibroblast differentiation in fibroblast cultures (31). Therefore, culturing primary
fibroblasts on plastic substrates may provide misleading information derived from the
differences in fibroblast and myofibroblast sensitivities to treatments. For this reason, the
effects of periostin on HTS fibroblast proliferation was assessed on type I collagen
substrates, the most abundant collagen in normal skin and mature scar tissue (8). As a
matricellular protein, periostin serves as a link between cells and their collagenous ECM,
and it can modify cellular behavior in response to external stimuli, including changes in
ECM stiffness (90). Using collagen substrates, periostin can be incorporated into a
collagenous ECM matrix to mimic its localization in vivo and provide a model system to
assess the effects of ECM-associated periostin on HTS fibroblast proliferation under
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physiological relevant conditions. Compliant 2D collagen gels have a Young’s modulus
of 300-400 Pa, which is equivalent to the ECM stiffness found in the provisional matrix
in vivo (31, 173). Since fibroblasts are recruited to a similarly compliant provisional
matrix during cutaneous wound healing (8), 2D collagen substrates provide a more
physiologically representative in vitro model.
Fibroblast proliferation was assessed using the WST-1 proliferation assay, which
measures cellular mitochondrial activity as an indicator of net cellular proliferation (the
combined effects of growth and apoptosis). While this approach provides an indirect
measure of proliferation, it is an optimal approach in this context because it avoids the
need to disrupt cellular interactions with periostin embedded into the collagen substrate.
Optimization studies in our laboratory have demonstrated a linear correlation between
manual cell counts and WST-1 absorbance over a range of 0.03 to 0.4 absorbance units at
450 nm with every 0.038 nm correlating to approximately 1000 cells (data not shown). In
addition, WST-1 absorbance values plateau in HTS fibroblasts cultured in the presence of
mitomycin C, an established inhibitor of cellular proliferation (204), on 2D collagen
substrates (data not shown). These findings indicate that this assay is a representative
measure of cellular proliferation under these culture conditions.
Periostin has been demonstrated to induce the proliferation of various cell types in other
culture systems (91, 132, 152, 178-180, 187). The data presented in this chapter indicates
that exogenous ECM-associated periostin significantly enhances HTS fibroblast
proliferation on 2D compliant collagen cultures. Based on these findings and the
accumulation of periostin in the dermis of excisional mouse wounds as early as three
days post wounding (98, 151), periostin may act as a growth factor during the initial
stages of wound healing to increase fibroblast numbers at the wound site. Fibroblast
proliferation in the provisional matrix and newly formed granulation tissue is vital for the
regeneration of a functional dermis (8). Therefore, the persistent and abundant levels of
periostin observed in the dermis of hypertrophic scars may continue to promote excessive
fibroblast proliferation after wound closure. Excessive fibroblast proliferation at the
wound site would be predicted to enhance the dermal density of the wound to abnormal
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levels and promote excessive myofibroblast differentiation, thereby enhancing
hypertrophic scar formation.
In contrast to HTS fibroblasts, exogenous periostin treatment had no effect on the
proliferation of NS fibroblasts. The mechanisms that explain these differences in
sensitivity to periostin between HTS and NS fibroblasts have yet to be elucidated. One
possibility is that a combination of fibrosis-associated growth factors is required to
“activate” NS fibroblasts to induce periostin sensitivity in these cells. This activation may
include the expression of a receptor(s) or other interacting molecules not normally
present in unwounded NS fibroblasts, or activation of a sequential or parallel pathway(s)
required for periostin signalling. These possibilities are further addressed in Chapter 4.6.
As NS fibroblasts appear relatively insensitive to ECM-associated periostin under these
culture conditions, that may suggest that periostin promotes pathological, rather than
normal, fibroblast proliferation. It remains unclear if periostin-induced fibroblast
proliferation is a normal or abnormal component of cutaneous wound healing in humans,
as normal scar tissue samples could not be obtained for primary cell derivation due to
ethical constraints. Collectively, these studies indicate that periostin specifically enhances
the growth of abnormal scar-derived fibroblasts cultured on 2D collagen substrates.
Therefore, periostin may be an attractive therapeutic target for therapies designed to
inhibit excessive fibroblast proliferation characteristically observed in hypertrophic
scarring.
The second component of this chapter was to identify the signalling intermediates utilized
by periostin to promote HTS fibroblast proliferation on 2D collagen cultures. As periostin
has been demonstrated to signal through the PI3K/Akt pathway to elicit tumour growth
(129-131) and proliferation of several cell types in vitro (132, 187), initial studies focused
on these intermediates. PI3K inhibition was shown to significantly attenuate both basal
and periostin-induced HTS fibroblast proliferation. These data were interpreted to
indicate that PI3K inhibition attenuates multiple pathways involved in cellular
proliferation and is therefore unlikely to be helpful for distinguishing the specific effects
of periostin from other signalling pathways that also induce proliferation in a PI3K
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dependent manner. Therefore, the effects of Akt inhibition, an established downstream
target of PI3K (205), were assessed on periostin-induced HTS fibroblast proliferation.
Akt inhibition significantly attenuated periostin-induced HTS fibroblast proliferation
while having no discernible effects on basal proliferation. These data are consistent with
previous reports demonstrating that periostin promoted the proliferation of rat
cardiomyocytes and retinal pigment epithelial cells through a PI3K/Akt dependent
pathway (132, 187). Although significant, the effects of Akt inhibition on periostininduced HTS fibroblast proliferation were quite modest and proliferation was attenuated
by approximately 19% over seven days relative to vehicle controls. The modest
cumulative reduction in proliferation across seven days led to the conclusion that Akt was
not the major signalling pathway intermediate utilized for periostin-induced HTS
fibroblast proliferation under these culture conditions.
While Akt inhibition significantly attenuated periostin-induced HTS fibroblast
proliferation using WST-1 assays, no evidence of periostin-induced Akt activation was
observed by western immunoblotting. These findings are inconsistent with previous
reports demonstrating that periostin enhanced Akt activation in other systems (130, 152,
187). The contrasting findings between the WST-1 and western immunoblotting studies
may be explained by the technical limitations of assessing matricellular interactions by
western immunoblotting. Unlike the WST-1 assays, where periostin was incorporated
into a collagen-rich matrix where it was constantly available to stimulate proliferation, it
was necessary to add periostin directly to the culture medium to assay for rapid changes
in Akt phosphorylation by western immunoblotting. Fibroblast attachment and spreading
onto collagen substrates after seeding takes several hours. If periostin was incorporated
into the collagen substrates prior to seeding, HTS fibroblasts would be exposed to
periostin throughout the attachment and spreading process. Once these fibroblasts had
achieved normal morphology, any effects of periostin on Akt activation may no longer be
detectable, as Akt phosphorylation is typically rapid and transient. Therefore, periostin
was added to the culture medium after the fibroblasts achieved normal morphology (130,
152, 187) in order to assess its effects on Akt activation. As it is a matricellular protein,
periostin interacts with cells while attached to the surrounding ECM and modifies cellular
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signalling and phenotype in response to changes in the microenvironment (90). It is
plausible that soluble periostin (added to the culture medium) is functionally distinct from
ECM-associated periostin and this may explain why no changes in kinase
phosphorylation were detected.
To identify additional signalling pathway(s) utilized by periostin to induce HTS
fibroblast proliferation, a series of pharmacological inhibitors targeted against GSK-3β,
ROCK and ERK1/2, each of which are established signalling intermediates in cellular
proliferation (201, 206, 207), were assessed. These studies demonstrated that inhibition
of GSK-3β and ERK had no discernible effects on basal or periostin-induced HTS
fibroblast proliferation in 2D collagen cultures, whereas ROCK inhibition significantly
attenuated periostin-induced HTS fibroblast proliferation.
In addition to its well established roles in mediating stress fiber formation, focal adhesion
formation and contraction of myofibroblasts (49-53, 208, 209), ROCK has also been
shown to mediate proliferation in corneal epithelial cells (200, 210), neuroblastoma cells
(211), hepatic stellate cells (201) and NIH 3T3 mouse fibroblasts (197). The ROCK
specific inhibitor, Y27632, used for the studies in Chapter 3 had no effect on basal levels
of proliferation relative to vehicle treated HTS fibroblasts, consistent with previous
reports in corneal epithelial cells and neuroblastoma cells (210, 211). These data
demonstrate that ROCK signalling is not essential for basal HTS fibroblast proliferation.
However, ROCK inhibition significantly attenuated periostin-induced HTS fibroblast
proliferation and this effect was more pronounced than that observed with Akt inhibition
(37% decrease vs 19% decrease in proliferation over seven days). These data indicate that
periostin also promotes HTS fibroblast proliferation in 2D collagen cultures through a
ROCK dependent pathway. To our knowledge, this is the first study to identify ROCK as
a signalling intermediate in periostin-induced proliferation in any model system.
Previous studies have demonstrated that ROCK induces the expression of cell cycle
progression proteins, including cyclin D1, through a Ras/ERK mediated pathway (197201). However, ERK inhibition had no discernible effect on periostin-induced HTS
fibroblast proliferation. Parallel studies of CCND1 expression, encoding cyclin D1, were
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performed by culturing HTS fibroblasts in serum free media for 72 hours in order to
synchronize the fibroblasts in G0 prior to stimulation with serum and soluble periostin.
No effects on CCND1 expression were evident in periostin treated samples relative to
serum controls after 3 hours (data not shown). As described for the western
immunoblotting assays for Akt activity, periostin was not incorporated in the collagen
substrates in these experiments, as it was necessary to synchronize the cells in G0 prior to
periostin stimulation. HTS fibroblasts secrete high levels of endogenous periostin, so it is
very likely that these cells were exposed to periostin during the synchronization process
prior to treatment, making these experiments difficult to interpret. It is currently unclear
if soluble and ECM-associated periostin have differential effects on the behavior of HTS
fibroblasts. Exposure to periostin during the synchronization process and treatment with
soluble periostin may explain why CCND1 expression was not altered in these
experiments. The downstream mechanisms involved in ROCK-dependent periostininduced HTS fibroblast proliferation will be a focus of future studies.
Previous studies have reported conflicting data in regards to the regulation of ROCK
activity by PI3K activation (130, 212, 213), and this interaction may be dependent on
particular cell type and/or specific treatment conditions (214). As PI3K inhibition
significantly attenuated HTS fibroblast proliferation, it is conceivable that PI3K
activation may be involved in periostin-induced ROCK activation in 2D collagen
cultures. Future studies, outside the scope of this thesis, will investigate whether PI3K or
a parallel pathway activates ROCK to promote periostin-induced HTS fibroblast
proliferation in 2D collagen cultures.
In summary, periostin enhances HTS fibroblast proliferation in 2D collagen cultures that
mimic the mechanical tension of the provisional matrix in the early stages of cutaneous
wound healing in vivo (31, 173). As a hallmark of abnormal scarring, excessive fibroblast
proliferation increases cell density and ECM deposition in the wound thereby increasing
the number of cells available for myofibroblast differentiation and promoting abnormal
dermal density. These studies demonstrate that periostin promotes HTS fibroblast
proliferation through an Akt dependent pathway, consistent with previous reports (132,
187). Furthermore, periostin was shown for the first time to enhance HTS fibroblast
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proliferation through a ROCK dependent pathway. As ROCK is better known as an
essential component of myofibroblast differentiation and contraction (30), and since
myofibroblasts are the cellular cause of excessive contraction and remodelling of the
dermis during scar formation, the remainder of this thesis focuses on the roles of periostin
on myofibroblast differentiation and persistence.
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Chapter 4

4

In vitro analysis of the effects of periostin on
myofibroblast differentiation and persistence in
hypertrophic scarring

4.1 Rationale
The myofibroblast is a major cellular contributor in both normal cutaneous wound
healing and abnormal scar formation (27, 28, 56-58). Myofibroblasts combine the
contractile features of smooth muscle cells with the extensive ECM production of
fibroblasts, thereby allowing them to deposit, contract and remodel granulation tissue (29,
31). In normal cutaneous wound healing, myofibroblast numbers increase during the
proliferation phase and gradually undergo apoptosis in the remodelling phase. However,
in abnormal scarring conditions, myofibroblast populations are maintained at high levels
(56, 57, 92-94) due, at least in part, to a prolonged proliferation phase (59). An abnormal
excess of myofibroblasts results in an “overhealing” phenomenon characterized by
excessive collagen production and contracture of the ECM (56, 57, 92-94). The
molecules that promote excessive myofibroblast differentiation and their persistence
during hypertrophic scar formation are unclear.
Previous studies have demonstrated that periostin induces myofibroblast differentiation in
animal models of normal cutaneous wound repair (133) and in primary human palmar
fascia fibroblasts (91). In addition, changes in periostin levels over time have been
demonstrated to parallel αSMA levels in murine models of cutaneous wound healing (98)
suggesting a role for periostin in myofibroblast differentiation. These studies led to the
hypothesis that periostin promotes excessive myofibroblast differentiation and
persistence in hypertrophic scars.
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4.2 Assessment of the basal contractility of hypertrophic
scar- and normal skin-derived fibroblasts in stressed
fibroblast populated collagen lattices (sFPCL)
The basal contractility of primary fibroblasts derived from HTS and NS tissue was
assessed and compared using sFPCL contraction assays as described in 2.2.5. In brief,
primary fibroblasts were seeded into 3D collagen lattices and maintained in culture for 72
hours in 2% FBS-αMEM to promote their tension-mediated differentiation into
myofibroblasts, modelling their differentiation during wound closure in vivo (30, 183).
After 72 hours, the collagen lattices were released from the surrounding well and lattice
contraction was measured over a 24 hour period. As shown in Figure 4.1a, HTS
fibroblasts were significantly more contractile than NS fibroblasts (p<0.01) with
significant increases in contraction observed immediately after release (designated as 0
hr), 6 hours and 24 hours after release (p<0.05, N=6 patients, n=3). Similarly, fibroblasts
derived from keloid scar (KS) tissue, an abnormal scarring condition with similarities to
hypertrophic scarring including increased periostin levels (58, 59, 62, 97, 215), displayed
a non-significant trend (p=0.118) towards increased contractility relative to NS
fibroblasts (Figure 4.1b, N=3 patients, n=3).

4.3 Assessment of the effects of periostin on the
contractility of HTS and NS fibroblasts in sFPCLs
To assess the effects of increased periostin levels in the dermis of hypertrophic scar tissue
on collagen lattice contraction, primary fibroblasts were seeded in sFPCLs with 2 μg/ml
human recombinant periostin or vehicle incorporated into the collagen lattice. A
significant interaction between periostin treatment and time was observed in HTS
fibroblasts (p<0.01) and periostin enhanced HTS fibroblast contractility over 24 hours
relative to vehicle controls with significant differences evident at all time points assessed
(Figure 4.2a, p<0.05, N=8 patients, n=3). Periostin also significantly increased the
contractility of KS fibroblasts above basal levels (p<0.05) with significant differences
evident at lattice release (Figure 4.2b, p<0.05, N=3 patients, n=3). In contrast, a periostinenriched matrix had no discernible effects on the contractility of NS fibroblasts relative to
basal levels (Figure 4.2c, N=6 patients, n=3).
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Figure 4.1 Hypertrophic scar-derived fibroblasts have enhanced contractility
relative to normal skin-derived fibroblasts. To assess the basal contractility of primary
fibroblasts derived from hypertrophic scar (HTS), keloid scar (KS) and normal skin (NS)
tissue, stressed fibroblast populated collagen lattices were used as described in 2.2.5.
Primary fibroblasts were cultured within three-dimensional, tethered collagen lattices for
72 hours to induce myofibroblast differentiation. After 72 hours, collagen lattices were
mechanically released from the surrounding wells allowing for myofibroblast-mediated
contraction of the free floating collagen lattices. Area measurements were taken over a 24
hour period following release. (a) HTS fibroblasts significantly contracted collagen
lattices to a greater extent than NS fibroblasts (N=6 patients, n=3). (b) A non-significant
trend (p=0.118) towards enhanced collagen lattice contraction was observed in KSderived fibroblasts relative to NS fibroblasts (N=3 patients, n=3). Significant overall
treatment effects are denoted by ^^p<0.01 (ANOVA of repeated measures). Significant
treatment effects at individual time points are denoted by *p<0.05 and **p<0.01 (t-tests).
Data are presented by mean values and SEM.
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Figure 4.2 Periostin enhances collagen lattice contraction in abnormal scar-derived
fibroblasts. To assess the effects of periostin (PN) on collagen lattice contraction,
primary hypertrophic scar (HTS)-, keloid scar (KS)- and normal skin (NS)-derived
fibroblasts were cultured in stressed fibroblast populated collagen lattices containing 2
µg/ml PN or vehicle (veh, 0.1% BSA in PBS). (a) Exogenous PN treatment significantly
enhanced HTS fibroblast collagen lattice contraction over 24 hours relative to vehicle
controls (N=8 patients, n=3). (b) Exogenous PN treatment also significantly enhanced KS
fibroblast collagen lattice contraction relative to vehicle controls (N=3 patients, n=3). (c)
Exogenous PN treatment had no discernible effect on NS fibroblast collagen lattice
contraction (N=6 patients, n=3). Significant overall treatment effects are denoted by
^p<0.05 and significant treatment/time interactions are denoted by ##p<0.01 (ANOVA of
repeated measures). Significant treatment effects at individual time points are denoted by
*p<0.05 and **p<0.01 (t-tests and simple main effects analyses). Data are presented by
mean values and SEM.
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4.4 Identification of the mechanisms utilized by periostin to
enhance HTS fibroblast contractility
These findings suggested that, unlike NS fibroblasts, HTS fibroblasts were sensitive to
periostin in their ECM and responded to its presence by increasing collagen lattice
contraction. Periostin could potentially induce collagen lattice contraction through
several mechanisms. These include increasing fibroblast proliferation and/or viability in
the collagen lattice, increasing fibroblast migration and adhesion within the lattice, or by
enhancing myofibroblast differentiation. Each of these mechanisms was assessed in turn
to identify the molecular mechanism(s) utilized by periostin to induce collagen lattice
contraction.

4.4.1

Assessment of the effects of periostin on cell viability in
sFPCLs

To determine the effects of periostin on HTS fibroblast viability in sFPCLs, cell
membrane permeability and BCL2/BAX mRNA ratio, independent markers of cell
viability, were independently assessed using flow cytometry (2.2.8) and real time PCR
(2.2.7), respectively. Exogenous periostin treatment had no discernible effect on HTS
fibroblast membrane permeability in sFPCLs after 72 hours in culture (Figure 4.3a, N=4
patients, n=3) or BCL2/BAX ratio after 48 hours in sFPCL culture relative to vehicle
controls (Figure 4.3b, N=3 patients, n=3). Similarly, exogenous periostin treatment had
no discernible effect on the BCL2/BAX ratio in KS fibroblasts after 48 hours in sFPCL
culture relative to vehicle controls (Figure 4.3c, N=3 patients, n=3).

4.4.2

Assessment of the effects of periostin on proliferation in
sFPCLs

To determine if periostin induced HTS fibroblast proliferation in 3D cultures, CCND1
expression was measured by real time PCR 48 hours after culture in a sFPCL, with or
without periostin treatment. In contrast to periostin-induced HTS fibroblast proliferation
in compliant 2D cultures over a seven day period, periostin had no effect on CCND1
expression in HTS fibroblasts cultured under mechanical tension (Figure 4.4a, N=3
patients, n=3). Exogenous periostin treatment also had no discernible effect on CCND1
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Figure 4.3 Periostin had no effect on hypertrophic scar fibroblast viability in
stressed fibroblast populated collagen lattices. Primary hypertrophic scar (HTS) and
keloid scar (KS) fibroblasts were cultured in stressed fibroblast populated collagen
lattices (sFPCLs) containing periostin (PN, 2 µg/ml) or vehicle (veh). (a) The effects of
PN on HTS fibroblast membrane permeability, an indicator of cellular viability, was
assessed after 72 hours in sFPCL culture using flow cytometry as described in 2.2.8. PN
had no discernible effect on HTS fibroblast viability relative to vehicle controls (N=4
patients, n=3). (b and c) The effects of PN on BCL2/BAX expression, a marker of
apoptosis, were assessed in HTS and KS fibroblasts cultured in sFPCLs for 48 hours by
real time PCR (2.2.7). PN had no effect on the BCL2/BAX ratio in (b) HTS or (c) KS
fibroblasts relative to vehicle controls when cultured under mechanical tension. Values
were normalized to vehicle controls (N=3 patients, n=3). Ultraviolet (UV) irradiation of
HTS cells for 60 minutes was utilized as a positive control to induce cell death. Data are
presented by mean values and SEM. RQ=relative quantification.
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Figure 4.4 Periostin had no effect on hypertrophic scar fibroblast proliferation in
stressed fibroblast populated collagen lattices. Primary hypertrophic scar (HTS) and
keloid scar (KS) fibroblasts were cultured in stressed fibroblast populated collagen
lattices (sFPCLs) containing periostin (PN, 2 µg/ml) or vehicle (veh) for 48 hours.
CCND1 expression, a marker of proliferation, was assessed in total RNA by real time
PCR as described in 2.2.7. Exogenous periostin treatment did not affect CCND1
expression in (a) HTS or (b) KS fibroblasts cultured under mechanical tension relative to
vehicle controls. Values were normalized to vehicle controls (N=3 patients, n=3).
Transforming growth factor (TGF)β-1 (5 ng/ml) was utilized as a control to inhibit
CCND1 expression. Data are presented by mean values and SEM. RQ=relative
quantification.
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expression in KS fibroblasts cultured under identical conditions (Figure 4.4b, N=3
patients, n=3).

4.4.3

Assessment of the effects of periostin on adhesion and 3D
migration in rFPCLs

Relaxed FPCLs (rFPCLs), described in 2.2.5, were utilized to assess the effects of
periostin on HTS fibroblast adhesion and migration in 3D collagen cultures. Fibroblasts
cultured in rFPCLs are not subjected to mechanical tension and do not undergo cultureinduced myofibroblast differentiation (183). Instead, lattice contraction is induced by
tractional forces generated by cellular adhesion to the collagen and migration within the
lattice (183, 216, 217). Periostin treatment had no discernible effect on HTS or KS
fibroblast contractility in rFPCLs (Figure 4.5a and b, N=3 patients, n=3).

4.4.4

Assessment of the effects of periostin on myofibroblast
differentiation in sFPCLs

To determine if periostin-induced HTS fibroblast contraction of sFPCLs was the result of
enhanced myofibroblast differentiation, cell lysates were derived from sFPCLs
immediately prior to collagen lattice release (after 72 hours of culture in the restrained
lattice). αSMA and OB cadherin levels, established markers of myofibroblast
differentiation (30, 218), were assessed by western immunoblotting and densitometry.
Exogenous periostin treatment significantly increased αSMA levels in HTS fibroblasts
relative to vehicle controls under identical culture conditions (Figure 4.6a, p<0.05, N=5
patients, n=3). A non-significant trend (p=0.066) towards increased OB cadherin levels
was observed in periostin treated HTS fibroblasts relative to vehicle controls (Figure
4.6b, N=5 patients, n=3). Periostin had no discernible effects on αSMA or OB cadherin
levels in KS fibroblasts relative to vehicle controls (Figure 4.6c and d, N=3 patients,
n=3).
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Figure 4.5 Periostin had no effect on hypertrophic scar fibroblast adhesion and
migration in three dimensional collagen cultures. To assess the effects of exogenous
periostin (PN) treatment on fibroblast adhesion and migration in three-dimensional (3D)
collagen cultures, primary hypertrophic scar (HTS) and keloid scar (KS) fibroblasts were
cultured in relaxed fibroblast populated collagen lattices containing PN (2 µg/ml) or
vehicle (veh) as described in 2.2.5. Area measurements of the contracted collagen lattices
were performed 24 hours after collagen lattice release. PN had no discernible effect on
(a) HTS or (b) KS fibroblast migration in 3D collagen cultures (N=3 patients, n=3).
Platelet-derived growth factor (PDGF) treatment (100 ng/ml) was utilized as a positive
control to induce fibroblast migration based on previous studies (219). Data are presented
by mean values and SEM.
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Figure 4.6 Periostin enhances myofibroblast differentiation in hypertrophic scarderived fibroblasts. Primary hypertrophic scar (HTS) and keloid scar (KS) fibroblasts
were cultured in stressed fibroblast populated collagen lattices containing periostin (PN,
2µg/ml) or vehicle (veh) for 72 hours as described in 2.2.5. Total cell lysates were
assessed for alpha smooth muscle actin (αSMA) and OB cadherin immunoreactivity,
markers of myofibroblast differentiation, by western immunoblotting and densitometry,
as described in 2.2.6. (a) Exogenous PN treatment significantly increased αSMA levels in
HTS fibroblasts cultured in sFPCLs relative to vehicle controls (N=5 patients, n=3). (b) A
non-significant trend (p=0.066) towards increased OB cadherin levels were observed in
HTS fibroblast cultured in sFPCLs embedded with PN relative to vehicle controls (N=5
patients, n=3 patients). Exogenous PN treatment had no discernible effects on (c) αSMA
and (d) OB cadherin levels in KS fibroblasts relative to vehicle controls. Values were
normalized to vehicle controls. β-actin immunoreactivity was assessed to ensure equal
protein loading. Significant treatment effects are denoted by *p<0.05 (t-tests). Data are
presented by mean values and SEM. Representative immunoblots of the mean
densitometry data are shown. AU=arbitrary units.
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4.5 Assessment of the effects of periostin-depletion of HTS
myofibroblast differentiation in sFPCLs
As shown in Figure 3.1b, HTS fibroblasts exhibit increased endogenous periostin levels
relative to NS cells. The effects of exogenous periostin treatment on HTS fibroblasts
described in the previous sections were therefore over and above the effects of
endogenous periostin signalling. To obtain further support for the central hypothesis of
this section, loss of function studies were performed in HTS fibroblasts by transducing
them with an adenoviral vector containing a shRNA targeted against POSTN.

4.5.1

Assessment of POSTN expression and periostin levels in
HTS fibroblasts following adenoviral transduction with
shRNAs against POSTN

HTS fibroblasts were transduced with adenoviral vectors expressing either shRNAs
against POSTN or scrambled control shRNAs. Transduction was at a multiplicity of
infection (MOI) of 25 and the transduced fibroblasts were cultured on plastic tissue
culture dishes for 72 hours in 2% FBS-αMEM. Transduction efficiency was then
determined by assessing the percentage of cells expressing green fluorescent protein
(GFP) by epifluorescence microscopy. As shown in Figure 4.7a and b, adenovirus
transduction efficiency approximated 100% for all experiments assessed. Transduced
HTS fibroblasts were then seeded into sFPCLs and POSTN and periostin levels were
assessed after 72 hours in culture under 3D tension by real time PCR and western
immunoblotting, respectively. As shown in Figure 4.7c and d, adenoviral transduction
with shRNAs against POSTN significantly reduced POSTN expression by 92% and
periostin levels by 60% relative to scrambled shRNA controls (p<0.001, N=4 patients,
n=3).

4.5.2

Assessment of the effects of periostin depletion on HTS
myofibroblast differentiation in sFPCLs

To assess the effects of periostin depletion on HTS myofibroblast differentiation in
sFPCLs, HTS fibroblasts were transduced with adenovirus expressing shRNAs against
POSTN or scrambled control shRNAs for 72 hours in 2% FBS-αMEM prior to seeding in
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Figure 4.7 POSTN expression and periostin levels are significantly depleted in
hypertrophic scar fibroblasts transduced with adenovirus expressing shRNAs
against POSTN. Primary hypertrophic scar (HTS)-derived fibroblast were transduced
with adenoviral vectors encoding shRNAs against POSTN or scrambled control shRNAs
at a multiplicity of infection of 25. The adenoviral vector co-expresses green fluorescent
protein, allowing transduction efficiency to be assessed by epifluorescence microscopy.
(a) Comparisons of epifluorescence and (b) differential interference contrast microscopy
indicate that transduction efficiency approximated 100% in all experiments. (c and d)
Following adenoviral transduction, HTS fibroblasts were cultured in sFPCLs for 72
hours. (c) POSTN expression was assessed in total RNA by real time PCR as described in
2.2.7. Periostin depletion by shRNA treatment significantly decreased POSTN expression
in HTS fibroblasts by 92% relative to scrambled controls (N=3 patients, n=3). (d) Total
cell lysates were assessed for periostin immunoreactivity by western immunoblotting and
densitometry as described in 2.2.6. Periostin depletion by shRNA treatment significantly
decreased periostin levels by 60% relative to scrambled controls (N=4 patients, n=3).
Values were normalized to scrambled shRNA controls. β-actin immunoreactivity was
assessed to ensure equal protein loading. Significant treatment effects are denoted by
***p<0.001 (t-tests). Data are presented by mean values and SEM. Representative
immunoblots of the mean densitometry data are shown. RQ=relative quantification,
AU=arbitrary units.
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sFPCLs. No significant effects on the ability of HTS fibroblasts to contract sFPCLs were
observed in periostin-depleted HTS or KS fibroblasts relative to scrambled controls
(Figure 4.8a and b, N=3 patients, n=3 for each). Periostin depletion by shRNA treatment
had no discernible effect on αSMA levels in HTS fibroblasts relative to scrambled
shRNA controls (Figure 4.9a, N=4 patients, n=3). However, a significant decrease in
αSMA levels was observed in periostin-depleted fibroblasts relative to scrambled shRNA
controls in two of the four HTS patient fibroblast lines assessed (p<0.05, Figure 4.9b).
Periostin depletion by shRNA treatment had no effect on OB cadherin levels in HTS
fibroblasts relative to scrambled shRNA controls (Figure 4.9c, N=4 patients, n=3).
Additionally, periostin depletion by shRNA treatment had no significant effect on αSMA
or OB cadherin levels in KS fibroblasts relative to scrambled shRNA controls (Figure
4.10a and b, N=3 patients, n=3).

4.6 Assessment of NS fibroblast responses to periostin
The contraction data presented in section 4.3 demonstrates that periostin induces collagen
lattice contraction in HTS fibroblasts but not in NS fibroblasts. As NS fibroblasts are
unlikely to be exposed to the growth factors and cytokines that promote abnormal wound
healing, it was proposed that NS fibroblasts might need to be “activated” by fibrosisassociated factors before they can respond to periostin treatment. While not a major
focus of this thesis, the following section describes pilot studies to identify some of the
factors required for NS fibroblast “activation” in this model system.

4.6.1

Assessment of the effects of TGFβ-1 priming on NS
fibroblast contractility

During cutaneous wound healing, TGFβ-1 is released following injury to the dermis and
plays a critical role in many processes essential to normal wound repair (8, 13, 41, 174177, 220). With relevance to the roles of periostin described in the previous sections,
TGFβ-1 signalling is required for myofibroblast differentiation (40, 41). Therefore, it was
proposed that priming with TGFβ-1 might be required to sensitize NS fibroblasts to the
presence of periostin. To assess this, cultures were pretreated with 5 ng/ml human
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Figure 4.8 Periostin depletion had no effect on collagen lattice contraction in
hypertrophic scar-derived fibroblasts. Primary hypertrophic scar (HTS) and keloid
scar (KS)-derived fibroblasts were transduced with adenoviral vectors expressing
shRNAs targeted against POSTN or scrambled control shRNAs for 72 hours on tissue
culture plastic. To assess the effects of periostin depletion on collagen lattice contraction,
shRNA treated HTS and KS fibroblasts were cultured in stressed fibroblast populated
collagen lattices described in 2.2.5. Collagen lattice contraction was assessed over a 24
hour period. Periostin depletion by shRNA treatment had no effect on (a) HTS or (b) KS
fibroblast collagen lattice contraction relative to scrambled shRNA controls (N=3
patients, n=3). Data are presented by mean values and SEM.
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Figure 4.9 Periostin depletion significantly decreases αSMA levels in fibroblasts
derived from a subset of HTS patients. Primary hypertrophic scar (HTS)-derived
fibroblasts were transduced with adenoviral vectors expressing shRNAs targeted against
POSTN or scrambled control shRNAs for 72 hours and then seeded into stressed
fibroblast populated collagen lattices. Total cell lysates were assessed for alpha smooth
muscle actin (αSMA) and OB cadherin immunoreactivity, by western immunoblotting
and densitometry, immediately prior to collagen lattice release. (a) Periostin-depletion
had no significant effects on αSMA levels in HTS fibroblasts assessed as a group (N=4
patients, n=3), (b) however, significant decreases in αSMA levels were observed
following periostin depletion in a subset of individual patient-derived fibroblast cultures.
Shown is a representative immunoblot and densitometry data for HTS patient #5. (c) No
discernible effects on OB cadherin levels were observed in periostin-depleted HTS
fibroblasts relative to scrambled shRNA controls (N=4 patients, n=3). Values were
normalized to scrambled shRNA controls. β-actin immunoreactivity was assessed to
ensure equal protein loading. Significant treatment effects are denoted by **p<0.01 (ttests). Data are presented by mean values and SEM. Representative immunoblots of the
mean densitometry data are shown. AU=arbitrary units.
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Figure 4.10 Periostin depletion had no significant effects on myofibroblast markers
in keloid scar fibroblasts. Primary keloid scar (KS)-derived fibroblasts were transduced
with adenoviral vectors expressing shRNAs targeted against POSTN or scrambled control
shRNAs for 72 hours on tissue culture plastic then seeded into stressed fibroblast
populated collagen lattices. Total cell lysates were assessed for alpha smooth muscle
actin (αSMA) and OB cadherin immunoreactivity, by western immunoblotting and
densitometry, immediately prior to collagen lattice release. Periostin-depletion had no
significant effects on (a) αSMA or (b) OB cadherin levels in HTS fibroblasts relative to
scrambled shRNA controls (N=3 patients, n=3). Values were normalized to scrambled
shRNA controls. β-actin immunoreactivity was assessed to ensure equal protein loading.
Data are presented by mean values and SEM. Representative immunoblots of the mean
densitometry data are shown. AU=arbitrary units.
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recombinant TGFβ-1 for 72 hours prior to being seeded into sFPCLs. As shown in Figure
4.11a, a significant increase in sFPCL contraction was evident in TGFβ-1 primed NS
fibroblasts in collagen lattices containing periostin (p<0.05) relative to TGFβ-1 primed
NS fibroblasts in the absence of periostin. This effect was only evident at release and no
significant effects were observed at any time point assessed after release (N=3 patients,
n=3).

4.6.2

Assessment of the effects of HTS-conditioned media on NS
fibroblast contractility in sFPCLs

TGFβ-1 is likely to be only one of many growth factors and cytokines secreted by HTS
fibroblasts. To determine if additional fibrosis-associated signalling molecules were
required to induce periostin sensitivity in NS fibroblasts, the effects of exposing NS
fibroblasts to HTS fibroblast-conditioned culture media were assessed. HTS fibroblasts
were grown to 80% confluency in serum-containing media, washed and cultured for 96
hours in serum free media, after which the conditioned media was collected. NS
fibroblasts were then cultured in sFPCLs in the presence of HTS-conditioned media for
72 hours, with or without periostin addition to the collagen matrix. The addition of HTSconditioned media had no effects on NS fibroblast contraction relative to fibroblasts
cultured in the presence of NS-conditioned media (Figure 4.11b, N=1 patient, n=5).
However, a significant periostin treatment and time interaction (p<0.01) was observed
and the presence of exogenous periostin significantly induced the contractility of NS
fibroblasts cultured in HTS-conditioned media over 24 hours relative to vehicle controls.
Significant increases in periostin-induced NS fibroblast contraction were observed at
collagen lattice release, 0.5 and 2 hours after release (Figure 4.11c, p<0.05, N=1 patient,
n=5).

4.6.3

Identification of potential periostin interactors in HTSconditioned media

A combination of periostin and HTS-conditioned media was found to significantly induce
NS fibroblast contractility, whereas neither of these treatments alone had discernible
effects on the ability of NS fibroblasts to contract collagen lattices. These data were
interpreted to suggest that periostin needed to interact with one or more molecules in
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Figure 4.11 Fibrosis-associated growth factors are required to induce periostin
sensitivity in normal skin fibroblasts. (a) Primary normal skin (NS) fibroblasts were
cultured on tissue culture plastic for 72 hours in 10% FBS-αMEM supplemented with 5
ng/ml transforming growth factor (TGF)β-1. TGFβ-1 primed NS fibroblasts were then
seeded into stressed fibroblast populated collagen lattices (sFPCLs) containing 2 µg/ml
periostin (PN) or vehicle (veh) and cultured for 72 hours. Collagen lattice contraction was
assessed over 24 hours. PN significantly enhanced TGFβ-1-primed NS fibroblast
contraction at collagen lattice release (N=3 patients, n=3). (b,c) Primary NS fibroblasts
were seeded into sFPCLs embedded with PN or vehicle and cultured for 72 hours in
hypertrophic scar (HTS)- or NS fibroblast-conditioned media (CM). (b) Culture in HTS
CM had no effect on NS fibroblast collagen lattice contraction relative to NS fibroblasts
cultured in NS CM (N=1 patient, n=3). (c) Exogenous periostin treatment significantly
enhanced NS fibroblast contractility when cultured in HTS CM over 24 hours relative to
vehicle controls (N=1 patient, n=5). Significant treatment/time interactions are denoted
by ##p<0.01 (ANOVA of repeated measures). Significant treatment effects at individual
time points are denoted by *p<0.05 and **p<0.01 (t-tests and simple main effects
analyses). Data are presented by mean values and SEM.
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HTS fibroblast-conditioned media to enhance the contraction of NS fibroblasts. In order
to identify potential periostin interactors, immunoprecipitation experiments were
performed on HTS-conditioned media. In brief, HTS-conditioned media, in the absence
of exogenous periostin, was concentrated 50 times and 1 mg of total protein was
incubated with an antibody specific to periostin and precipitated with protein A/G
magnetic beads. Eluted samples were separated using SDS-PAGE and analyzed by
coomassie staining and western immunoblotting. Coomassie staining identified bands at
approximately 85 and 90 kDa in periostin immunoprecipitated samples (Figure 4.12a)
and western immunoblotting confirmed the identity of these bands as endogenous
periostin (Figure 4.12b). Two additional bands were evident in the periostin
immunoprecipitated samples that were absent or extremely faint in the IgG control lane
(Figure 4.12a). These bands were excised and analyzed by liquid chromatography tandem
mass spectrometry (LC-MS/MS). They were identified as keratin-14 (user contamination)
and fragments of IgG and periostin. Optimization experiments utilizing a variety of
protocol modifications failed to identify potential periostin interactors in HTSconditioned media.

4.7 Assessment of the effects of periostin on HTS
myofibroblast persistence in sFPCLs
Normally, as cutaneous wounds heal and ECM stress is relieved, the myofibroblasts that
promote wound closure undergo apoptosis (8, 12). However, in abnormal scarring,
myofibroblasts fail to undergo apoptosis and persist, resulting in excessive collagen
production and contracture of the ECM (56, 57, 92-94) that promotes hypertrophic scar
formation. When sFPCLs are released, a rapid contraction of the collagen lattices
decreases the tension in the ECM. This release in ECM tension correlates with
disassembly of stress fibers in myofibroblasts (47). To determine if periostin promotes
myofibroblast persistence in HTS fibroblasts, αSMA levels were assessed in sFPCL
cultures immediately prior to release (under mechanical tension for 72 hours) and up to
48 hours after collagen lattice release (in the presence of decreased ECM tension) by
western immunoblotting and densitometry. HTS fibroblasts with high levels of
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Figure 4.12 Identification of potential periostin interactors in hypertrophic scarconditioned media. Hypertrophic scar (HTS) conditioned media was generated (2.2.9.2)
and concentrated 50 times. 1 mg of total protein was incubated with a periostin (PN)specific antibody and immunoprecipitated (IP) with protein A/G magnetic beads as
described in 2.2.9.3. IP samples were separated using SDS-PAGE and samples were
analyzed by (a) coomassie staining (2.2.9.4) and (b) western immunoblotting (2.2.6). (a)
Coomassie staining identified 4 bands at molecular weights of 90 kDa, 85 kDa, 65 kDa
and 60 kDa that were absent or extremely faint in IgG control samples. The 65 and 60
kDa bands were identified as keratin-14 and fragments of IgG and PN by liquid
chromatography tandem mass spectrometry (not shown). (b) The 90 and 85 kDa bands
were identified as endogenous PN by western immunoblotting with a PN-specific
antibody. Protein A/G magnetic beads (beads) and PN-specific antibody (ab) were used
as controls. Bands at 55 kDa in both images correlate to the size of IgG heavy chain.
Representative images are shown. MW= molecular weight ladder, WB= western
immunoblot.
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Figure 4.13 Periostin maintains myofibroblasts in a differentiated state under
conditions of decreasing ECM tension. Primary hypertrophic scar (HTS) fibroblasts
were cultured in stressed fibroblast populated collagen lattices (sFPCLs) and total cell
lysates were derived immediately prior to collagen lattice release (after 72 hours of
culture), 24 and 48 hours after collagen lattice release. The effects of periostin (PN)
addition or depletion on alpha smooth muscle actin (αSMA) levels were assessed by
western immunoblotting and densitometry. (a) HTS fibroblasts maintained αSMA levels
following collagen lattice release in the presence of endogenous PN. αSMA levels were
significantly increased in PN treated HTS fibroblasts relative to vehicle controls and
αSMA levels were maintained for at least 48 hours after lattice release.Values were
normalized to vehicle controls immediately prior to lattice release (N=5 patients, n=3).
(b) Periostin depletion by shRNA treatment resulted in a significant and ongoing decrease
in αSMA levels in HTS fibroblasts following collagen lattice release relative to
scrambled shRNA controls. Values were normalized to scrambled controls immediately
prior to lattice release (N=4 patients, n=3). β-actin immunoreactivity was assessed to
ensure equal protein loading. Significant overall treatment effects are denoted by ^p<0.05
(ANOVA of repeated measures). Significant treatment effects at individual time points
are denoted by *p<0.05 and **p<0.01 (t-tests). Data are presented as mean values and
SEM. Representative immunoblots of the mean densitometry data are shown.
AU=arbitrary units.
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endogenous periostin expression (vehicle treated fibroblasts) maintained αSMA levels
following collagen lattice release. HTS fibroblasts treated with exogenous periostin had
significantly higher αSMA levels (p<0.05) relative to vehicle treated fibroblasts cultured
under mechanical tension and were able to maintain these high levels of αSMA following
the release of ECM tension (Figure 4.13a, N=5 patients, n= 3). In contrast, periostindepleted HTS fibroblasts had significantly decreased αSMA levels (p<0.05) relative to
scrambled shRNA controls with significant decreases observed at 24 and 48 hours after
collagen lattice release (Figure 4.13b, p<0.05, N=4 patients, n=3).

4.8 Discussion
In order to assess periostin effects on myofibroblast differentiation and persistence, it was
necessary to perform studies in a model system that mimicked in vivo conditions of 3D
stress in a collagen-enriched environment. The stressed fibroblast populated collagen
lattice (sFPCL) assay was chosen on this basis. When initially seeded into sFPCL, the
fibroblasts experience an ECM environment similar to that of the provisional matrix in
vivo (31, 173). During ECM remodelling, tractional forces generated by migrating
fibroblasts increase the mechanical tension of the ECM thereby inducing protomyofibroblast and myofibroblast differentiation (30, 156). This mechanical tension is
sustained until the collagen lattice is released from its points of attachment (30). Upon
release, myofibroblast-mediated contraction rapidly contracts the collagen lattice.
To investigate periostin effects on myofibroblast differentiation in HTS fibroblasts, three
markers of myofibroblast differentiation were assessed: contractility, αSMA and OB
cadherin levels. The neo-expression of αSMA in their stress fibres is a distinguishing
feature of myofibroblasts and facilitates their hyper-contractile phenotype (30).
Incorporation of αSMA into stress fibers is specific to differentiated myofibroblasts, as
the stress fibers in proto-myofibroblast are composed solely of β- and γ-actins (38, 39).
OB cadherin, a membrane protein involved in adherins junctions (221), also enhances
collagen lattice contraction by myofibroblasts (218) and its expression is reported to be
upregulated in differentiated myofibroblasts relative to proto-myofibroblasts (218).
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The findings reported in this chapter indicate that periostin enhances myofibroblast
differentiation in human dermal fibroblasts derived from hypertrophic scar tissue. The
evidence supporting this conclusion includes significant increases in HTS fibroblast
contractility and αSMA levels in the presence of exogenous periostin. In addition, a nonsignificant trend towards increased OB cadherin levels in periostin treated HTS
fibroblasts was noted. The absence of any discernible effects of periostin treatment on
fibroblast proliferation, viability, adhesion or migration in 3D cultures suggests that they
are unlikely to explain periostin-induced HTS collagen lattice contraction. Furthermore,
periostin significantly enhanced KS fibroblast contractility above highly contractile basal
levels. These data suggest that periostin effects on myofibroblast differentiation may not
be specific to HTS fibroblasts but may be a common feature of fibrotic conditions of the
skin. Periostin also induces myofibroblast differentiation of fibroblasts derived from
Dupuytren’s disease, a fibrosis of the palmar fascia with similarities to scarring (91),
suggesting that these findings may be extendible to other tissues.
Since HTS fibroblasts express increased endogenous levels of periostin relative to NS
cells and as exogenous periostin addition promoted increased myofibroblast
differentiation in HTS-derived fibroblast, loss of function studies were performed to
confirm these findings. Adenoviral transduction was chosen as an optimal method for
shRNA delivery for several reasons. Transient transfection efficiency is typically low in
primary fibroblasts and selection for stable transfection is impractical in primary
fibroblasts that lose their in vivo characteristics after a limited number of passages.
Previous studies in our laboratory have demonstrated that, unlike transient transfection,
viral transduction efficiency approximates 100% in primary fibroblasts under optimal
conditions. An adenoviral transduction system was used in preference to a lentiviral
system because adenovirus remains episomal and does not integrate into the host
genome, thereby limiting the potential for non-specific disruption of gene expression
caused by viral DNA integration into the genome.
In contrast to the gain-of-function studies where exogenous periostin significantly
enhanced HTS myofibroblast differentiation, no significant effects of periostin depletion
on myofibroblast differentiation were evident in the loss-of-function studies. As markers
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of myofibroblast differentiation, a significant decrease in collagen lattice contraction,
αSMA or OB cadherin levels would have provided independent support for the gain-offunction studies. The lack of significant findings in these loss-of-function studies may be
explained in part by inter-patient variability. Factors including age, gender and race may
affect the sensitivity of periostin depletion between individual patients and make it
difficult to identify consistent effects. Future analyses of additional patients may be
required to overcome inter-patient variability and allow us to identify consistent effects in
all, or even a majority of, patients assessed. It is also a possibility that a 60% reduction in
endogenous periostin levels in HTS fibroblasts following POSTN shRNA treatment was
insufficient to induce detectible effects on contraction and myofibroblast differentiation.
Periostin is proposed to be a very stable protein with a long half-life that is difficult to
deplete under conditions of high ECM tension (222). Therefore, depletion of intracellular
periostin in HTS fibroblasts may not correlate with depletion of secreted and potentially
very stable ECM-associated periostin. Another possibility is that, while periostin can
modestly enhance myofibroblast differentiation above basal levels, its primary role is to
maintain, rather than induce, myofibroblast differentiation. Therefore, increased matrix
tension, such as that experienced by fibroblasts cultured in sFPCLs, may be sufficient to
induce HTS myofibroblast differentiation and periostin may play a modestly stimulatory,
but dispensable, role in this process.
Interestingly, no evidence of periostin-induced myofibroblast contraction was observed in
NS fibroblast cultured in sFPCLs. These findings suggest that periostin induces
pathological, rather than normal, collagen lattice contraction, as the effects were specific
to fibroblasts derived from abnormal scar tissue. It remains unclear if periostin-induced
contraction is a component of normal cutaneous wound healing, as, due to ethical
constraints, we were unable to obtain samples of normal human scar tissue from which to
derive primary fibroblasts. The mechanisms that explain the differences in sensitivity to
periostin between HTS and NS fibroblasts are currently unclear. It is feasible that NS
fibroblasts may need to be “activated” in order to respond to periostin. This activation
could include induction or activation of a receptor(s) not normally present in unwounded
NS fibroblasts or exposure to fibrosis-associated growth factors and cytokines required
for periostin signalling.
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Preliminary western immunoblotting studies demonstrated that both HTS and NS
fibroblasts express integrins αV, β3 and β5 subunits (data not shown) through which
periostin has been shown to signal in other systems (127-129, 131-134). Although HTS
and NS fibroblasts had similar expression profiles of individual integrin subunits, it is
unclear if HTS and NS fibroblasts express different integrin heterodimers and the
activation state of these dimers.
The hypothesis that exposure to fibrosis-associated growth factors and cytokines are
required to activate and induce periostin sensitivity in NS fibroblasts was also tested.
During cutaneous wound healing, TGFβ-1 is released following injury to the dermis and
plays a critical role in many processes essential to normal wound repair, including
myofibroblast differentiation (8, 13, 40, 41, 174-177, 220). Therefore, TGFβ-1 signalling
may be required to activate NS fibroblasts and induce periostin sensitivity in these cells.
These studies indicated that priming NS fibroblasts with recombinant TGFβ-1 was only
partially effective in inducing NS fibroblast sensitivity to periostin. It is likely that a
combination of fibrosis-associated growth factors that are expressed at high levels by
HTS fibroblasts (for example, CCN2 (223)), might be required to induce periostin
sensitivity in NS fibroblasts.
Since a large number of growth factors are secreted by fibroblasts during cutaneous
wound healing (8), it is feasible that HTS fibroblasts might secrete factors that can
activate NS fibroblasts. The data presented in this chapter supports this notion as
periostin significantly enhanced NS fibroblast contractility when cultured in HTSconditioned media. As HTS-conditioned media had no discernible effect on NS fibroblast
contractility in the absence of exogenous periostin, these data imply that periostin is
interacting with a component in the conditioned media to enhance contraction of NS
fibroblasts. Despite multiple optimization experiments, no periostin interacting molecules
that were specific to HTS-conditioned media were identified by immunoprecipitation
analyses. Future studies, beyond the scope of this thesis, will be required to identify the
elusive molecular interactions that induce periostin sensitivity in NS fibroblasts.
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The second component of this aim was to assess periostin effects on myofibroblast
persistence. Normally, as cutaneous wounds heal and ECM stress is relieved, the
myofibroblasts that promote wound closure undergo apoptosis (8, 12). However, in
abnormal scarring conditions, myofibroblasts fail to undergo apoptosis and persist, and
continue to remodel the ECM and increase dermal density to abnormal levels. Many
factors, most notably TGFβ-1 (41), have been demonstrated to induce myofibroblast
differentiation in combination with increased ECM tension (30, 38, 42). However, much
less is known about the factors that maintain myofibroblasts in a differentiated state in
hypertrophic scars that persist for month or years. Since periostin promotes myofibroblast
differentiation in HTS fibroblasts and is abundant and persistent in the dermis of
hypertrophic scars, it was hypothesized that periostin promotes myofibroblast persistence
in hypertrophic scarring.
To test this hypothesis, αSMA levels in HTS fibroblasts in sFPCLs cultured under
mechanical tension (pre-release) and up to 48 hours after collagen lattice release were
assessed. This model was designed to mimic the loss of ECM stress that induces
apoptosis in normal scar myofibroblasts (8, 12). While the rapid loss of ECM tension
induced by collagen lattice release in sFPCLs is much more abrupt than the physiological
process it is designed to mimic (183), it does provide a reproducible assay system for
myofibroblast persistence under rapidly diminishing ECM tension. These studies
demonstrate that HTS fibroblasts are able to maintain αSMA levels at constant levels
under conditions of decreasing ECM tension in the presence of endogenous periostin and
that these levels are significantly increased and maintained by the addition of exogenous
periostin. In contrast, αSMA levels were significantly decreased in periostin-depleted
HTS fibroblasts under conditions of decreasing ECM tension relative to scrambled
controls. It is unclear if this loss in αSMA levels following collagen lattice release was
due to the onset of myofibroblast apoptosis, myofibroblasts dedifferentiation or a
combination of both. These findings support the hypothesis that periostin maintains
myofibroblast differentiation in HTS fibroblasts under conditions of decreasing ECM
tension.
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In summary, these studies demonstrated that periostin induces HTS fibroblast contraction
and differentiation in 3D collagen lattices, a model that mimics the mechanical tension of
granulation tissue during cutaneous wound healing. In addition, periostin maintained
αSMA levels, a marker of myofibroblast differentiation, in sFPCL cultures exposed to
reduced ECM tension, mimicking wound remodelling after closure. Together these data
demonstrate novel roles for periostin in inducing and maintaining myofibroblast
differentiation and persistence in HTS fibroblasts.
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Chapter 5

5

In vitro analysis of the mechanisms utilized by periostin
to induce myofibroblast differentiation and persistence
in hypertrophic scarring

5.1 Rationale
Periostin was shown to induce dermal fibroblasts derived from hypertrophic scar tissue to
express α smooth muscle actin (αSMA) and differentiate into myofibroblasts in Chapter
4. However, the signalling pathway(s) and mechanisms activated by periostin to induce
and/or maintain myofibroblast differentiation had not been elucidated. Therefore, the
focus of Chapter 5 is to identify these pathway(s). Periostin has been previously reported
to signal through integrins in other cell types (127-134), and integrins have wellestablished roles in mediating signalling events that increase cellular attachment and
contraction of the ECM (46). The integrin-associated complexes that form between cells
and the matrix are known as focal adhesions (30, 46, 156). Previous studies have shown
that αSMA is only incorporated into the stress fibers of these cells when the mechanical
tension in the surrounding ECM is sufficient to induce the “maturation” of focal
adhesions (FAs) into “supermature” focal adhesions (suFAs, (30, 43)). As periostin
induces αSMA production and HTS myofibroblast contractility, the hypothesis for this
chapter was that periostin signals through integrins in HTS fibroblasts, activates integrinassociated signalling pathways, enhances the formation of suFAs between HTS
fibroblasts and the surrounding collagen matrix and promotes the incorporation of αSMA
into stress fibres. This hypothesis is illustrated in Figure 5.1.

5.2 Immunoprecipitation analyses of receptor interactions
with periostin in HTS fibroblasts.
To determine if periostin interacts with integrins in HTS fibroblasts, immunoprecipitation
analyses with a periostin-specific antibody were performed on total cell lysates derived
from HTS fibroblasts cultured on plastic as described in 2.2.9. Using this approach,
periostin immunoreactivity was evident in samples immunoprecipitated with a periostin-
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Figure 5.1 Schematic representation of the proposed signalling pathway utilized by
periostin to induce myofibroblast differentiation and persistence. The central
hypothesis of Chapter 5 is that ECM-associated periostin signals through integrins
(Chapter 5.2) in HTS fibroblasts to activate focal adhesion kinase (FAK, Chapter 5.3.1), a
tyrosine kinase that localizes to focal adhesion complexes. FAK activation promotes
myofibroblast differentiation and focal adhesion formation through RhoA-GTP and
ROCK (Chapter 5.3.2) and its downstream effectors cofilin (Chapter 5.3.3) and myosin
light chain (MLC, Chapter 5.3.4). Cofilin inhibition and MLC-mediated stress fiber
contraction promotes stress fiber maintenance, increased ECM tension and integrin
clustering resulting in the formation of supermature focal adhesions (suFA, Chapter 5.4),
a prerequisite for αSMA incorporation into stress fibers of differentiated myofibroblasts.
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specific antibody and absent in samples immunoprecipitated with a non-specific IgG
control, demonstrating the specificity of the antibodies for periostin. Western
immunoblotting analyses revealed interactions between periostin and integrins αv and α5
however, these interactions were also consistently evident in samples immunoprecipitated
with a non-specific IgG control. These data indicated that these interactions were not
specific to periostin. Several modifications of standard immunoprecipitation protocols
were trialed including the use of nickel (Ni) coated magnetic beads that bind specifically
to histidine-tagged human recombinant periostin, shorter incubation times and more
stringent washing conditions (described in detail in 2.2.10) to enhance the specificity of
interactions between periostin and integrin subunits. The approach of using Ni coated
magnetic bead to specifically isolate recombinant periostin from total cell lysates of HTS
fibroblasts exposed to treatment was successful (Figure 5.2a). However, interactions
between periostin and integrins αv and α5 were evident in HTS cell lysates in both the
presence and absence of recombinant periostin treatment, indicating a high background
level of non-specific interactions (Figures 5.2b and c). In addition to western
immunoblotting analyses, immunoprecipitated samples were stained with coomassie to
identify bands of unique molecular weight in comparisons between treated and untreated
samples, potentially indicating novel periostin interactors. Despite substantial method
optimization and multiple mass spectrometry analyses, no novel periostin interactors
were identified using this approach (data not shown). Therefore, this research effort was
refocused onto the identification of integrin-associated signalling intermediates that were
modified by periostin during myofibroblast differentiation.

5.3 Assessment of the effects of periostin on integrinassociated signalling molecules in HTS-derived
fibroblasts
The integrin-associated complexes that form between cells and the ECM are known as
focal adhesions (30, 46, 156). Focal adhesion kinase (FAK) is a tyrosine phosphorylated
protein that localizes to focal adhesions (224, 225) and its activation is required for
adhesion-mediated myofibroblast differentiation (226) and suFA formation (43). FAK
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Figure 5.2 Immunoprecipitation analyses of receptor interactions with periostin in
HTS fibroblasts. Primary hypertrophic scar (HTS) fibroblasts were cultured to 85%
confluency on tissue culture plastic trays and treated with 2 µg/ml periostin (PN) or
vehicle (veh) in 2% FBS-αMEM overnight prior to formaldehyde fixation. 1 mg of total
cell lysate was precipitated using nickel (Ni) coated magnetic beads to bind histidinetagged human recombinant periostin as described in 2.2.10. Eluted precipitation
complexes were subjected to SDS-PAGE and assessed for periostin, αv and α5 integrin
immunoreactivity by western immunoblotting as described in 2.2.6. (a) Ni coated
magnetic beads specifically precipitated recombinant periostin as demonstrated by the
presence of a band at 90 kDa that is absent in the vehicle control lane. (b and c) Ni coated
magnetic beads non-specifically precipitated integrins αv and α5 as demonstrated by the
presence of bands at (b) 140 kDa and (c) 150 kDa in both the periostin and vehicle
treated samples. Representative immunoblots are shown. MW= molecular weight,
WB=western immunoblot.
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can promote myofibroblast differentiation and focal adhesion formation by modifying
Rho Kinase (ROCK) activity and the activities of its downstream targets. These targets
include cofilin and myosin light chain (MLC), which regulate stress fiber stabilization
and stress fiber-mediated contraction, respectively. Therefore, it was hypothesized that
periostin promotes myofibroblast differentiation and persistence through a FAK-ROCK
dependent signalling pathway.

5.3.1

Assessment of the effects of periostin on FAK activation in
HTS fibroblasts cultured in sFPCLs

To assess the contribution of FAK activation in periostin-induced HTS myofibroblast
differentiation and persistence, phosphorylated FAK levels were assessed in sFPCL
lysates immediately prior to release and up to 48 hours after release by western
immunoblotting and densitometry. A significant interaction between periostin treatment
and time was observed (p<0.01) and exogenous periostin treatment enhanced FAK
phosphorylation following collagen lattice release relative to vehicle controls with a
significant increase in FAK phosphorylation evident at 48 hours after lattice release
(Figure 5.3a, p<0.05, N=3 patients, n=3). A significant overall treatment effect was also
evident in periostin-depleted HTS fibroblasts (p<0.05) with periostin-depleted HTS
fibroblasts displaying increased levels of phosphorylated FAK relative to scrambled
shRNA controls. Significant increases in FAK phosphorylation were evident in periostindepleted HTS fibroblasts immediately prior to collagen lattice release and at 48 hours
after release (Figure 5.3b, p<0.05, N=3 patients, n=3). Periostin addition or depletion had
no discernible effects on total FAK levels (data not shown, N=3 patients, n=3).

5.3.2

Assessment of the effects of ROCK inhibition on periostininduced HTS myofibroblast differentiation

ROCK plays a central and essential role in activating and maintaining myofibroblast
differentiation and contractility (30, 43, 51-53). To confirm that periostin signalling
required ROCK activity to induce HTS myofibroblast-mediated collagen lattice
contraction, a ROCK specific inhibitor, Y27632, was included in a subset of sFPCL
cultures of HTS fibroblasts, with or without exogenous periostin treatment, and collagen

111

Figure 5.3 Periostin enhances focal adhesion kinase phosphorylation. Primary
hypertrophic scar (HTS) fibroblasts were cultured in stressed fibroblast populated
collagen lattices (sFPCLs) as described in 2.2.5 and total cell lysates were derived
immediately prior to sFPCL release (72 hours after polymerization), 24 and 48 hours
after release. Levels of phosphorylated focal adhesion kinase (pFAK, tyr397) were
assessed in HTS lysates by western immunoblotting and densitometry as described in
2.2.6. (a) Periostin significantly enhanced FAK phosphorylation in HTS fibroblasts
cultured in conditions of decreasing ECM tension relative to vehicle controls. Values
were normalized to vehicle controls immediately prior to lattice release (N=3 patients,
n=3). (b) Periostin depletion by shRNA treatment significantly increased FAK
phosphorylation in HTS fibroblasts in a model of decreasing ECM tension relative to
scrambled shRNA controls. Values were normalized to scrambled shRNA controls
immediately prior to lattice release (N=3 patients, n=3). β-actin immunoreactivity was
assessed to ensure equal protein loading. Significant overall treatment effects are denoted
by ^p<0.05 and significant treatment/time interactions are denoted by ##p<0.01
(ANOVA of repeated measures). Significant treatment effects at individual time points
are denoted as *p<0.05 (t-tests and simple main effect analyses). Data are presented by
mean values and SEM. Representative immunoblots of the mean densitometry data are
shown. AU=arbitrary units.
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Figure 5.4 Rho kinase inhibition significantly attenuates hypertrophic scar
fibroblast contraction of stressed fibroblast populated collagen lattices. To assess the
effects of Rho kinase (ROCK) inhibition of hypertrophic scar (HTS) fibroblast
contractility, primary HTS fibroblasts were seeded in stressed fibroblast populated
collagen lattices containing periostin (PN) or vehicle (veh) as described in 2.2.5 and
cultured in 2% FBS-αMEM supplemented with 10 µM ROCK inhibitor, Y27632
(ROCKi), or vehicle control (water) for 72 hours. Collagen lattice contraction was
assessed over 24 hours. ROCK inhibition significantly attenuated basal HTS fibroblast
collagen lattice contraction at all time points assessed. The addition of exogenous PN was
unable to rescue HTS fibroblast contraction in the presence of Y27632 (N=1 patient,
n=3). Significant treatment/time interactions are denoted by #p<0.05 (ANOVA of
repeated measures). Significant treatment effects at individual time points are denoted by
*p<0.05, **p<0.01, ***p<0.001 (simple main effect analyses). Data are presented by
mean values and SEM.
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lattice contraction was assessed over 24 hours. A significant interaction between Y27632
treatment and time was observed (p<0.01) and ROCK inhibition strongly attenuated HTS
fibroblast contractility relative to vehicle controls with significant differences observed at
all time points assessed (p<0.05). The addition of exogenous periostin did not rescue
HTS fibroblast contraction in the presence of Y27632 (Figure 5.4, N=1 patient, n=3).

5.3.3

Assessment of the effects of periostin on cofilin activation in
HTS fibroblasts cultured in sFPCLs

Cofilin is an actin-binding protein that is a downstream target of ROCK and promotes
actin stress fiber depolymerization (227). ROCK activation leads to the phosphorylation
and inhibition of cofilin activity, thereby preventing actin depolymerization (228). To
assess the contribution of cofilin in periostin-induced HTS myofibroblast differentiation,
phosphorylated cofilin levels were assessed in sFPCL lysates immediately prior to release
and up to 48 hours after release by western immunoblotting and densitometry.
Exogenous periostin treatment had no significant effect on cofilin phosphorylation
relative to vehicle controls when HTS fibroblasts were assessed as a group (Figure 5.5a,
N=3 patients, n=3). However, it was noted that periostin significantly increased cofilin
phosphorylation at individual time points in two of the three individual patients assessed
(Figure 5.5b, p<0.05).
Periostin depletion by shRNA treatment had no significant effects on cofilin
phosphorylation in HTS fibroblasts when assessed as a group (Figure 5.5c, N=3 patients,
n=3). However, a significant treatment effect was observed (p<0.05) in one of the three
patient-derived fibroblast lines assessed and phosphorylated cofilin levels were found to
be significantly decreased in periostin-depleted HTS myofibroblasts relative to scrambled
shRNA controls. In addition, phosphorylated cofilin levels were found to be significantly
decreased at individual time points in the other two patient-derived fibroblast lines
assessed (Figure 5d, p<0.05). Periostin addition or depletion had no discernible effects on
total cofilin levels (data not shown, N=3 patients, n=3).
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Figure 5.5 Periostin enhances cofilin phosphorylation in conditions of decreasing
ECM tension in a subset of patients. Primary hypertrophic scar (HTS) fibroblasts were
cultured in stressed fibroblast populated collagen lattices (sFPCLs) and total cell lysates
were derived immediately prior to sFPCL release (72 hours after polymerization), 24 and
48 hrs after release. Levels of phosphorylated cofilin (pCofilin, ser3) were assessed in
HTS lysates by western immunoblotting and densitometry. (a) Periostin had no
discernible effect on cofilin phosphorylation relative to vehicle controls when assessed as
a group (N=3 patients, n=3 patient). (b) However, periostin significantly enhanced cofilin
phosphorylation relative to vehicle controls in a subset of individual patients. Shown is a
representative immunoblot and densitometry data for HTS patient #5.Values were
normalized to vehicle controls immediately prior to lattice release. (c) Periostin depletion
by shRNA treatment had no significant effects on cofilin phosphorylation relative to
scrambled shRNA controls when assessed as a group (N=3 patients, n=3). (d) In contrast,
periostin depletion by shRNA treatment significantly decreased cofilin phosphorylation
relative to scrambled shRNA controls in a subset of individual patients. Shown is a
representative immunoblot and densitometry data for HTS patient #5. Values were
normalized to scrambled shRNA controls immediately prior to lattice release. β-actin
immunoreactivity was assessed to ensure equal protein loading. Significant treatment
effects at individual time points are denoted by *p<0.05 (t-tests). Data are presented by
mean values and SEM. Representative immunoblots of the mean densitometry data are
shown. AU=arbitrary units.
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5.3.4

Assessment of the effects of periostin on MLC activation in
HTS fibroblasts cultured in sFPCLs

The contractile forces induced by myofibroblasts on their ECM are generated by
contractile stress fibres composed of actin bundles, non-muscle myosin, and actinbinding proteins and is regulated by the activity (phosphorylation) of MLC (30, 45-47).
To assess the contribution of MLC in periostin-induced HTS myofibroblast
differentiation, phosphorylated MLC levels were assessed in sFPCL lysates immediately
prior to release and up to 48 hours after release by western immunoblotting and
densitometry. Exogenous periostin addition to sFPCL cultures had no significant effect
on MLC phosphorylation in HTS fibroblasts cultured under mechanical tension or
following the release of tension relative to vehicle controls (Figure 5.6a, N=3 patients,
n=3). No significant changes in MLC phosphorylation were observed in periostindepleted HTS fibroblasts relative to scrambled shRNA controls cultured under
mechanical tension and following the release of tension (Figure 5.6b, N=3 patients, n=3).
However, a significant treatment effect was observed (p<0.05) in one of three patientderived fibroblast lines assessed with phosphorylated MLC levels being significantly
lower in periostin-depleted HTS fibroblasts relative to vehicle controls (Figure 5.6c).
Periostin addition or depletion had no discernible effects on total MLC levels (data not
shown, N=3 patients, n=3).
As described earlier in this chapter, FAK activity enhances suFA formation and
myofibroblast differentiation through the activation of ROCK and its downstream targets
cofilin and MLC. ROCK-mediated cofilin inhibition prevents stress fiber
depolymerization, whereas MLC activation leads to myofibroblast contraction that
increases the mechanical tension in the ECM and induces integrin clustering resulting in
the formation of larger focal adhesion complexes. Although no consistent effects of
periostin on cofilin inhibition and MLC activation could be discerned in HTS fibroblasts
when assessed as a group, the significant effects noted in individual fibroblast lines were
invariably consistent with periostin promoting suFA formation during myofibroblast
differentiation. Therefore, the potential for periostin to enhance suFA formation was
assessed in HTS fibroblasts as a group.
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Figure 5.6 Periostin depletion reduces myosin light chain phosphorylation in HTS
myofibroblasts cultured in sFPCLs in a subset of individuals. Primary hypertrophic
scar (HTS) fibroblasts were cultured in stressed fibroblast populated collagen lattices
(sFPCLs) and total cell lysates were derived immediately prior to sFPCL release (72
hours after polymerization), 24 and 48 hours after release. Levels of phosphorylated
myosin light chain (pMLC, ser19) were assessed in HTS lysates by western
immunoblotting and densitometry. (a) Periostin had no significant effect on MLC
phosphorylation in HTS fibroblasts cultured in sFPCLs relative to vehicle controls.
Values were normalized to vehicle controls immediately prior to collagen lattice release
(N=3 patients, n=3). (b) Periostin depletion by shRNA treatment had no significant
effects on MLC phosphorylation in HTS fibroblasts relative to scrambled shRNA
controls when assessed as a group (N=3 patients, n=3). (c) While periostin treatment did
not significantly affect MLC phosphorylation at any specific time point, an overall
treatment effect indicating a significant decrease in MLC phosphorylation in periostindepleted HTS fibroblasts relative to scrambled shRNA controls was detected in a subset
of individual patients. Shown is a representative immunoblot and densitometry data for
HTS patient #9. Values were normalized to scrambled shRNA controls immediately prior
to collagen lattice release. β-actin immunoreactivity was assessed to ensure equal protein
loading. Significant overall treatment effects are denoted by ^p<0.05 (ANOVA of
repeated measures). Data are presented by mean values and SEM. Representative
immunoblots of the mean densitometry data are shown. AU=arbitrary units.
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5.4 Supermature focal adhesions
Focal adhesions are integrin-associated complexes that facilitate communication between
cells and their surrounding ECM (30, 46, 156). Fibroblasts typically exhibit a mixture of
immature and mature focal adhesions (FAs, (229)) and, when they differentiate into
myofibroblasts, the formation of suFAs corresponds with the incorporation of αSMA into
stress fibres (43, 184, 230). suFAs can be identified by the coexpression of αSMA with
other proteins normally found in FAs including ED-A fibronectin, vinculin, paxillin and
tensin (230). suFAs can also be distinguished by size, where suFAs are defined as FAs
that are greater than 6 μm in length, mature focal adhesions are typically between 2 and 6
μm in length, and immature FAs are typically less than 2 μm in length (43, 184, 230,
231). The incorporation of αSMA in suFAs is essential to allow myofibroblasts to exert a
greater (typically 2 to 4-fold) higher contractile force on the surrounding ECM thereby
enhancing ECM tension and maintaining the myofibroblast phenotype (30, 43).

5.4.1

Assessment of the effects of periostin on the formation of
supermature focal adhesions

To determine if periostin enhances suFA formation, a novel approach was developed to
measure focal adhesion length in sFPCLs by immunofluorescence confocal microscopy
based on modifications of protocols described in previous studies (184, 232). In brief,
“mini” sFPCL cultures were designed to be thin enough to allow confocal microscopy of
the cells within a three-dimensional matrix and while under mechanical tension. These
cultures of HTS fibroblasts were prepared in the presence or absence of matrix-associated
periostin and, after a 72 hour incubation to induce myofibroblast differentiation, the mini
sFPCLs were co-stained with αSMA to confirm myofibroblast differentiation, and
vinculin, a focal adhesion protein found in all three focal adhesion classes (Figure 5.7,
(184)). Focal adhesion length was measured in serial optical sections of individual cells
cultured under 3D matrix tension in collagen using Image-Pro Plus 7.0 and the straightline tool in Image J as described in 2.2.12.3. The total number of focal adhesions, their
average length and their classification as immature (≤ 2 μm), mature (2-6 μm) and
supermature (≥ 6 μm) FAs were determined in 30 cells per treatment in HTS fibroblasts
derived from three patients.
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As shown in Figure 5.8a, periostin treatment had no significant effects on the total
number of focal adhesions present in HTS fibroblasts cultured in sFPCLs relative to
vehicle controls (53.5 FAs ± 10.8 vs 47 FAs ± 9.9, N=3 patients, n=30 cells per
treatment). However, the average length of FAs were significantly increased in periostin
treated HTS fibroblasts (4.55 μm ± 0.26 in length) compared to vehicle treated controls
(4.02 μm ± 0.24 in length, Figure 5.8b, N=3 patients, n=30 cells per treatment). Vehicle
treated HTS fibroblasts contained significantly more immature FAs (10.00 % ± 1.63 vs
7.04 % ± 1.61) and mature FAs (76.95 % ± 1.32 vs 72.91% ± 1.28) than periostin treated
fibroblasts. Conversely, periostin treated HTS fibroblasts contained a significantly higher
percentage of suFAs than vehicle treated cells (20.04 % ± 2.53 vs 13.12 % ± 2.58)
cultured under identical conditions (Figure 5.8c, N=3 patients, n=30 cells per treatment).

5.5 Discussion
The objectives of this chapter were to identify the signalling pathways utilized by
periostin to induce myofibroblast differentiation in hypertrophic scarring and to identify
the structural consequences of activating this pathway. The in vitro studies presented here
demonstrate that periostin promotes/maintains myofibroblast differentiation through the
formation of supermature focal adhesions by activating FAK-ROCK mediated
pathway(s).
The first objective of this chapter was to identify the receptor(s) utilized by periostin to
induce myofibroblast differentiation. Changes in mechanical tension within the ECM are
transmitted between the ECM and cells through integrin-adhesion complexes (46). Since
periostin has been reported to signal through integrins in other systems (127-134), it was
hypothesized that periostin promotes myofibroblast differentiation and persistence
through an integrin-mediated pathway. Immunoprecipitation experiments were performed
to address this question. When performing immunoprecipitation experiments for
receptors, disruption of the cell membrane with harsh detergents, denaturing buffers or
mechanical lysing can lead to receptor deactivation and loss of receptor-ligand
interaction, especially if the interaction is weak. To account for this, immunoprecipitation
experiments were performed in non-denaturing lysis buffers with gentle detergents and a
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Figure 5.7 Periostin enhances supermature focal adhesion formation in
hypertrophic scar-derived fibroblasts. (a) Primary hypertrophic scar (HTS) fibroblasts
were cultured in “mini” stressed fibroblast populated collagen lattices (sFPCLs) for 72
hours in the presence or absence of periostin (PN, 2 µg/ml) as described in 2.2.12.1.
Lattices were fixed and assessed for vinculin immunoreactivity (red), alpha smooth
muscle actin (αSMA) immunoreactivity (green), co-stained with Hoescht (blue) to
identify nuclei and imaged using immunofluorescence confocal microscopy as described
in 2.2.12.2. Focal adhesion length was measured as described in 2.2.12.3 and
supermature focal adhesions (<6 µm in length) are indicated by arrows. Representative
photographs are shown. Scale bar = 20 µm.
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Figure 5.8 Periostin enhances focal adhesion length and supermature focal adhesion
formation in hypertrophic scar-derived fibroblasts. Primary hypertrophic scar (HTS)derived fibroblasts were cultured in mini stressed fibroblast populated collagen lattices
for 72 hours and focal adhesion numbers and length were assessed by
immunofluorescence confocal microscopy as described in 2.2.12. (a) Exogenous PN
treatment had no discernible effects on the total number of focal adhesions present in
HTS fibroblasts cultured under mechanical tension (N=3 patients, n=30 cells per
treatment). (b) The average focal adhesion length was significantly greater in PN treated
HTS fibroblasts relative to vehicle (veh) controls (N=3 patients, n=30 cells per
treatment). (c) Vehicle treated HTS fibroblasts had significantly more immature and
mature focal adhesions relative to PN treated fibroblasts. However, PN treated HTS
fibroblasts had significantly more supermature focal adhesions relative to vehicle treated
cells under these culture conditions (N=3 patients, n=30 cells per treatment). Significant
treatment effects are denoted by *p<0.05 (t-tests). Data are presented by mean values and
SEM.
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subset of samples were formaldehyde fixed prior to lysis to stabilize potential interactions
(233, 234). Optimization studies demonstrated that formaldehyde fixation prior to cell
lysis had no discernible negative effects on the ability of the periostin antibody or nickel
coated magnetic beads to bind periostin in the samples (data not shown).
Multiple assay conditions were tested to optimize the detection of direct interactions
between periostin and integrins. Initial immunoprecipitation studies were performed in
sFPCLs to model 3D interactions in vivo, however neither endogenous nor recombinant
periostin could be detected in the subsequent immunoprecipitation analyses. While the
technical roadblocks that prevented periostin detection in these assays remains unclear,
one possibility was that the abundance of collagen caused non-specific antibody binding
and/or interfered with antibody-epitope binding. Therefore, despite being potentially less
physiologically relevant, subsequent immunoprecipitation experiments were performed
on HTS fibroblasts cultured on plastic dishes in the absence of a collagen substrate.
While periostin and integrin subunits were consistently co-immunoprecipitated in these
analyses, apparently non-specific, yet consistent, integrin binding was also observed in
samples immunoprecipitated with non-antigen specific IgG controls, making it
impossible to demonstrate that these interactions were specific to periostin. Optimization
studies were undertaken with the aim of reducing non-specific integrin binding in the IgG
immunoprecipitated samples. These included 1) the use of different IgG controls from
different suppliers, 2) the use of Ni coated magnetic beads to bind histadine tags at the
amino terminus of the recombinant periostin, 3) various combinations of incubation times
and 4) more stringent binding and washing conditions. None of these modifications
proved to be effective for reducing non-specific binding between these integrin subunits
and IgG controls.
To our knowledge, there are currently no examples of immunoprecipitation experiments
demonstrating interactions between periostin and integrins in the literature. Previous
studies investigating periostin interactions with integrins have utilized blocking
antibodies that are targeted against specific integrins in functional assays (128, 131, 134).
Experiments designed to assess these interactions with HTS fibroblasts in sFPCLs using
blocking antibodies against integrin αvβ3 and β1 induced very modest decreases in lattice
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contractility that were indistinguishable to the effects induced by non-specific IgG
controls (data not shown). Co-localization experiments for periostin and integrins were
also performed using immunofluorescence confocal microscopy. However, HTS
fibroblasts that were fixed and probed with a fluorescently labeled periostin antibody
exhibited abundant and saturated staining throughout the collagen matrix, making it
impractical to use this approach to identify specific areas of co-localization with integrins
in these cultures (data not shown).
In the event that periostin might interact with and signal through molecules other than
integrins, multiple immunoprecipitation experiments were performed using a periostinspecific antibody and coomassie staining to detect differential banding patterns between
periostin and IgG immunoprecipitated samples. No differential banding patterns were
observed in these assays. Coomassie staining is insensitive relative to some other protein
stains, such as silver nitrate, however these stains were incompatible with subsequent
mass spectrometry analyses. In summary, no specific interactions between periostin and
integrins or other molecules could be demonstrated. The development of substantially
more sensitive and specific methodologies will be required for future studies assessing
protein interactions with periostin in more physiologically relevant, 3D collagen matrices.
The second objective of this chapter was to identify the signalling pathway(s) utilized by
periostin to induce myofibroblast differentiation and persistence. The ROCK signalling
pathway was an obvious focus for these studies, as ROCK activation plays a central and
essential role in activating and maintaining myofibroblast differentiation and contractility
(30, 51-53). ROCK inhibition was shown to significantly attenuate basal HTS fibroblast
contractility, and this effect could not be rescued by exogenous periostin treatment.
Inhibiting such a central and essential regulator of myofibroblast differentiation and
contraction is unlikely to be helpful for distinguishing the specific effects of periostin
from multiple signalling pathways that also induce differentiation and contraction in a
ROCK dependent manner. Therefore, gain- and loss-of-function studies were performed
to assess the effects of periostin addition or depletion on upstream and downstream
effectors of ROCK-mediated myofibroblast differentiation and contraction.
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Integrin-associated complexes known as focal adhesions (30, 46, 156) mediate
communication between cells and the ECM. These complexes transmit external signals
from the microenvironment to modulate cellular phenotypes (235). Focal adhesion kinase
(FAK) has been shown to localize to focal adhesions (224, 225), regulate ROCKdependent stress fiber formation and maintenance (236), promote suFAs formation (43)
and to be involved in adhesion-mediated myofibroblast differentiation (226). Since
periostin has been shown to enhance FAK phosphorylation in other systems (130, 133,
134, 187, 237, 238), it was hypothesized that periostin promotes HTS myofibroblast
differentiation and maintenance through a FAK-ROCK dependent signalling pathway.
The findings presented in this chapter demonstrate that, when cultured under isometric
tension, periostin had no significant additive effects on FAK phosphorylation in HTS
fibroblasts. However, after the release of isometric tension, a significant increase in FAK
phosphorylation was observed in periostin treated HTS fibroblasts for up to 48 hours
relative to vehicle controls. While these results are not informative regarding FAK
activation during myofibroblast differentiation, these data suggest that periostin enhances
FAK activation in HTS fibroblasts under conditions of decreasing mechanical tension.
Surprisingly, phosphorylated FAK levels were also significantly increased in periostindepleted HTS fibroblasts 48 hours after collagen lattice release relative to vector
transduced controls. These findings may be explained in the context of previous studies
demonstrating that FAK signalling can both promote and inhibit ROCK activation and
stress fiber maintenance (236, 239-241).
FAK signalling can promote stress fiber formation and contraction through the
phosphorylation and activation of p190 RhoGEF (236, 241). p190 RhoGEF is a Rho
specific guanine nucleotide exchange factor (GEF) that activates RhoA by promoting the
dissociation of guanosine-5’-diphosphate (GDP) and the binding of GTP to RhoA (242,
243). RhoA-GTP binding to ROCK induces a conformational change in ROCK that
activates the protein (244, 245). FAK signalling can also promote the phosphorylation
and activation of p190 RhoGAP, a GTPase activating protein (GAP), which inhibits
RhoA activity by promoting binding of GDP to RhoA (236, 246). Inhibition of RhoA
prevents downstream activation of signalling intermediates involved in stress fiber
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maintenance and contraction. It is possible that, following the release of mechanical
tension in sFPCLs, periostin signalling is able to maintain positive FAK-ROCK
activation and thereby promote myofibroblast persistence.
This hypothesis could be tested by assessing the effects of periostin on the activity of
RhoA and ROCK. The RhoA activity assays currently available utilize the Rho binding
domain of the Rho effector protein, Rhotekin, to specifically bind RhoA-GTP. However,
these analyses require the precipitation of Rhotekin-RhoA-GTP complexes using
glutathione affinity beads. Unfortunately, the amount of total cell lysate required for this
assay would be unattainable in practice for 3D collagen cultures. As ROCK is activated
by a conformational change induced by RhoA-GTP binding, its activity cannot be
assessed using western immunoblotting. Therefore, to gain additional insights into
periostin effects on ROCK activation, the activation of downstream ROCK targets were
assessed using gain- and loss-of-function studies.
ROCK activation can promote stress fiber maintenance, focal adhesion formation and
myofibroblast differentiation through two divergent pathways. Cofilin, a downstream
target of ROCK, is an actin-binding protein that promotes actin stress fiber
depolymerization (227). ROCK-mediated cofilin phosphorylation inhibits cofilin activity
and actin depolymerization, thereby promoting stress fiber maintenance (228). ROCK
activation also induces myofibroblast-mediated contraction through phosphorylation and
activation of the regulatory MLC (51-53). In combination, these signalling events
promote the formation and maintenance of stress fibers and increase ECM tension
through myofibroblast contraction, resulting in integrin clustering, the formation of suFA
complexes and myofibroblast differentiation and/or persistence (247).
No significant changes in the phosphorylation states of cofilin or MLC were consistently
detected in HTS myofibroblasts cultured under isometric tension or following the release
of tension irrespective of treatment. It is likely that the lack of significant findings in
these studies can be explained by inter-patient variability. Gender, age, scar location, scar
maturity and additional co-morbidities may influence periostin sensitivity between
individual patients and this variability can make it difficult to detect significant
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differences when patients are assessed as a group. This was evident in several of these
studies as statistically significant treatment effects were observed in a subset of individual
patients but significance was lost when the patients were assessed as a group. Future
analyses of much larger numbers of patient-derived fibroblast lines may be required to
overcome this inter-patient variability, and sub-group analyses of those that yield
significant results may shed new light on the source(s) of variability. These findings also
illustrate the importance of assessing treatment effects in primary fibroblast lines derived
from multiple patients, as such variability might not be observed in an immortalized cell
line derived from a single patient.
Although inconclusive, these studies did not rule out the possibility that periostin
signalled through these intermediates to enhance suFA formation, myofibroblast
differentiation and/or persistence. Therefore, independent analyses of suFA formation
were performed. As described previously in this chapter, αSMA is only incorporated into
stress fibers of myofibroblasts when the mechanical tension in the ECM passes a critical
threshold that allows for the formation of suFAs (30). The formation of suFAs and the de
novo expression and incorporation of αSMA into stress fibers allows myofibroblasts to
exert much greater contractile forces on the ECM (43), thereby contributing to the
abnormal dermal density that characterizes scar formation. As periostin promotes
myofibroblast differentiation and persistence in hypertrophic scarring (Chapter 4.4 and
4.7), potentially by activating focal adhesion signalling molecules (Chapter 5.3), it was
hypothesized that exogenous periostin treatment would enhance the formation of suFAs.
To assess suFA formation, two markers of suFAs, αSMA and vinculin, were assessed by
immunofluorescence confocal microscopy. The combination of αSMA and vinculin was
optimal for confirming the differentiated state of the myofibroblasts while simultaneously
visualizing all three FA classes (184). The length of each FA was assessed along its
longest axis regardless of orientation as described in previous studies (184). Using this
approach, periostin treated HTS fibroblasts cultured under mechanical tension were
shown to exhibit significantly larger focal adhesions and a higher percentage of suFAs (>
6 μm in length) per cell relative to vehicle controls. A feedback mechanism between
enhanced suFA formation and increased ECM tension above threshold levels promotes
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myofibroblast differentiation and persistence (43, 44) leading to the excessive deposition
and contracture of the ECM characteristically seen in hypertrophic scarring. These data
suggest that periostin signalling may promote and maintain suFA formation and
myofibroblast differentiation in patients prone to hypertrophic scarring.
In summary, periostin was shown to promote myofibroblast differentiation by enhancing
suFA formation in HTS myofibroblasts. Although the receptor(s) utilized by periostin to
induce suFA formation are yet to be identified, these findings are consistent with
periostin enhancing myofibroblast differentiation and persistence in hypertrophic scarring
through a FAK-ROCK dependent pathway. This is the first study to link periostin
activation of these signalling pathways to suFA formation in hypertrophic scarring. As
hypertrophic scarring and related benign fibrotic conditions are characterized by
enhanced myofibroblast differentiation and the persistence of these highly contractile
cells within the dermis, periostin may have potential as a therapeutic target for novel
therapies designed to induce myofibroblast de-differentiation and/or apoptosis and,
thereby, enhance hypertrophic scar resolution.
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Chapter 6

6

Conclusion

Hundreds of millions of patients in developed countries develop scars each year
following surgical procedures, with the incidence rate for hypertrophic scar formation
varying between 40-70% in many centers (66, 67, 248). Hypertrophic scars and other
abnormal scarring conditions are the result of aberrant wound healing after an insult to
the deep dermis. Scarring imposes morbidity that is difficult to quantify, but includes
pain and loss of mobility, especially if the scar is associated with a joint (60). As well as
imposing a financial burden, scars are often disfiguring and can adversely affect a
patient’s quality of life, both physically and psychologically (60, 61). Unfortunately,
there are few, if any, truly effective treatment options for abnormal scarring conditions
(58, 60). Prevention of hypertrophic scarring is also difficult, as abnormal skin
remodelling may not become evident until 4-8 weeks after wound closure (59). Current
treatment strategies have therefore focused on improving hypertrophic and keloid scar
resolution, rather than on prevention.
The findings presented in this thesis suggest that increased and persistent levels of
periostin in the dermis of human hypertrophic scar tissue contribute to excessive
fibroblast proliferation and myofibroblast differentiation and persistence (Figure 6.1).
Periostin depletion in the dermis of hypertrophic scars may therefore have utility as a
therapeutic target for novel therapies designed to improve scar resolution by attenuating
fibroblast proliferation and promoting myofibroblast apoptosis and/or dedifferentiation.
In addition to hypertrophic scars, periostin is abnormally abundant in keloid scars and
periostin may play a similar role in promoting and maintaining myofibroblast
differentiation of keloid scar-derived fibroblasts. These data suggest that the effects of
periostin described in this thesis may not be specific to HTS but may be a common
feature of other benign fibroses. This concept is supported by findings that periostin
promotes myofibroblast differentiation of primary fibroblasts derived from Dupuytren’s
Disease, a benign fibrosis of the palmar fascia (91). Therefore, periostin may not only be
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Figure 6.1 Schematic representation of the roles of periostin in hypertrophic
scarring. Increased and persistent levels of ECM-associated periostin in the dermis of
hypertrophic scar tissue contribute to hypertrophic scar formation by enhancing fibroblast
proliferation and myofibroblast differentiation and persistence through a Rho kinase
mediated pathway. Enhanced fibroblast proliferation and myofibroblast differentiation
leads to excessive ECM deposition and remodelling leading to the formation of raised,
dense collagenous scars.
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an attractive therapeutic target to improve abnormal scar resolution but may have utility
as a more universal target for treating a variety of benign fibrotic conditions.
Non-healing chronic wounds are a less obvious but potentially relevant application of
these findings. Chronic non-healing wounds do not progress beyond the inflammatory
phase of wound healing (54), display decreased growth factor activity and increased
fibroblast senescence relative to normal healing wounds (249). The prevalence of nonhealing wounds within the Canadian healthcare system is approximately 35% (250) and
may result in amputation of the affected limb due to lack of effective treatment options
(251). Since periostin expression is decreased in chronic non-healing wounds (97),
exogenous periostin treatment may stimulate fibroblast proliferation and myofibroblastmediated ECM deposition and remodelling resulting in wound closure.
In order to assess the role(s) of periostin in normal and abnormal cutaneous wound repair,
an appropriate model system was required. Unfortunately, there is a lack of representative
and physiological relevant in vivo animal models of hypertrophic scarring (59).
Hypertrophic or any other forms of fibrotic dermal scarring do not normally occur in
mice (163) as they can regenerate dermal wounds very efficiently (160). While several
scarring-prone mouse models have been developed after genetic modifications or
chemical treatments (165, 252), the physiological relevance of these models are unclear.
There are significant anatomical differences between the inter-follicular area (161),
epidermal thickness and turnover rate (159) and dermal thickness (160) of mouse and
human skin, limiting our ability to translate findings between these species (253, 254).
More recently, the red duroc pig has been utilized as a model for human cutaneous
wound healing. Swine have a similar dermal and epidermal architecture (255-257) and
heal wounds by re-epithelialization in a similar manner to humans (258). In contrast to
mouse models, red duroc pigs readily form raised collagenous scars that are similar to
hypertrophic scars following insult to the deep dermis (255, 259). Nonetheless, the
clinical relevance of these extremely expensive models (257) remains unclear. Very little
is known about the complex array of single nucleotide polymorphisms or other genetic or
epigenetic changes that predispose some patients to scarring, and these details will need
to be elucidated before any truly representative animal models can be developed. As it is
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not ethically feasible to perform scarring experiments on humans, it can be argued that
the best available models of hypertrophic scarring are the tissues or tissue-derived cells
derived from surgical scar resection. In this thesis, primary human dermal fibroblasts
derived from hypertrophic scar, keloid scar and normal skin from multiple patients were
chosen to assess periostin effects in in vitro models.
While the clinical relevance of analyzing primary dermal fibroblasts obtained from
normal and abnormal human tissue is obvious, these cells have inherent characteristics
that can make them challenging to interpret. Scars are generally resected months or years
after their initial formation, making it difficult or impossible to identify the earliest
signalling events that promote abnormal scar formation (59). The major challenge,
however, is inter-patient variability. Differences in gender, race, age, scar location, and
other co-morbidities may affect the sensitivity of individual patient-derived fibroblasts to
treatment and can make it extremely difficult to identify consistent effects on fibroblast
proliferation and/or myofibroblast differentiation in all, or even the majority, of patients.
This was evident in several studies presented in this thesis, as significant treatment effects
were evident in a subset of patients but absent in others. Additionally, variation can arise
from selection between passages, as the fibroblasts derived from patient tissues are a
heterogeneous population of cells. Therefore, there is the potential to select for different
subsets of fibroblasts that have differing tolerances to in vitro culture with each passage.
With inter-patient and inter-passage variability, it can be difficult to identify statistically
significant effects when assessing the mean data derived from a mixed population. Thus,
several trends have been identified in this thesis that may or may not represent real
effects in a subset of patient-derived fibroblasts. Assessment of very large numbers of
patients may be required to identify the source of this inter-patient variability and yield
significant findings within pre-identified sub groups of patients. However, such
variability may also be impossible to avoid in practice due to the very large number of
variables between individuals.
Another limitation of using primary cells is their limited replicative potential compared to
immortalized cell lines. The pilot studies that led to this project in our laboratory
demonstrated that HTS fibroblasts lose their initial characteristics after approximately
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four passages. Due to their short “shelf life,” it is difficult to genetically modify primary
fibroblasts by conventional transfection techniques and obtain meaningful results in four
passages or less. It could be argued that an immortalized human HTS fibroblast cell line,
which currently does not exist to our knowledge, would be beneficial in reducing
experimental variability in these assays and in identifying and characterizing periostininduced specific signalling pathways in more detail. However, the “trade off” with such a
cell line is that it would be even more difficult to translate the findings in these
immortalized cells to a clinical setting. A single cell line could only provide a detailed
assessment of periostin effects in a single patient that may, or may not, be representative
of the broad and variable population of individuals affected by abnormal scarring. Thus,
despite their inherent limitations, this thesis focused on in vitro analyses of primary
fibroblasts derived from surgically resected scar tissue of multiple patients, and on
identifying and characterizing the signalling pathways that were activated by periostin in
most or all of these patients. With further development, the approach of using primary
cell “banks” derived directly from patients may have great potential for providing
clinically relevant information about the cellular processes that cause the abnormal
persistence of scars.
The molecular focus of this thesis was periostin, a TGFβ-1-inducible secreted ECM
protein (101) that is transiently expressed during normal cutaneous wound repair (98,
151, 152), and is abnormally abundant and persistent in abnormal scars and other benign
fibroses (91, 97-99, 148, 150, 179, 260-263). This protein is often described as a
“matricellular” molecule, a term originally coined by Bornstein (90, 124) to describe
extracellular proteins that do not contribute directly to the structure of the ECM but
instead serve to modulate cell-matrix interactions and cell function. Periostin has been
demonstrated to enhance fibroblast proliferation and myofibroblast differentiation in
other models of variable physiological relevance to humans (91, 132, 133, 152, 178-180).
To assess the functional consequences of enhancing or depleting any matricellular
protein, it is essential that an appropriate 3D cell culture system be in place to assess
signalling effects from the ECM that may or may not occur in the absence of a
physiologically relevant ECM as a culture substrate. Previous studies have demonstrated
that culturing fibroblasts on rigid tissue culture plastic dishes results in spontaneous
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proto- and myofibroblast differentiation (31) and that substrate-induced effects can
overshadow treatment effects on cellular phenotypes (133). Our laboratory is one of
many that have shown that variations in substrate stiffness can modify gene expression
and protein levels in primary human fibroblasts (171). Others have shown that, when
cultured on tissue culture plastic, cells can adopt very different structures to in vivo and
fail to respond to appropriate stimuli. However, if the same cells are cultured on
substrates that mimic the in vivo microenvironment, they adopt in vivo-like structures and
function (264-266). The effectiveness of therapeutic treatments has also been shown to
differ between cells cultured on plastic and on in vivo-like matrices (267-269). Taken
together, these studies highlight the importance of the microenvironment in regulating
cellular phenotype in in vitro cultures, particularly in the context of matricellular
signalling.
For these reasons, the primary human fibroblasts examined in this thesis were cultured on
two- and three-dimensional type I collagen substrates, the most abundant collagen in the
skin and mature scars (8), to more closely mimic the microenvironment and substrate
stiffness experienced by these fibroblasts in vivo. Although the dermal ECM is much
more complex than polymerized type I collagen, the use of collagen substrates allows for
the incorporation of periostin within a collagenous ECM matrix, mimicking its
localization in vivo, and provides a simple and reproducible physiological relevant in
vitro culture system for assessing the effects of periostin on hypertrophic scar formation.
To gain additional insight into the roles of periostin in promoting abnormal scar
formation, future in vitro studies should focus on culturing fibroblasts directly on
decellularized hypertrophic scar and normal skin tissue to achieve even better models of
the microenvironments in normal and abnormal conditions. Alternatively, much more
complex mixtures of purified collagens and other ECM molecules, or co-culture
experiments with other cell types involved in cutaneous wound repair such as
keratinocytes, may be used for in vitro analyses to enhance the physiological relevance of
the cellular environment.
Despite the methodological challenges in achieving such complex culture systems, there
is a clear and urgent need for better in vitro models that are physiologically relevant to
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humans and representative of a genetically diverse population. Recent high profile reports
(270) have described how the majority of peer reviewed medical research publications
describing novel drug targets and similar findings cannot be independently reproduced.
Amongst many other contributing factors, a lack of physiologically relevant and
representative models is likely to have contributed significantly to this problem. We
should not be surprised that novel drug targets identified in immortalized human cells
derived from a single individual, and then “verified” in animal models with significant
physiological differences to humans and with much less individual variability, fail to
progress in clinical trials on human populations.
The identification of molecules that promote aberrant wound healing signals will improve
our current understanding of the processes involved in abnormal scar formation. The
findings presented in this thesis indicate that periostin enhances fibroblast proliferation in
compliant collagen cultures, a model designed to mimic the low mechanical tension of
the provisional matrix in the early stages of wound healing, through an Akt and ROCK
dependent pathway. When subjected to isometric tension in sFPCLs, a model that mimics
aspects of wound closure in vivo, periostin induces myofibroblast differentiation, as
evidenced by an increase in αSMA levels, collagen lattice contraction and supermature
focal adhesion formation. Additionally, periostin signalling maintained αSMA levels in
myofibroblasts in an environment of decreasing ECM stress, indicating a role for
periostin in myofibroblast persistence, potentially through a FAK-ROCK dependent
pathway. Since periostin had no discernible effects on NS-derived fibroblast proliferation
or differentiation, these data support the central hypothesis that periostin promotes
pathological effects leading to abnormal scar formation.
The function of an organ, including the skin, is dependent on the numerous cell types that
make up the organ and the organization of the surrounding extracellular matrix (235).
Interactions between the cells and the surrounding ECM through integrins and cell-cell
interactions through adherens junctions determine the gene expression and phenotype of
the resident cells without altering the genotype (235, 271). Therefore, the
microenvironment provides necessary signalling to maintain tissue homeostasis and
suppress malignant or abnormal phenotypes. However, aberrant signalling from the
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microenvironment can lead to loss of tissue homeostasis and promote abnormal or
malignant behaviours in the resident cells (271).
Wounding events have been shown to be an effective stimulus for promoting malignancy
(272). Stromal fibroblasts are responsible for the production, deposition and remodelling
of the ECM (271) and increased stromal density (changing tissue microenvironment) has
been correlated with an increase risk of cancer progression (273, 274). Increased
myofibroblast differentiation within the stroma has been correlated with increased risk of
cancer development and the induction of an inflammatory response by an established
tumour can further promote a fibrotic stroma (271). Studies in mouse models of epithelial
cancer progression have demonstrated that increased stromal density enhanced epithelial
cell proliferation, tumourgenesis, tumour growth, migration and invasion (275-277),
some of which may be induced by FAK and Rho signalling within epithelial cells (278280).
These finding may be relevant to this thesis because, in addition to being an upregulated
component of benign fibroses, periostin expression is also increased in malignant
diseases. Periostin is upregulated in a variety of tumours and associated stroma and its
increased expression is correlated with malignancy (108, 128, 129, 141, 180, 281).
Periostin can interact with several integrins to induce tumour cell migration, growth,
EMT and survival (128-131, 142). Over expression of periostin in colon cancer cells
increased the size and number of metastatic colonies at secondary sites (129). A recent
study by Malanchi et al., (281) demonstrated that metastatic colonies required periostin
expression by stromal fibroblasts in order to successfully colonize at those locations. As
periostin enhanced fibroblast proliferation and myofibroblast differentiation in fibroblasts
derived from hypertrophic scar tissue, the findings in this thesis may enhance our
understanding of periostin’s roles in tissue remodelling in metastatic conditions.
Increased levels of periostin in the stroma of metastatic diseases may promote excessive
fibroblast proliferation and myofibroblast differentiation, causing abnormal stromal
density and enhanced tumour formation, growth and invasion. A normal
microenvironment can induce some malignant cells to regain a normal phenotype in vitro
(235, 282) stressing the importance of the microenvironment in tissue homeostasis and
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disease progression. Therefore, periostin depletion in the stroma surrounding malignant
cells may be an attractive therapeutic target for novel therapies designed to reduce
stromal density.
It has become increasingly evident that achieving normal tissue homeostasis is the
ultimate treatment outcome and that targeting the microenvironment may have profound
clinical benefits (271). The findings presented in this thesis demonstrate that increased
levels of periostin in the wound microenvironment of hypertrophic scar tissue results in
excessive fibroblast proliferation and myofibroblast differentiation. Even in conditions of
decreasing ECM tension, abundant and persistent levels of periostin in the
microenvironment “shield” HTS myofibroblasts from the mechanotransduction signalling
events associated with changes in ECM tension, thereby allowing these cells to maintain
a differentiated state. Identification of the molecular components and mechanisms
involved in periostin regulation and degradation may have profound clinical benefits for
improving scar resolution in patients affected by abnormal scarring.
Periostin levels are increased and persistent in the ECM of benign fibrotic conditions
such as hypertrophic scarring. It is plausible that the pathways that normally regulate
periostin levels in the ECM are atypical in these conditions and that their identification
may reveal attractive therapeutic agents for depleting periostin levels in the
microenvironment of hypertrophic scar tissue. Periostin expression is reported to be
regulated by a number of factors essential for normal cutaneous wound healing such as
TGFβ-1, platelet derived growth factor, interleukins, fibroblast growth factor and
mechanical tension (101, 103, 104, 283) and these would be difficult to target in a clinical
setting. The factors that regulate periostin depletion in normal cutaneous wound healing
are unclear. As periostin is proposed to be a very stable protein with a long half-life, and
to be difficult to deplete under conditions of high ECM tension (222), active degradation
of periostin in the dermis may be responsible for decreased periostin levels in the dermis
during the remodelling phase of normal cutaneous wound healing.
Unfortunately, nothing is known about periostin degradation. Previous studies have
shown that matricellular proteins thrombospondin-1, SPARC and CCN1 are targets of
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several proteases including plasmin, MMP-1 and MMP-9 (284-286). As levels of
plasmin, MMP-1 and MMP-9 are decreased in hypertrophic and keloid scarring (287289), these or similar proteases may have roles in the degradation of the matricellular
protein periostin in hypertrophic scarring. This hypothesis should be assessed initially in
a cell free system to determine if individual proteases degrade periostin in solution, and
then verified in 3D restrained collagen in vitro model systems like those described in this
thesis. If periostin levels were significantly reduced following protease treatment relative
to controls, addition of these proteases to sFPCL cultures should inhibit periostin-induced
HTS myofibroblast differentiation and promote myofibroblast apoptosis and/or
dedifferentiation in conditions of decreasing ECM tension.
Another intriguing possibility is that dermal periostin levels may be regulated by
receptor-mediated endocytosis and lysosomal degradation. The matricellular protein
SPARC has been shown to be regulated by interacting with stabilin-1 (290), a scavenger
receptor involved in receptor-mediated endocytosis expressed in macrophages and
endothelial cells (291). Periostin and stabilin-1 both belong to the fasciclin family of
proteins characterized by the presence of FAS-1 domains involved in cell adhesion and
protein-protein interactions (108). Therefore, it is possible that interactions between
periostin and stabilin-1 may regulate periostin levels in normal and abnormal wound
healing.
Identification of proteases and/or mechanisms involved in periostin degradation may
have profound benefits as therapeutic treatments designed promote myofibroblast
apoptosis and reduce dermal density in patients affected by hypertrophic scarring.
Conversion of the disease microenvironment to a more homeostatic state should improve
scar resolution and eliminate the need for costly surgical and therapeutic interventions. It
is hoped that these studies will encourage research in the area of periostin regulation in
excessive cutaneous wound repair with the goal of uncovering new therapeutic
approaches for disease resolution.
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